CURRICULUM VITÆ

Personal Data

Name: Hélder A. Santos

Date of birth and Birthplace: 27th January 1981, Portugal Highest Academic degree: D.Sc. Tech. (Chem. Eng.) Present position: Associated Professor (tenure-track) & Principal Investigator (group leader) in Pharma-ceutical Nanotechnology and Head of Research Unit Professional address: Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, P.O. Box 56 (Viikinkaari 5 E), FI-00014 University of Helsinki, Finland

Professional Phone: +358-2941-59661. Homepage: http://www.helsinki.fi/~hsantos/ Email Address: helder.santos@helsinki.fi University of Helsinki Profile: https://tuhat.halvi.helsinki.fi/portal/en/person/hsantos Facebook: @SantosLabNano Twitter: @Santos_Lab15

Education, Research & Professional Experience Jan. 2018 – Dec. 2021 Director of the Doctoral Programme in Drug Research (DPDR), Faculty of Pharmacy, University of Helsinki Jan. 2018 – Dec. 2021 Head of the Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki Jun. 2017 – Current Associate Professor, Faculty of Pharmacy, University of Helsinki Jan. 2016 – Current Head of the Preclinical Drug Formulation and Analysis Group, Faculty of Pharmacy, University of Helsinki Jan. 2014 – Dec. 2017 Head of the Research Unit Pharmaceutical Nanotechnology and Chemical Microsystems (NAMI), Faculty of Pharmacy, University of Helsinki Jun. 2013 – Permanent University Researcher. Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki. Sept. 2011 – Permanent Adjunct Professor & Principal Investigator in Pharmaceutical Nanotechnology. Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki. Public trial lecture for docentship (Adjunct Professor) in Pharmaceutical Nanotechnology: Nanoporous silicon materials for improved drug bioavailability, 25.8.2011.

Sep. 2011 – Aug. 2016 Academy of Finland Research Fellow / Associate Researcher. Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki. Jan. 2009 – Aug. 2011 Academy of Finland Postdoctoral Fellow. Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki. Mar. 2007 – Dec. 2008 Researcher. Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki. Oct. 2003 – Oct. 2007 Doctor of Science in Technology. Department of Chemical Technology, Laboratory of Physical Chemistry and Electrochemistry, Helsinki University of Technology, October 2007, Finland. Currently: Department of Chemistry, Aalto University, School of Science and Technology.

Title of the thesis: Improving the biomimetic properties of liquid/liquid interfaces: electrochemical and physicochemical characterisation (in English), 110 pp + 6 original research papers. Final classification: cum laude (Pass with distinction/honors). Major Subject: Physical Chemistry & Electrochemistry. Minor Subject: Analytical Chemistry.

Oct. 2003 – Nov. 2005 Licentiate of Science in Technology. Department of Chemical Technology, Laboratory of Physical Chemistry and Electrochemistry, Helsinki University of Technology, November 2005, Finland. Currently: Department of Chemistry, Aalto University, School of Science and Technology.

Title of the thesis: Electrochemical and Physicochemical Characterisation of Dextran Sulfate–Modified Phospholipid Monolayers at Soft Interfaces (in English), 49 pp + 3 original research papers. Final classification: cum laude (Pass with distinction/honors). Major Subject: Physical Chemistry & Electrochemistry.

Sep. 1999 – July 2003 Licentiate in Chemistry. Department of Chemistry, Faculty of Sciences, University of Porto, July 2003, Portugal.

Title of the thesis: Adsorption Studies of Phosphatidylcholines at Air-Liquid and Liquid-Liquid Interfaces (in Portuguese), 124 pp. Final classification: 18 (0–20 scale). Pass with distinction/honors. Major subject: 5.

Prizes/Awards & Honours [1] Main supervisor of the Ph.D. Thesis of Mónica Ferriera "Approved with Distinction" (Faculty of Pharmacy, University

of Helsinki (December 2017) – Honor given to the top 5–10 % theses of the Faculty. This thesis received then the Albert Wuokko Award (Finland's most prestigious Pharmaceutical Award bestowed by the Finnish Pharmaceutical Society worth of 4000 EUR), the Best Doctoral Thesis by the Viikki Research Group Organization (October 2018).

[2] Best Poster Award: N. Z. Ezazi, M.-A. Shahbazi, Y. V. Shatalin, E. Nadal, E. Mäkilä, J. Salonen, M. Kemell, A. Correia, J. Hirvonen, H. A. Santos, "Conductive vancomycin-loaded mesoporous silica polypyrrole-based scaffolds for bone regeneration", 12th FinPharmaNet Symposium 2018, 14-15 June 2018, Espoo, Finland. (Poster Presentation).

[3] Main supervisor of the PhD Thesis of Mónica Ferreira "Approved with Distinction" (Faculty of Pharmacy, University of

Helsinki (January 2018) – Honor given to the top 5–10 % theses of the Faculty. [4] Top 4 Nominees for The Universal Scientific Education and Research Network (USERN) Prize in Biological Sciences,

Kharkiv, Ukraine on 8-10 November 2017. [5] Global Impact Camp Prize, Helsinki Challenge, 27.9.2017, Brussels, Belgium. [6] Finalist of Helsinki Challenge 2017: “Team POCKit". [7] Helsinki Institute of Life Science (HiLIFE) professorship and research funds (~1 m€ / 3-years).

[8] Academy of Finland 2016 Award for Social Impact, 24th November 2016, Academy of Finland, Finland. [9] Finalist (interview stage) for the Novo Nordisk Foundation Young Investigator Awards (20 mDKK or ~2.7 m€), 2016. [7] Main supervisor of the Master’s thesis of Giulia Capasso, University of Pavia (Italy), receiving the Recipharm Italia Award

2016 for the Best thesis on topical formulation. The thesis was supervised by Adj. Prof. Hélder A. Santos at the Faculty of Pharmacy, University of Helsinki, and co-supervised by Prof. Carla Caramella at University of Pavia.

[8] Main supervisor of the Best doctoral thesis of the University of Helsinki in 2015 to Mohammad-Ali Shahbazi, for its highest and outstanding research quality. The award was worth of 3000 EUR and the thesis was supervised by Adj. Prof. Hélder A. Santos and co-supervised by Prof. Jouni Hirvonen (April 2016).

[9] Main supervisor of the PhD Thesis of Neha Shrestha "Approved with Distinction" (Faculty of Pharmacy, University of Helsinki (April 2016) – Honor given to the top 5–10 % theses of the Faculty, and the APV Award for one of the Most Outstanding Doctoral Thesis in the Pharmaceutical Sciences attributed by the International Association for Pharmaceutical Technology (APV) (20th March 2018).

[10] Main supervisor of the Best Thesis in Pharmacy in Finland in 2014–2015 of the PhD Thesis of Mohammad-Ali Shahbazi, awarded by the National FinPharma Doctoral Program Pharmacy Section (FPDP-P).

[11] Main supervisor of the Best doctoral thesis of the University of Helsinki in 2014 to Dr. Dongfei Liu, for its highest and outstanding research quality. The award was worth of 5000 EUR and the thesis was supervised by Adj. Prof. Hélder A. Santos and co-supervised by Prof. Jouni Hirvonen (April 2015).

[12] Main supervisor of the PhD Thesis of Mohammad-Ali Shahbazi "Approved with Distinction" (Faculty of Pharmacy, University of Helsinki (March 2015) – Honor given to the top 5–10 % theses of the Faculty.

[13] Main supervisor of the The Best Young Researcher of Pharmaceutical Sciences Award attributed to Mohammad-Ali Shahbazi at The 20th Razi Medical Sciences Research Festival in Tehran, Iran. This research work was supervised by Adj. Prof. Hélder A. Santos and co-supervised by Prof. Jouni Hirvonen (14th January 2015).

[14] Reward 2014 by the Faculty of Pharmacy, University of Helsinki (Finland), for the exceptionally productive research work of Dr. Santos’ group in 2014 (> 29 papers in 2014).

[15] Main supervisor of the PhD Thesis of Dongfei Liu "Approved with Distinction" (Faculty of Pharmacy, University of Helsinki (August 2014) – Honor given to the top 5–10 % theses of the Faculty.

[16] Hongbo Zhang*, Dongfei Liu, Mohammad-Ali Shahbazi, Ermei Mäkilä, Jarno Salonen, Jouni Hirvonen, and Hélder A. Santos. “Microfluidic Templated Multistage Porous Silicon Based Platform for Enhanced Enteric Cancer Drug Delivery”. Outstanding Oral Drug Delivery Paper Award, 41st Annual Meeting & Exposition of the Controlled Release Society,

Chicago, USA (July 13-16), 2014. [17] Best Poster Award: Shahbazi, M.-A.*, Hamidi M., Mäkilä E., Zhang H., Almeida P., Kaasalainen M., Salonen J., Hirvonen

J., Santos, H.A. “The mechanisms of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility”, International Autumn School, "Nanostructured Materials in Biomedical Applications", 2nd to 6th of September 2013, Turku, Finland.

[18] Young Researcher's Award 2013 by the Faculty of Pharmacy, University of Helsinki, Finland [19] European Research Council Starting Grant Recipient (2013–2017) [20] Centre for International Mobility (CIMO) Grant Recipient (1.8.2012–31.3.2013) [21] Main supervisor of the Ph.D. Thesis of Luis M. Bimbo "Approved with Distinction" (Faculty of Pharmacy, University of Helsinki

(February 2012) – Honor given to the top 5–10 % theses of the Faculty. This thesis received then the Albert Wuokko Award (Finland's most prestigious Pharmaceutical Award bestowed by the Finnish Pharmaceutical Society worth of 4000 EUR), the Best Doctoral Thesis by the Viikki Research Group Organization (November 2012), and the APV Award for one of the Most Outstanding Doctoral Thesis in the Pharmaceutical Sciences attributed by the International

Association for Pharmaceutical Technology (APV) (1st April 2014). [22] 4BBBB Young Researcher Award Poster: Bimbo L. M.*, Sarparanta M., Mäkilä E., Laaksonen T., Peltonen L., Lehto V.-P.,

Airaksinen A.J., Salonen J., Hirvonen J., Santos H.A. Mesoporous silicon particles as biocompatible drug delivery agents. 4th BBBB – Bled International Conference on Pharmaceutical Sciences, 29th September–1st October 2011, Bled, Slovenia. *Presenter.

[23] Adjunct Professor (Docent) in Pharmaceutical Nanotechnology Position (13.9.2011 –>). [24] Academy of Finland Research Fellow Position: 1.9.2011–31.8.2016. [25] Top Reviewer in Pharmaceutical Sciences 2010 – Elsevier. [26] Formal tribute of Câmara Munincipal de Tarouca to Dr. Hélder A. Santos for the Award in the “Prémio Talento 2009”

(Science Talent Award 2009), 29th July 2010, Tarouca, Portugal. [27] Nominated and Winner of the ‘Prémio Talento 2009’ (Science Talent Award 2009), Portuguese Government, Ministério

dos Negócios Estrangeiros (Ministry of Foreigner Affairs), Secretaria de Estado das Comunidades Portuguesas (State

Secretary of the Portuguese Communities), 23rd July 2010, Lisbon, Portugal. [28] Travel Grant From the Finnish Association of Pharmacy Teachers and Researchers (FOTY ry) for the 23rd European

Conference on Biomaterials (ESB2010), 11–15 September 2010, Tampere, Finland. [29] University of Helsinki Research Grant Recipient: 1.1.2009–31.12.2011. [30] Academy of Finland Postdoctoral Research Position: 1.1.2009–31.12.2011. [31] Chancellor’s Travel Grant (University of Helsinki) for the 6th World Meeting on Pharmaceutics, Biopharmaceutics and

Pharmaceutical Technology, 7–10th April, Barcelona, Spain, 2008.

[32] Travel Grant From Saarland University for the 7th Conference and Workshop on Biological Barriers and Nanomedicine – Advanced Drug Delivery and Predictive non vivo Testing Technologies, 20–29th February, Saarland University, Saarbrücken, Germany, 2008.

[33] Stipends at Helsinki University of Technology for accelerated completion of all postgraduate courses, Licentiate and Doctoral degrees (cum laude), Finland (2005 and 2007).

[34] Supervisor & instructor of the work Effects of Nicotine on a Primary Lipid of Lung Surfactant: Testing the Stability and Efficiency Using Subphases of Different Ionic Strengths and pH of Klaara Kanisto (Senior Secondary Student), carried out at the Department of Chemical Technology, Laboratory of Physical Chemistry and Electrochemistry, Helsinki University of Technology, and First Prize Winner (stipends) in the Finnish competitions: Tutki Kokeile Kehitä (Research-Experiment-Develop, from Finnish Science and Technology) and Viksu (from Academy of Finland Annual Science), Finland, 2006; and representing Finland with the same work at the 19th EU Contest for Young Scientists – València, Spain 14–19th September 2007.

[35] Scholarship From the Home City Municipal (Tarouca, Portugal) during the Degree in Chemistry (Licentiate degree), at the Department of Chemistry, Faculty of Sciences, University of Porto, Portugal, 2000–2003.

[36] Awards/Stipends for the best class student at the Secondary School C+S of Tarouca (1995) and at the High School Latino Coelho of Lamego, Portugal (1999).

Participation in Tutoring/Teaching/Supervision ONLINE TALKS (1) [1] Nanomedicine Series, Edited by Prof. Thomas J. Webster, Northeastern University, Boston, USA.

Applications of nanomedicine: Cancer diseases – “Fabrication of nanomedicines for precisely controlled combination therapy” (53 mins)

Participation in tutorials/teaching of courses for undergraduate and postgraduate students (15) [1] Eramus Teaching Exchange, University of Chieti – Pescara “G. d’Annunzio”, Department of Pharmacy, 18-22.6.2018. [2] Coordinator and co-teacher in the course Research practice at the division of pharmaceutical chemistry and technology,

PROV-201, 5-40 cr. [3] Coordinator and co-teacher in the course Introduction to cell and molecular biology methods in pharmacy, PROV-004,

5 cr, 09.01.2018 - 06.03.2018, Master's Programme in Pharmacy [4] Coordinator and teacher in the course Nanomedicines for biomedical applications, PROV-710, Course, 5 cr, 14.05.2018-

25.05.2018, Master's Programme in Pharmacy [5] Teacher in the ULLA Summer School, course: Microfluidics For Pharmaceutical Applications: From Nano/Micro Systems

Fabrication To Controlled Drug Delivery, University of Leuven, 8−15 July 2017, Leuven, Belgium. [6] Co-teacher in the course 590239 Biopharmaceutical Drugs II (Biologiset lääkevalmisteet II; 4 ECTS), Division of

Biosciences, Faculty of Pharmacy, University of Helsinki, May 2017, Finland. [7] Coordinator and co-teacher in the course Microfluidics and Nanotechnology In Pharmaceutical Applications, PROV-607,

5 ECTS, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, May–June, 2015–currently, Finland.

[8] Co-teacher in the course 590336 Lääkevalmiste II (Pharmaceutical Technology), 6 cr (course no. 590336, 6 ECTS), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, August–September, 2014– currently, Finland.

[9] Coordinator of the course Farmasian teknologia laskutentti (590016A; 8 op/cr), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, Autumn 2013, Finland.

[10] External students’ consultant and tutor for the basic Chemistry course at the University of Beira Interior, Bioengineering degree, 2010–2011, Covilhã, Portugal.

[11] Co-lecturer in the course: Nanoscience III: Molecular Nanoscience course, 5 cr (course no. Tfy-125.4003, 5 ECTS), Spring 2012, Aalto University, Finland.

[12] Co-lecturer in the course: Controlled Release Drug Delivery Systems course, 5 cr (course no. 59072, 3 ECTS, 18 h), Autumn 2011, Faculty of Pharmacy, University of Helsinki, Finland.

[13] Co-lecturer in the course: Biopharmaceutics in Pharmaceutical Product Development (Biofarmasia farmaseuttisessa tuotekehityksessä), 3 cr (course no. 590278, 3 ECTS, 18 h), Division of Industrial Pharmacy & Finnish Graduate School in Pharmaceutical Research, Faculty of Pharmacy, University of Helsinki, August 29–September 1, 2011, Finland.

[14] Co-coordinator and co-lecturer of the course: Solid State Analysis of Pharmaceutics, 5 cr (course no. 590176, 3 ECTS, 14 h), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki. Autumn 2009–currently, Finland.

[15] Coordinator, chairman and moderator of the course: Farmasian Teknologian Syventävien ja Jatkoopintojen Seminaarit / Seminars in Pharmaceutical Technology (Advanced Studies in Pharmaceutical Technology), 2 cr (course no. 59171, 2 ECTS, 15 h), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki. Autumn 2009–Spring 2012, Finland.

Mentor of Post-Doctoral researchers (24) [1] Dr. Mohammad-Ali Shahbazi (PhD Pharm.): A Thermo-responsive Biopolymeric Microimplant for Autoimmune

Disorders. Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (10.2018–current, project supported by Academy of Finland), Finland.

[2] Dr. Mónica Ferreira (PhD Pharm.): Towards personalized nanomedicines for targeted drug delivery and imaging for ischemic myocardial injury. Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (9.2018–current, project supported by Academy of Finland), Finland.

[3] Dr. Shiqi Wang (PhD Chem. Eng.): NANO CARRIER - Porous Silicon Nano particles will be produced and studied, in vitro and in vivo for cancer diagnostics, therapy and imaging. Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (6.2018–6.2019, project supported by The Research Council of Norway), Finland.

[4] Dr. Chang-Fang Wang (PhD Pharm.): Targeted nanomedicines to the brain for therapy of neurodegenerative diseases. Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.2018–12.2018,

project supported by Tekes – 3iRegeneration), Finland. [5] Dr. Peng Quan (PhD): Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki,

(11.2017–11.2018; Chinese Scholarship Council), Finland. [6] Dr. Habib Baghirov (PhD): Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of

Helsinki, (11.2017; EU’s Marie Curie), Finland. [7] Dr. Yaping Ding (PhD Mater. Sci. Eng.): Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy,

University of Helsinki, (8.2017–current, project supported by Academy of Finland), Finland. [8] Dr. Antti Rahikkala (D.Sc. Tech., Chem. Eng.): Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy,

University of Helsinki, (2.2016–current, project supported by the Finnish Cultural Foundation and Academy of Finland), Finland.

[9] Dr. Wei Li (PhD Biomater.): GDNF Mimetics, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy,

University of Helsinki, (10.2015–9.2017, GDNF Mimetics, EU’s Marie Curie IAPP initiative under 7th Framework Programme and by the European Research Council, ERC, Multistage–multifunctional porous silicon nanovectors for directed theranostic), Finland.

[7] Dr. Dongfei Liu (PhD Pharm.): Porous Silicon-Based Multicomposites for Controlled Drug Delivery, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (9.2014–current, project supported by the Academy of Finland), Finland.

[8] Dr. Vimalkumar Balasubramanian (PhD Chem.): Targeted drug delivery into injured myocardium with porous silicon nanoparticles: myocardial remodelling and repair. Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Finland (3.2014–current).

[9] Dr. Vilma Petrikaite (PhD Pharm.): Visiting scholar – Department of Drug chemistry, Faculty of Pharmacy, Lithuanian University of Health Sciences, Lithuania (4.2017–6.2017).

[10] Dr. Sanjeev Ranjan (PhD Biomed. Eng.): Multistage–multifunctional porous silicon nanovectors for directed theranostic, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.2016–12.2016, project supported by the European Research Council, ERC), Finland.

[11] Dr. Bárbara Herranz-Blanco (PhD Pharm.): Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (6.2016, project supported by the European Research Council, ERC; Multistage–multifunctional porous silicon nanovectors for directed theranostic), Finland.

[12] Dr. Neha Shrestha (PhD Pharm.): Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (4.2016–5.2016, project supported by the University of Helsinki Research Funds), Finland.

[13] Dr. Mohammad-Ali Shahbazi (PhD Pharm.): Multistage–multifunctional porous silicon nanovectors for directed theranostic, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (2.2015– 5.2016, project supported by the European Research Council, ERC), Finland.

[14] Dr. Hongbo Zhang (PhD Pharm.): Biomimetic immune cell membrane encapsulated mesoporous silicon vector for targeted and personalized cancer therapy. Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Finland (6.2012–9.2016).

[15] Dr. Usama Abo-Ramadan (PhD Phys.). Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Finland (1–30.7.2015).

[16] Dr. Chang-Fang Wang (PhD Pharm.): Multistage–multifunctional porous silicon nanovectors for directed theranostic, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (3.2015–30.6.2015, project supported by the European Research Council, ERC), Finland.

[17] Dr. Yuri Shatalin (PhD Biol.) from Pushchino State University (Russia). Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.1.–30.4.2015, project supported by CIMO), Finland.

[18] Dr. Remigijus Vasiliauskas (Ph.D. Phys.) from the Institute of Biotechnology, Vilnius University (Lithuania): Development of novel drug delivery systems by PDMS microfluidics. Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Finland (1.9.2014–31.1.2015).

[19] Dr. Sabiruddin Mirza (PhD Pharm.): Porous silicon nanovectors for directed theranostics. Division of Pharmaceutical Technology Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Finland (1.2013–8.2013).

[20] Dr. Anne Soikkeli (PhD Pharm.): Novel porous silica-based materials for biomedical applications. Division of Pharmaceutical Technology Technology, Faculty of Pharmacy, University of Helsinki, Finland (11.2012–4.2013).

[21] Dr. Luis M. Bimbo (PhD Pharm.): Liposome-based porous silicon platforms for cancer therapy. Division of Pharmaceutical Technology Technology, Faculty of Pharmacy, University of Helsinki, Finland (2.2012–2.2013).

Supervisor of Doctoral students (25) [1] Main supervisor of the Doctoral thesis: Targeted tumour immunization therapy combined with controlled drug release using

biomimetic engineering compartmentalized nanoreactors, Ruoyu Cheng (M.Sc. Chem.; Soochow University, China), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (9.2018–current, ongoing project supported by the Chinese Scholarship Council), Finland.

[2] Main supervisor of the Doctoral thesis: Development of polymer-based nano drug delivery system for targeted therapy to gliomas, Voitto Känkänen (M.Sc. Tech., Tampere University of Technology, Finland), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (9.2018–current, ongoing project supported by Bayer Oy), Finland.

[3] Main supervisor of the Doctoral thesis: Development of multifunctional hybrid cell membrane/exosome-based nanovectors for myocardial reprograming and repair, Giulia Torrieri (M.Sc. Pharm., Università Degli Studi 'G. D'annunzio' Di Chieti, Italy), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.10.2017–current, ongoing project supported by University of Helsinki Research Funds, HiLIFE and CIMO), Finland.

[4] Co-supervisor of the Doctoral thesis: Design of novel protein fibrils-based biomaterials for the regeneration of injured myocardium tissue, Tiago Carvalho (M.Sc. Eng.), CICECO – Aveiro Institute of Materials, University of Aveiro, Portugal/Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.1.2018– current, ongoing project supported by the Portuguese Fundaҫão para a Ciência e Tecnologia, Portugal), Finland.

[5] Main supervisor of the Doctoral thesis: Fc Receptor-mediated transcytosis of bioengineered nanoparticles towards systemic delivery of antidiabetic drugs and protein, João Martins (M.Sc. Genet & Biotechnol.), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (15.1.2016–current, ongoing project supported by the Sigrid Juselius Foundation), Finland.

[6] Co-supervisor of the Doctoral thesis: Theranostic nanocomposites for simultaneous cancer immunotherapy and imaging, Tomás Ramos (M.Sc. Pharm.), INEB – Instituto Engenharia Biomédica, Porto, Portugal/Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.11.2015–current, ongoing project supported by the Portuguese Fundaҫão para a Ciência e Tecnologia, Portugal), Finland.

[7] Main supervisor of the Doctoral thesis: Biofunctionalization of biodegradable conductive patch for myocardial infarction treatment, Nazanin Ezazi (M.Sc. Biomed. Eng.), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (5.10.2015–current, ongoing project supported by the European Research Council, ERC, Finland.

[8] Main supervisor of the Doctoral thesis: A novel targeting system to cope with the different environments in vivo transport and achieve efficient combination therapy, Feng Zhang (M.Sc. Chem. Eng.), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (5.10.2015–current, ongoing project supported by the European Research Council, ERC, and the Chinese Scholarship Council), Finland.

[9] Supervisor and instructor of the Doctoral thesis: Porous silicon nanoparticles for anti-cancer drug delivery and biomedical imaging, Zehua Liu (M.Sc. Pharm.), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.10.2015–current, ongoing project supported by the European Research Council, ERC, and the Chinese Scholarship Council), Finland.

[8] Main supervisor of the Doctoral thesis: Lignin nanoparticles for biomedical applications, Patrícia Figueiredo (M.Sc. Biochem.), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.9.2015– current, ongoing project supported by the European Research Council, ERC), Finland.

[9] Main supervisor of the Doctoral thesis: Microfluidics template platforms for intracellular drug delivery and cancer therapy, Flavia Fontana (M.Sc. Pharm.), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.1.2015–current, ongoing project supported by the European Research Council, ERC), Finland.

[10] Co-supervisor of Doctoral thesis: Non-linear label-free optical imaging of cells, nanocrystal cellular uptake and solid-state analysis in pharmaceutics, Jukka Saarinen (M.Sc. Pharm.). Division of Pharmaceutical Technology Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.9.2014–2.3.2018, supported by UH Funds), Finland.

[11] Main supervisor of the Doctoral thesis: Targeted drug delivery into injured myocardium with porous silicon nanoparticles: myocardial remodelling and repair, Mónica Ferreira (M.Sc. Pharm.). Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (9.9.2013–31.12.2017, project supported by Doctoral Program in Drug Research, Faculty Pharmacy), Finland.

[12] Co-supervisor of the Doctoral thesis: GLP-1 and GLP-1 analogs nanotechnology based systems for prevention and

therapy of diabetes, Francisca Araújo (M.Sc. Heath Sciences), INEB – Instituto Engenharia Biomédica, Porto, Portugal/Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.1.2013– 10.3.2017, project supported by the Portuguese Fundaҫão para a Ciência e Tecnologia, Portugal, and after 1.3.2013 also by the by the Centre for International Mobility, CIMO), Finland.

[13] Co-supervisor of the Doctoral thesis: Mesoporous silicon systems for oral protein/peptide-based diabetes mellitus

therapy, Neha Shrestha (M.Sc. Pharm.), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.1.2013–1.4.2016, project supported by the Centre for International Mobility, CIMO, and after 1.9.2013 by the University of Helsinki Research Funds), Finland. Accepted with Honours.

[14] Main supervisor of the Doctoral thesis: Multifunctional porous silicon based nanocomposites for cancer targeting and drug delivery, Patrick Almeida (M.Sc. Pharm.), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.1.2013–6.4.2018, ongoing project supported by the European Research Council, ERC), Finland.

[15] Main supervisor of the Doctoral thesis: Multi-approach design and fabrication of hybrid composites for drug delivery and cancer therapy, Barbara Herranz-Blanco (M.Sc. Pharm.), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.9.2012–6.2016; project supported by the Academy of Finland and after 1.1.2013 by the European Research Council, ERC), Finland.

[16] Co-supervisor of the Doctoral thesis: Fabrication and characterization of porous silicon materials for biomedical applications, Ermei Mäkilä (M.Sc. Phys.), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (21.11.2011–current, ongoing project supported by the Academy of Finland and after 1.9.2013 by the European Research Council, ERC), Finland.

[17] Main supervisor of the Doctoral thesis: Chemical surface modification of porous silicon nanoparticles for cancer therapy, Chang-Fang Wang (M.Sc. Chem.), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (2.10.2012–2.3.2015, supported by the Chinese Scholarship Council and after 1.9.2013 by the European Research Council, ERC), Finland.

[18] Main supervisor of the Doctoral thesis: Effect of surface chemistry on the immune responses and cellular interactions of porous silicon nanoparticles, Mohammad-Ali Shahbazi (M.Sc. Pharm.), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (1.7.2012–13.2.2015, supported by the Ministry of Health and Medical Education, Iran; Centre for International Mobility, CIMO; and after 1.1.2014 by the European Research Council, ERC), Finland.

[19] Main supervisor of the Doctoral thesis: Porous Silicon-Based Multicomposites for Controlled Drug Delivery, Dongfei Liu (M.Sc. Med. Pharm.), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, (21.11.2011–29.8.2014, project supported by the Academy of Finland), Finland. Accepted with Honours.

[20] Main supervisor of the Doctoral thesis: Biofunctionalization of porous silicon nanoparticles for brain cancer therapy, Päivi Kinnari (M.Sc. Pharm.), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki,

(2.2.2011–31.3.2013, project supported by The National Graduate School in Nanoscience), Finland. [21] Co-supervisor of the Doctoral thesis: Towards enhanced bioavailability of poorly soluble drugs utilizing porous silicon

(ENBIPSi), Maria Tahvanainen (M.Sc. Pharm.), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, (1.1.2008–31.12.2012, project was supported by the pharmaceutical industry – Boehringer Ingelheim), Finland.

[22] Main supervisor of the Doctoral thesis: Biodistribution and biofunctionalization of mesoporous silicon particles, Luis M. Bimbo (M.Sc. Pharm.), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, (1.2.2009– 4.2.2012, project was supported by the University of Helsinki Research Funds), Finland. Accepted with Honours; Awarded with the Albert Wuokko Prize (Finland's most prestigious Pharmaceutical Award bestowed by the Finnish Pharmaceutical Society) and Best Doctoral Thesis by the Viikki Research Group Organization, which was supervised by Adj. Prof. Hélder A. Santos and Prof. Jouni Hirvonen.

[23] Co-supervisor of the Doctoral thesis: Mesoporous silica- and silicon-based materials as carriers for poorly water soluble drugs, Tarja Limnell (M.Sc. Health Biosciences), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, (1.4.2007–15.10.2011, project was supported by the Academy of Finland), Finland.

Host and mentor of Visiting Researchers – PhD students (13) [1] Supervisor of the Saowanee Wannasarit (Prince of Songkla University, Thailand), PhD visiting student in my Lab, Division

of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, August 2018–April 2019, Finland.

[2] Supervisor of the Serena Bertoni (University of Bologna, Italy), PhD visiting student in my Lab, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, July–August 2018, Finland.

[3] Supervisor of the Clarinda Costa (Nova University of Lisbon, Portugal), PhD visiting student in my Lab, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, June–November 2018, Finland.

[4] Supervisor of the Sara Gomes (University of Porto, Portugal), PhD visiting student in my Lab, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, September 2017–February 2018, Finland.

[5] Supervisor of the Serena Bertoni (University of Bologna, Italy), PhD visiting student in my Lab, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, July–December 2017, Finland.

[6] Supervisor of the Nayab Tahir (University of Bahawalpur, Pakistan), PhD visiting student in my Lab, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, November–August 2017, Finland.

[7] Supervisor of the Nattha Kerdsakundee (Prince of Songkla University, Thailand), PhD visiting student in my Lab, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, August 2016–April 2017, Finland.

[8] Supervisor of the Hanif Ullah (Department of Pharmacy, COMSATS Institute of Information Technology, Pakistan), PhD visiting student in my Lab, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, November 2015–August 2016, Finland.

[9] Supervisor of the Agne Vegyte (Institute of Biotechnology, Vilnius University, Lithuania), PhD visiting student in my Lab, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, January–April 2016, Finland.

[10] Supervisor of the Marlene Lopes (Department of Pharmaceutics, Faculty of Pharmacy, University Coimbra, Portugal), PhD visiting student in my Lab, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, March–September 2015, Finland.

[11] Supervisor of the Chigusa Okano (Department of Innovation Systems Engineering, Graduate School of Engineering, Utsunomiya University, Japan), PhD visiting student in my Lab, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, December 2014–February 2015, Finland.

[12] Supervisor of the Michela Terracciano (Institute for Microelectronics and Microsystems Unit of Naples National Research Council, Italy), PhD visiting student in my Lab, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, September 2014–January 2015, Finland.

[13] Supervisor of the Michela Mori (University of Pavia, Italy), PhD visiting student in my Lab, Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, October 2013, Finland.

Supervisor of Master students (42) [1] Main supervisor of Francesca Eburnea’s thesis: XXXXX (Master student in Pharmacy, University of Urbino, Italy) Division

of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, August 2018–March 2019, Finland.

[2] Main supervisor of Giuseppina Molinaro’s thesis: XXXXX (Master student in Pharmacy, University of Urbino, Italy) Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, August 2018–March 2019, Finland.

[3] Main supervisor of Khalil El­badr’s thesis: XXXXX (Master student in Biotechnology, University of Helsinki, Finland) Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, June–December 2018, Finland.

[4] Main supervisor of Rami Lifländer’s thesis: XXXXX (Master student in Pharmacy, University of Helsinki, Finland) Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, January–December 2018, Finland.

[5] Main supervisor of Mattia Tiboni’s thesis: Mannose-decorated lignin nanoparticles: a new potential carrier for targeted therapy (Master student in Pharmacy, University of Urbino, Italy) Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, February–July 2018, Finland.

[6] Main supervisor of Rita Machado’s thesis: Bacterial cell wall based nanovaccines for immunostimulation (Master student in Pharmacy, University of Lisbon, Portugal) Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, February–April 2018, Finland.

[7] Main supervisor of Silvia Valentino’s thesis: Development of nanopsrticles for FcRn-targeted diabetes therapies (M.Sc. Pharmacy, University of Pavia, Italy) Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, January–April 2018, Finland.

[8] Main supervisor of Rebecca Valenti’s thesis: Development of surface-modified nanoparticles and scaffolds for delivery experiments (Master student in Pharmacy, University of Pavia, Italy) Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, November 2017–January 2018, Finland.

[9] Main supervisor of Roberto D'Auria’s thesis: pH-Sensitive albumin-modified porous silicon nanoparticles for oral delivery of insulin (University of Urbino "Carlo Bo", Italy), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, February–July 2017, Finland.

[10] Main supervisor of Silvia Albertini’s thesis: Development of innovative biomimetic nanoparticulate carriers as vaccines and drug delivery formulations for the treatment of autoimmune diseases (Master student in Pharmacy, University of Pavia, Italy) Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, February– July 2017, Finland.

[11] Main supervisor of Federica Calandra’s thesis: Development of ascorbyl palmitate based micro-sized composite microparticles for oral drug delivery applications using microfluidics (Master student in Pharmacy, Università Degli Studi 'G. D'annunzio' Di Chieti, Italy), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, January–June 2017, Finland.

[12] Main supervisor of Gonçalo Marques’ thesis: Development of pH-sensitive polymeric nanoparticles for drug delivery to the ischemic heart (Master student in Pharmacy, University of Lisbon, Portugal), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, February–April 2017, Finland.

[13] Main supervisor of Cláudio Ferro’s thesis: Functionalization of carboxylated lignin nanoparticles for cancer therapy (Master student in Pharmacy, University of Lisbon, Portugal), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, February–April 2017, Finland.

[14] Main supervisor of Júlia Santamaria Martínez’s thesis: Development of nanovectors with microfluidics for cancer immunotherapy (Master student in Pharmacy, Universitat de Barcelona, Spain), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, August 2016–January 2017, Finland.

[15] Main supervisor of Daniela A. Muftieva’s thesis: CARS analysis of silicon nanoparticles and nanowires (Master student in Physics, Moscow State University, Russia), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, September 2016–January 2017, Finland.

[16] Main supervisor of Manuel Negrão Master’s thesis: Development and characterization of chitosan-iminothiolane modified porous silicon nanoparticles for oral delivery of curcumin (Master student in Pharmacy, University of Coimbra, Portugal), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, January– May 2016, Finland.

[17] Main supervisor of Cristina Bernuz Master’s thesis: Ultra-high drug loaded nanovectors for controlled drug delivery (Master student in Pharmacy, University of Barcelona, Spain), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, September–December 2015, Finland.

[18] Main supervisor of Anita Ncube Master’s thesis: Encapsulation and characterisation of DNA and FITC coloaded nanoplexes (Master student in Pharmacy, University of East Anglia, UK), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, September–December 2015, Finland.

[19] Main supervisor of Giulia Capasso Master’s thesis: Self-assembled polymersomes and acetalated-dextran nanoparticles as potential nanocarriers for the treatment of non-healing wounds (Master student in Pharmacy, University of Pavia, Italy), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, September– December 2015, Finland.

[20] Main supervisor of Nikolina Dakic Master’s thesis: Preparation and characterization of polymersomes for cancer therapy (Master student in Pharmacy, University of Zagreb, Croatia), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, January–May 2015, Finland.

[21] Main supervisor of Federica Pavesi Master’s thesis: Preparation and characterization of polymeric nanocarriers for wound healing applications (Master student in Pharmacy, University of Pavia, Italy), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, January–May 2015, Finland.

[22] Co-supervisor of Jukka Saarinen Master’s thesis: Label-free imaging of cells and particle interactions based on coherent anti-Stokes Raman scattering (CARS) (Master student in Pharmacy, University of Helsinki, Finland), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, August 2013–May 2014, Finland.

[23] Main supervisor of Ricardo Rosa Master’s thesis: Microfluidic fabrication of porous silicon/polymer nanocomposites for drug delivery (Master student in Pharmacy, University of Coimbra, Portugal), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, January–April 2014, Finland.

[24] Main supervisor of Tomás Ramos Master’s thesis: EpCAM-conjugated porous silicon nanoparticles for targeted cancer chemoimmunotherapy (Master student in Pharmacy, University of Coimbra, Portugal), Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, January–April 2014, Finland.

[25] Main supervisor of Flavia Fontana Master’s thesis: In vitro assessment of platelet-lysate-loaded porous silicon microparticles on fibroblast cellse (ERASMUS student from University of Pavia, Italy), Division of Pharmaceutical Chemistry and Technology, University of Helsinki, August 2013–Juky 2014, Finland.

[26] Co-supervisor of Emilia Larsson Master’s thesis: Development of an in vitro model for evaluating the pharmacological effects of new formulations of insulin and GLP-1 (NORDPLUS exchange student from Uppsala University, Sweden), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, August–December 2013, Finland.

[27] Main supervisor of Robert Lang Master’s thesis: Controlled delivery of oligonucleotide-and siRNA-loaded porous silicon nanoparticles (ERASMUS exchange student from Ludwig-Maximilians-Universit, Germany), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, August–December 2013, Finland.

[28] Main supervisor of Mátyás Pétervári Master’s thesis: Cyclodextrin-modified porous silicon nanoparticles for controlled drug delivery (ERASMUS student from University of Debrecen, Hungary), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, August–November 2013, Finland.

[29] Co-supervisor of Erkan Sözeri Master’s thesis: Label-free imaging of live intestinal cells with CARS microscopy (ERASMUS student from University of Münster, Germany), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, May–October 2013, Finland.

[30] Co-supervisor of Jenni Pessi Master’s thesis: Microfluidic approach to preparing polymer microspheres for enhanced oral protein drug deliver (M.Sc. student from Finland), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, February–June 2013, Finland.

[31] Main supervisor of Michela Cola Master’s thesis: In vitro assessment of biopolymer-modified porous silicon microparticles: preparation and characterization (ERASMUS student from University of Pavia, Italy), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, February–December 2013 & January–March 2014, Finland.

[32] Co-supervisor of the Heleen Vande Capelle Master’s thesis: Characterisation of drug loaded porous silica using different analytical techniques (ERASMUS student from University of Ghent, Belgium), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, February–May 2013, Finland.

[33] Main supervisor of the Giulia Anselmi Master’s thesis: Surface modification of porous silicon materials for wound healing applications, (ERASMUS student in Pharmacy from University of Pavia, Italy), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, September 2012–January 2013, Finland.

[34] Main supervisor of the Gerson Schiler Master’s thesis: Dissolution and permeability studies of novel fenofibrate loaded porous silica (ERASMUS student from University of Greifswald, Germany), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, November–December 2012, Finland.

[35] Main supervisor of the Francesca Villanova Master’s thesis: Characterization and in vitro evaluation of dual drug loaded porous silicon particles (ERASMUS student in Pharmacy from University of Pavia, Italy), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, September 2011–January 2012, Finland.

[36] Main supervisor of the Katharina Strommer Master’s thesis: Biofunctionalization of porous silicon materials for pharmaceutical applications (ERASMUS student in Pharmacy from Ludwig-Maximilians-Universität München, Germany), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, March–June 2011, Finland.

[37] Co-supervisor of the Kristýna Jelínková Master’s thesis: Preparation and characterization of pharmaceutical salts and cocrystals with itraconazole (ERASMUS student in Pharmacy from University Brno, Czech Republic), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, February–May 2011, Finland.

[38] Main supervisor of the Päivi Kinnari Master’s thesis: Loading of itraconazole into porous silica and silicon microparticles: characterization and dissolution tests (MSc. student in Pharmacy, Finland), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, February–November 2010, Finland.

[39] Main supervisor of the Diogo Neves Master’s thesis: Indomethacin dissolution profiles of loaded porous silicon particles and effect of modified porous silicon particles on cellular interactions (ERASMUS student in Pharmacy from University of Porto, Portugal), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, March–June 2010, Finland.

[40] Main supervisor of the Michela Mori Master’s thesis: Evaluation of physicochemical and biopharmaceutical properties of fluoro-indomethacin (ERASMUS student in Pharmacy from University of Pavia, Italy), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, January–June 2008, Finland.

[41] Co-supervisor of the Thomas Lautenschlager Master’s thesis: Mesoporous silicon materials as drug carriers for low solubility drugs (MSc. student in Pharmacy, Finland), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, April–December 2007, Finland.

[42] Main supervisor of the Cecilia Pizaro Master’s thesis: Dissolution profiles of mesoporous silica microparticles loaded with indomethacin and beclomethasone (ERASMUS student in Pharmacy from University of Chile, Chile), Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, Autumn 2007, Finland.

Supervisor of Research Assistants (10) [1] Main supervisor of the laboratory work of Giulia Torrieri (M.Sc. Pharmacy, Università Degli Studi 'G. D'annunzio' Di Chieti,

Italy). Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, May–August 2017, Finland.

[2] Main supervisor of the laboratory work of Eloy Nadal (M.Sc. Forest tree, Universidad Politecnica de Valencia, Spain). Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, April–June 2016, Finland.

[3] Main supervisor of the laboratory work of Tomás Ramos (M.Sc. Pharm., University of Coimbra, Portugal). Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, February–May 2015, Finland.

[4] Main supervisor of the laboratory work of Eloy Nadal (Undergraduate Student, Universidad Politecnica de Valencia, Spain). Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, February–July 2014, Finland.

[5] Main supervisor of the laboratory work of Patrícia Figueiredo (M.Sc. Molecular Oncology, University of Porto, Portugal). Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, January–July 2014, Finland.

[6] Main supervisor of the laboratory work of Sérgio Almeida (B.Sc. Genetics and Biotechnology, University of Trás-os-Montes e Alto Douro, Portugal). Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, January–June 2014, Finland.

[7] Main supervisor of research assistant Mónica Ferreira (M.Sc. Pharm., University of Coimbra, Portugal). Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, 16.5.2013–31.5.2014, Finland.

[8] Main supervisor of research assistant Alexandra Correia (M.Sc. Chem. Eng., Instituto Politécnico de Bragança, Portugal). Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, 1.1.–31.12.2013, Finland.

[9] Main supervisor of research assistant Patrick Almeida (M.Sc. Pharm., University of Coimbra, Portugal). Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, 1.9.–31.12.2012, Finland.

[10] Main supervisor of research assistant Barbara Herranz Blanco (M.Sc. Pharm., Universidad Complutense de Madrid, Spain).

Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, 1.3.–30.6.2012, Finland. Participation in tutorials/teaching of undergraduate students (15) [1] Main supervisor of the laboratory work of Hanna Lindstedt (B.Sc. Pharm., University of Helsinki, Finland). Division of

Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, June–August 2018, Finland. [2] Main supervisor of the laboratory work of Claudia Olvera (B.Sc. Pharm., Universidad Nacional Autónoma de México,

Mexico). Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, January–December 2018, Finland.

[3] Main supervisor of the laboratory work of Maria Heilala (B.Sc. Biosci., University of Helsinki, Finland). Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, May–August 2017, Finland.

[4] Main supervisor of the laboratory work of Garmiyan Amiri (University of Helsinki, Finland). Division of Pharmaceutical Chemistry and Technology, University of Helsinki, November 2015–April 2016, Finland.

[5] Main supervisor of the laboratory work of Sofia Ferrand (University of Coimbra, Portugal). Division of Pharmaceutical Chemistry and Technology, University of Helsinki, August–September 2015, Finland.

[6] Main supervisor of the laboratory work of Avelino Ferreira (University of Porto, Portugal). Division of Pharmaceutical Chemistry and Technology, University of Helsinki, August–September 2014, Finland.

[7] Main supervisor of the laboratory work of Eloy Ginestar (Universidad Politécnica de Valenci, Spain). Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Spring 2014 & 2015, Finland.

[8] Main supervisor of the laboratory work of Matic Dolinar (University of Ljubljana, Slovenia). Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Summer 2013, Finland.

[9] Main supervisor of the laboratory work of Luke Spooner (University of Toronto, Canada). Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Summer 2013, Finland.

[10] Main supervisor of the laboratory work of Sérgio Almeida (University of Trás-os-Montes e Alto Douro, Portugal). Division of Pharmaceutical Technology, University of Helsinki, Spring 2013, Finland.

[11] Main supervisor of the laboratory work of Seema Kanber (Laboratory Technician Trainee, Heltech Helsinki City College of

Technology, Helsinki, Finland). Division of Pharmaceutical Technology, University of Helsinki, Autumn 2013, Finland.

[12] Main supervisor of the laboratory work of Marianne Kurttila (Laboratory Technician Trainee, Heltech Helsinki City College of Technology, Helsinki, Finland). Division of Pharmaceutical Technology, University of Helsinki, Spring 2012, Finland.

[13] Main supervisor of the laboratory work of Iira Mustonen (Laboratory Technician Trainee, Savo Vocational College – Savon ammatti- ja aikuisopisto, Kuopio, Finland). Division of Pharmaceutical Technology, University of Helsinki, Autumn 2011, Finland.

[14] Main supervisor of the laboratory work: Effects of Nicotine on a Primary Lipid of Lung Surfactant: Testing the Stability and Efficiency Using Subphases of Different Ion Strengths and pH, Klaara Kannisto (Senior Secondary Student, Helsingin Suomalainen Yhteiskoulu, Helsinki, Finland). Department of Chemical Technology, Laboratory of Physical Chemistry and Electrochemistry, Helsinki University of Technology, Summer 2005, Finland.

[15] Advanced Physicochemical undergraduate laboratory course (Kem-31.119 Fysikaalinen kemia II): Determination of Critical Micelle Concentration by Surface Tension Measurements. Department of Chemical Technology, Laboratory of Physical Chemistry and Electrochemistry, Helsinki University of Technology, Autumns 2004–2006, Finland.

Doctoral Theses Under Dr. Santos Supervision (11)

11. Patrick Almeida: "Multifunctional porous silicon based nanocomposites for cancer targeting and drug delivery", 2018. Approved!

10. Jukka Saarinen: "Non-linear label-free optical imaging of cells,nanocrystal cellular uptake and solid-state analysis in pharmaceutics", 2018. Approved! (co-supervision)

9. Mónica Ferreira: "Multifunctional nanoparticles for targeted drug delivery and imaging for ischemic myocardial injury", 2017. Approved with Honors!

8. Francisca Araújo: "Glucagon-Like Peptide-1 Nanotechnology Based Systems for Prevention and Therapy of Diabetes", 2017. Approved with Honors! (co-supervision)

7. Bárbara Herranz-Blanco: "Multi-approach design and fabrication of hybrid composites for drug delivery and cancer therapy", 2016. Approved!

6. Neha Shrestha: "Mesoporous silicon systems for oral protein/peptide-based diabetes mellitus therapy", 2016. Approved with Honors!

5. Chang-Fang Wang: "Chemical surface modification of porous silicon nanoparticles for cancer therapy", 2015. Approved! 4. Mohammad Ali Shahbazi: "Effect of surface chemistry on the immune responses and cellular interactions of porous

silicon nanoparticles", 2015. Approved with Honors! 3. Dongfei Liu: "Porous silicon-based multicomposites for controlled drug delivery", 2014. Approved with Honors! 2. Luis Bimbo: "Biocompatibility and biofunctionalization of mesoporous silicon particles", 2012. Approved with Honors! 1. Tarja Limnell: "Mesoporous silica- and silicon-based materials as carriers for poorly water soluble drugs", 2011.

Approved! (co-supervision) Other Teaching Activities & Personal Training

Leadership Workshop for all Leaders at University of Helsinki, 15-16 February 2018, Porvoo.

Commercialization Training, Helsinki Innovation Services, University of Helsinki, January – February 2018, Finland

Tekes Pitch Training, 31st October 2014, Finnish Funding Agency for Innovation (Tekes). Specialist: Marianne Poulsen, Exact Innovation

Leadership Program for Academic Staff, November 2013March 2014, University of Helsinki Training and Development Unit. Human Resource Specialist: Sanna-Marja Heinimo

University pedagogy IV – Assessment of Learning, Spring 2013 (5 cr), Centre for Research and Development of Higher

Education, Institute of Behavioural Sciences, University of Helsinki, Finland. Final Grade: Excellent.

Seminar – Malvern Instruments: Zetasizer Instrumentation and GPC Technologies, Faculty of Pharmacy, 18th April and 29th June 2012, University of Helsinki, Finland.

Research Ethics, University of Helsinki, 13th January 2011, University of Helsinki, Finland. Workshop on teaching methods and their cultural underpinnings, Helsinki Education and Research Area (HERA),

University of Helsinki, 14 & 26.10.2010, Finland.

Supervision and guidance in higher education, Spring 2010 (5 cr), Centre for Research and Development of Higher Education, Institute of Behavioural Sciences, University of Helsinki, Finland. Final Grade: Excellent.

University pedagogy I, Spring 2010 (10 cr) UP 1 Teaching and learning in higher education (5 credits) and UP 2 Constructive alignment in course design (5 credits), Centre for Research and Development of Higher Education, Institute of Behavioural Sciences, University of Helsinki, Finland. Final Grade: Excellent.

The ABC of animal experiments 2010 – FELASA accredited scientists' competence (Category C), Viikki Campus, 4–15 January 2010, University of Helsinki, Finland.

First aid: theory and practice (Red Cross, 6-h), Division of Pharmaceutical Technology, Faculty of Pharmacy, 7th December 2009, University of Helsinki, Finland.

Managing staff and finances, Viikki Campus (Biocenter 2), 26th November 2009, University of Helsinki, Finland.

Certification in the practice of Industrial Hygiene (IH) by the American Board of Industrial Hygiene (3.5 certification maintenance (CM) points). Approval Number: 09-3557; Course Name/Location: 4th International Conference on Nanotechnology, Helsinki, Finland; Sponsor: Occupational and Environmental Health; Start/End Date & MultiOffering Year 26–29.8.2009, Paasitorni, Helsinki, Finland.

How to write a competitive proposal for Framework 7, Dr. Sean McCarthy, 3rd September 2008, University of Helsinki, Finland.

Research Projects – Funding ID (Total 2009–2021, >5.5 M€) 1.9.2018–31.3.2022: Bayer Oy: Development of polymer based nano drug delivery system for targeted therapy to brain. Total

fund: 350 000 €. 1.1.2019–31.5.2020: European Research Council (Proof of concept grant): Biohybrid and biodegradable nanovaccines for cancer

immunotherapy (grant no. 825020). Total fund: 150 000 € 1.9.2018–31.8.2021: Academy of Finland: Towards personalized nanomedicines for targeted drug delivery and imaging for

ischemic myocardial injury (Project # 317042), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 300 000 €

1.6.2018–31.12.2019: Academy of Finland: Remote-controlled therapeutic manipulation and release from magnetic porous silicon nanoparticles (Project # 319330), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 20 900 €

1.6.2018–31.5.2019: Norwegian Research Council: Consortium together with Nacamed AS (Norway) company: NANO CARRIER - Porous Silicon Nano particles will be produced and studied, in vitro and in vivo for cancer diagnostics, therapy and imaging. Total fund: ~600 000 €. Dr. Santos’ team share: ~200 000 €

1.7.2017–31.7.2020: HiLIFE Membership, University of Helsinki: P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 180000€

1.1.2017–31.12.2018: Academy of Finland: Consortium together with Aalto University: Autonomous Microrobotics for Studying

Cell-Particle Interactions and Responses (AUROCH, Project #1304844). Total fund: 546 990 €. Dr. Santos’ team share: 279 495 €

1.5.2016–30.4.2019: Sigrid Jusélius Foundation: Development of Nanovaccines for Cancer Therapy (Decision no. 9-3-2016), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 159 000€

1.1.2016–30.6.2016: Centre for International Mobility, CIMO: Neonatal Fc Receptor-mediated transcytosis of bioengineered nanoparticles towards systemic delivery of antidiabetic drugs and proteins (Decision no. TM-15-9802), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 9000€

1.1.2015–30.4.2015: Centre for International Mobility, CIMO: Advanced multifunctional platforms for bone regeneration (Decision no. TM-14-9353), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 6000€

1.1.2015–31.8.2016: Academy of Finland (additional research costs): Porous silicon nanodelivery systems for enhanced targeted cancer therapy (NANOPSi-CAN, Project #281300), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 183 333 €

1.3.2014–28.2.2019: TEKES: 3i Innovative Induction Initiative. Consortium between University of Helsinki, Helsinki University Central Hospital, and Aalto University. Total fund: 7 512 363 €. Dr. Santos’ team share: ~300 000 €.

1.3.2014–30.11.2014: Centre for International Mobility, CIMO: GLP-1 and GLP-1 analogues nanotechnology based systems for prevention and therapy of diabetes (Decision no. TM-13-9048), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 10 800€

1.1.2014–31.12.2017: Drug research doctoral programme (DRDP), Faculty of Pharmacy (University of Helsinki): Targeted drug delivery into injured myocardium with porous silicon nanoparticles: myocardial remodelling and repair. P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 159 290€.

1.1.2014–31.12.2016: Biocentrum Helsinki Membership (2014–2016), University of Helsinki: (Decision no. 429/51/2013), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 105 000€

1.9.2013–31.3.2014: Centre for International Mobility, CIMO: Targeted drug delivery into injured myocardium with porous silicon nanoparticles: myocardial remodelling and repair (Decision no. KM-13-8622), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 8400€

1.1.2013–31.12.2017: University of Helsinki Research Funds: Total fund: 125 000 € 1.1.2013–31.12.2017: European Research Council (Starting Grant): Multistage–multifunctional porous silicon nanovectors for

directed Theranostics (grant no. 310892), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 1499603€ 1.8.2012–31.3.2013: Centre for International Mobility, CIMO: Nanoporous silicon for targeted immunotherapy (Decision no.

TM-12-8201), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 9600€

1.9.2011–31.12.2014: Academy of Finland (additional research costs): Porous silicon nanodelivery systems for enhanced targeted cancer therapy (NANOPSi-CAN, Project #256394), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 366 665 €

1.9.2011–31.8.2016: Academy of Finland: Porous silicon nanodelivery systems for enhanced targeted cancer therapy (NANOPSi-CAN, Project #252215), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 391 478 €

24.2.2011: Pharmaceutical Technology and Industrial Pharmacy (PARTICLE): Participation in the Research Evaluation 2011, Faculty of Pharmacy, University of Helsinki.

1.2.2011–31.12.2013: The National Doctoral Programme in Nanoscience (NGS-NANO): Biofunctionalization of porous silicon nanoparticles for brain cancer therapy, P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 69 000 €

1.1.2009–31.12.2011: University of Helsinki Research Funds: Biodistribution and biofunctionalization of nanoporous silicon particles (BioNanoPSi-Project #490039), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 120 000 €

1.1.2009–31.12.2011: Academy of Finland: In vitro/in vivo toxicity and bioavailability of mesoporous silica/silicon based materials (VIVOTOXSi-Project #127099), P.I.: Dr. Hélder A. Santos (University of Helsinki). Total fund: 195 450 €

1.1.2008–31.12.2011: Academy of Finland: Mesoporous silicon based composite materials as oral drug delivery systems (ComPSi-Project #122314), P.I.: Prof. Jouni Hirvonen (University of Helsinki).

1.1.2008–31.12.2011: Boehringer Ingelheim GmbH (Germany): Towards enhanced bioavailability of poorly soluble drugs utilizing PSi (ENBIPSi project, 20082011), P.I.: Prof. Jouni Hirvonen (University of Helsinki).

1.4.2007–31.12.2007: Academy of Finland: Mesohuokoiset materiaalit oraalisessa lääkeannostelussa (HUMALA-Project #211048), P.I.: Prof. Jouni Hirvonen (University of Helsinki).

1.3.2006–31.3.2007: Academy of Finland: ESPOM graduate school, P.I.: Prof. Kyösti Kontturi (Helsinki University of Technology). 22.9.2003–28.2.2006: Training and Mobility Research EU network: Supramolecular Self-Assembly of Interfacial Nanostructures

(SUSANA), RTN, IHP programme of the EU, contract number HPRN-CT-2002-00185. P.I.: Prof. Kyösti Kontturi (Helsinki University of Technology); Network Coord.: Prof. Han J. Vos (Dublin City University).

Main Research Interests Fields of research: Pharmacy/Pharmaceutical Technology, Biomaterials, Nanoscience and Nanotechnology, Biomedicine, Nanomedicine, Medical Engineering and Biotechnology, Chemical Engineering Research areas: Pharmaceutical nanotechnology, improving the physicochemical properties of poorly soluble drugs, porous silicon/silica, nanoparticle/microparticles, targeting and drug delivery, in vitro and in vivo, cellular interactions, biodistribution,biocompatibility, toxicity, surface biofunctionalization, radiolabelling, and bio-imaging, cancer therapy, theranostic nanosystems, nanomedicines

Important National/International Academic Activities [1] Harvard University, Experimental Soft Condensed Matter Group, School of Engineering and Applied Sciences/Department of

Physics, visiting researcher, November 2012, USA (Research group leader: Prof. David A. Weitz). [2] Saarland University, Department of Biopharmaceutics and Pharmaceutical Technology, visiting researcher, February–

March 2008, Germany (Research group leader: Prof. Claus-Michael Lehr). [3] University of Porto, Laboratory of Analytical Chemistry and Electrochemistry, Department of Chemistry, visiting

researcher (through the EU Training and Mobility programme – SUSANA), June 2005, Portugal (Research group leader: Prof. Eng. Antonio F. Silva).

[4] Ecole Polytechnique Fédérale de Lausanne, Laboratory of Electrochemical Physics and Analytical, visiting researcher (through the EU Training and Mobility programme – SUSANA), March 2005, Switzerland (Research group leader: Prof. Hubert Girault).

[5] University of Warwick, Division of Electrochemistry and Interfaces, Department of Chemistry, visiting researcher (through the EU Training and Mobility programme – SUSANA), June 2004, England (Research group leader: Prof. Patrick Unwin).

[6] University of Liverpool, Laboratory of Electrochemistry and Nanochemistry, Department of Chemistry, visiting researcher (through the EU Training and Mobility programme – SUSANA), February 2004, England (Research group leader: Prof. David Schiffrin).

[7] University of Kuopio, Department of Pharmaceutics, visiting researcher, December 2003, Finland (Research group leader: Prof. Arto Urtti).

Invited/Selected Public Talks (Note: *Speaker)

[138] H. A. Santos*, "Hydrogel nanofibrous scaffolds for rapidly recruiting angiogenesis relative cells in diabetic wounds", 2nd Diabetic Wound Healing Workshop, 3-4 January 2019, Roskilde University, Roskilde, Denmark (invited talk).

[137] H. A. Santos*, "Multifunctional nanomedicine for ischemic myocardial injury, Biohybrid nanovaccine for melanoma, and Microfluidics for drug delivery and biomedical applications", Course on Nanomedicine and Nanotechnology, 3-7 December 2018, University of Tromsø – The Arctic University of Norway, Norway (invited talk).

[136] H. A. Santos*, "Nanomedicines for targeted drug delivery and precision medicine", Course on Biosensor Assemblies and their Applications, Health and Biosciences Doctoral Programme (HBS-DP), 3-4 November 2018, Oulu, Finland (invited talk).

[135] H. A. Santos*, "Biohybrid nanovaccines for improved treatment of aggressive melanoma", Cancer Immunotherapy Worskhop and Training, 20-23 November 2018, Riga Stradins University, Riga, Latvia (invited talk).

[134] H. A. Santos*, "Homing-targeted nanomedicines for biomedical applications", The Royal Society of Chemistry Finnish section Annual Seminar 2018, 2 November 2018, Åbo Akademi University, Turku, Finland (invited talk).

[133] H. A. Santos*, "Small size particles for a big medical revolution", FinPharmSci 2018, 31 October 2018, Helsinki, Finland (invited talk).

[132] H. A. Santos*, "Engineered nanomedicines for enhanced tumor-penetration, prevent cancer recurrence, and tissue regeneration", College of Life Science and Technology, Huazhong University of Science and Technology, 20 October 2018, Wuhan, China (invited talk).

[131] H. A. Santos*, "Engineered nanomedicines for enhanced tumor-penetration and tissue regeneration", Department of Chemistry and Materials Science, University of Nanjing Forestry University, 17 October 2018, Nanjing, China (invited talk).

[130] H. A. Santos*, "Engineered materials to improve tumor-penetration, prevent cancer recurrence, promote vascularization and tissue regeneration", Seminar Cycle in Biophysical Sciences, Scuola Normale Superiore - Pisa, 17 September 2018, Pisa, Italy (invited talk).

[129] H. A. Santos*, "Nanoparticles for imaging and therapy", Workshop "From Nanotoxicology to Nanomedicine", 7 September 2018, Tallinn, Estonia (invited talk).

[128] H. A. Santos*, "Multifunctional nanomedicines for targeted drug delivery and imaging for ischemic myocardial injury", CLINAM 2018, 2–5 September 2018, Basel, Switzerland (invited talk).

[127] H. A. Santos*, "Advanced multifunctional nanomedicines for biomedical applications", Frontiers in Delivery of Therapeutics, 21-24 August 2018, Tartu, Estonia (invited talk).

[126] H. A. Santos*, "Nanomedicines for personalized medicines", Università degli Studi “G. d´Annunzio” di Chieti – Pescara, 18-22 June 2018, Chieti, Italy (Erasmus staff mobility for teaching).

[125] H. A. Santos*, "Popularising science", FinPharmaNet Symposium 2018, 14-15 June 2018, Hotel Korpilampi/Nuuksio, Finland (invited lecture).

[124] H. A. Santos*, "Fabrication of multifunctional nanoparticles by microfluidics for drug delivery and biomedical applications", International Workshop in Microfluidics and Pharmaceutical Nanotechnology, 7-8 June 2018, Viikki campus - University of Helsinki, Helsinki, Finland (invited talk).

[123] H. A. Santos*, "Fabrication of multifunctional nanoparticles by microfluidics for drug delivery and biomedical applications", Micronano System Workshop, 13-18 May 2018, Otaniemi campus - Aalto University, Espoo, Finland (invited talk).

[122] H. A. Santos*, "Nanomedicine - the 'MacGyver' Swiss Army knife to regenerate a healthy heart", TEDxHelsinkiUniversity 2018, 11 May 2018, Helsinki, Finland (selected talk).

[121] H. A. Santos*, "Nanomedicines and biomedical engineering", Scientific Teaser Talks, Faculty of Medicine – Biomedicum, 22 March 2018, Helsinki, Finland (invited lecture).

[120] H. A. Santos*, "Biohybrid multistage nanovaccines based on acetalated dextran-coated pSi nanoparticles: development of an innovative formulation", PSST 2018, 11-16 March 2018, La Grande Motte, France. (selected lecture).

[119] H. A. Santos*, "Multifunctional nanoparticles targeted to the endocardial layer of the injured heart", Faculty of Medicine – Biomedicum, 15 November 2017, Helsinki, Finland (invited lecture).

[118] H. A. Santos*, "Multifunctional nanohybrid based on porous silicon nanoparticles, gold nanoparticles and acetalated dextran for liver regeneration and acute liver failure theranostics", Leibniz Institute for Photonic Technologies (IPHT), 12-14 November 2017, Jena, Germany (invited lecture).

[117] H. A. Santos*, “Nanomedicines that will revolutionize the healthcare” (Virtual Talk), Kharkiv National Medical University, 8–10 November 2017, Ukraine (invited talk).

[116] H. A. Santos*, "Multifunctional nanoparticles for drug delivery and pharmaceutical applications ", Faculty of Pharmaceutical Science, Prince of Songkla University, 24 October 2017, Songkhla, Thailand (invited lecture).

[115] H. A. Santos*, "Targeted nanomedicines for biomedical applications ", Medical School, Zhejiang University, 22 October 2017, Hangzhou, China (invited lecture).

[114] H. A. Santos*, "Multifunctional nanoparticles for biomedical applications ", School of Life Science and Technology, Huazhong University of Science and Technology, 20 October 2017, Wuhan, China (invited lecture).

[113] H. A. Santos*, "Porous silicon based nanocomposites for biomedical applications: from cancer to cardiovascular diseases", 6th International Symposium on Surface and Interface of Biomaterials, 16–19 October 2017, Chengdu, China (invited plenary talk).

[112] H. A. Santos*, "Multifunctional nanoparticles for biomedical applications ", Department of Biomedical Engineering, Chongqing University, 15 October 2017, Chongqing, China (invited lecture).

[111] H. A. Santos*, "Fighting diseases with invisible and tiny drug carriers (nano-medicines)", Faculty of Pharmacy, 14 September 2017, Helsinki, Finland (invited talk).

[110] H. A. Santos*, "Targeted nanomedicines for cancer, diabetes and cardiovascular diseases: why the size matters?", YUCOMAT 2017, 4–8 September 2017, Herceg Novi, Montenegro (invited plenary talk).

[109] H. A. Santos*, "Course - Microfluidics for pharmaceutical applications: From nano/micro systems fabrication to controlled drug delivery", KU Leuven, 11-13 July 2017, Leuven, Belgium (1 Day course, invited).

[108] H. A. Santos*, "Lessons from nanomedicines: from the nanoworld to biomedical applications", Institute of Biotechnology, Vilnius University, 30 June 2017, Vilnius, Lithuania (invited talk).

[107] H. A. Santos*, "Multifunctional nanomaterials for drug delivery and theranostic applications", 3rd International Conference Current Trends in Cancer Theranostics (CTCT-2017), 25-29 June 2017, Pakruojis Castle, Lithuania (invited keynote talk).

[106] H. A. Santos*, “Small is more: nanomaterials for drug delivery and theranostic applications”, Centre of Excellence in Computational Nanoscience Seminar − Aalto University, 9 June 2017, Espoo, Finland (invited talk).

[105] H. A. Santos*, "Homing-target nanoporous silicon nanoparticles for myocardium infarcted therapy", 2017 E-MRS Spring Meeting and Exhibit, 22-25 May 2017, Strasbourg, France (invited talk).

[104] H. A. Santos*, "Targeting drug nanosystems for cancer, diabetes and cardiovascular diseases", II International Congress in Health Sciences Research: Towards Innovation and Entrepreneurship, 17-20 May 2017, Covilhã, Portugal (invited talk).

[103] H. A. Santos*, "Preclinical development of nanomedicines for biomedical applications", Deptartment of Rheumatology and Inflammation Research, University of Göteborg, Göteborg, Sweden (invited talk).

[102] H. A. Santos*, "Targeted nanomedicines for cancer, diabetes and cardiovascular diseases: from concept to application", Spring workshop, 10-12 May 2017, Tartu, Estonia (invited talk).

[100] H. A. Santos*, “Targeted nanosystems for imaging and therapy: why the size matters?”, Biomedicum Helsinki Seminar

– University of Helsinki, 17th March 2017, Helsinki, Finland (invited talk). [100] H. A. Santos*, “Nanomedicines: Bridging Between Chemistry and Pharmaceutical Nanotechnology”, Finnish Chemical

Society Spring Meeting, 8th March 2017, Helsinki, Finland (invited talk). [99] H. A. Santos*, “Nanomedicines for Healthcare Applications”, 3rd BiotechHealth Symposium - "Emerging technologies in Health

Sciences", 21st June 2016, i3s – Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal (invited talk).

[98] H. A. Santos*. “Preclinical Development of Porous Silicon Nanocomposites For Translational Biomedical Research”,

Faculty of Pharmacy Research Seminar 2016, 31st May 2016, Koskenranta – Helsinki, Finland (invited talk). [97] H. A. Santos*, “Bridging between engineering and medicine – Current applications of nanomedicines for cancer,

diabetes and cardiovascular diseases”, The 5th Portuguese Young Chemists Meeting (5th PYCheM) and 1st European Young Chemists Meeting (1st EYCheM), 26–29 April 2016, Centro Cultural Vila Flor – Guimarães, Portugal (Plenary Lecture).

[96] H. A. Santos*, “Innovative Biomaterials for Healthcare Applications”, Aveiro Institute of Materials, University of Aveiro, Portugal, 26 April 2016, Aveiro, Portugal (invited talk).

[95] H. A. Santos*, “The invisible nano-world for treating diseases”, Meilahti Campus Day – Biomedicum Helsinki, Faculty of

Medicine, 22nd March 2016, University of Helsinki, Helsinki Finland (invited talk). [94] H. A. Santos*, “Past, present and future of nanomedicines”, Department of Pharmacy, Faculty of Health and Medical

Sciences, 18th March 2016, University of Copenhagen, Copenhagen, Denmark (invited talk). [93] H. A. Santos*, “Porous silicon based drug delivery systems”, Introduction to Nanoscience course, Faculty of Pharmacy,

22nd February 2016, University of Helsinki, Helsinki, Finland (invited talk). [92] H. A. Santos*, “Targeted drug delivery using nanocarriers”, Orion Pharma, 12 February 2016, Espoo, Finland (invited

talk). [91] H. A. Santos*, “Innovative nanomedicines for heart and brain diseases”, Biomedicum Helsinki, Institute of Biomedicine

– University of Helsinki, Heart Regeneration & Repair Investigators' Meeting, 16 December 2015, Helsinki, Finland (invited talk).

[90] H. A. Santos*, “Innovative micro and nanocomposites for biomedical applications”, I3s/INEB – University of Porto, 2 December 2015, Porto, Portugal (invited talk).

[89] H. A. Santos*, “Targeted nanomedicines for cancer therapy”, The 11th Conference in Organic and Medicinal Chemistry by the Portuguese Chemical Society (SPQ), 1-3 December 2015, Porto, Portugal (invited talk).

[88] H. A. Santos*, “Pre-clinical development of micro and nanocomposites for translational medicine”, NanotechItaly 2015,

25–27th November 2015, Bologna, Italy (invited talk). [87] H. A. Santos*, “Preclinical development of nanomedicines − bridging the gap between engineering and medicine”,

Department of Chemistry, University of Basel, 24th November 2015, Basel, Switzerland (invited talk). [86] H. A. Santos*, “Innovative drug delivery systems”, 3i Regeneration Partnering Event, 28 October 2015, Helsinki, Finland

(invited talk). [85] H. A. Santos*, “Micro- and nanocomposites for translational medicine: bridging the gap between nanotechnology and

medicine”, Department of Chemistry, University of Eastern Finland, 22 October 2015, Joensuu, Finland (invited talk). [84] H. A. Santos*, “In vivo biocompatibility of porous silicon-based materials for controlled drug delivery applications”,

pSiMedica, Malvern Hills Science Park, 28 July 2015, Worcestershire, UK (invited talk). [83] H. A. Santos*, “Hybrid multicomposites for biomedical applications”, School of Life Sciences, Fudan University, 27 June

2015, Shanghai, China (invited talk). [82] H. A. Santos*, “Preclinical development of biomaterials for translational medicine: from bench to bedside”, Jiangsu

Province Hospital, 26 June 2015, Nanjing, China (invited talk). [81] H. A. Santos*, “Porous biomaterials and microfluidics for biomedical applications”, Orthopedic Institute, Soochow

University, 25 June 2015, Suzhou, China (invited talk). [80] H. A. Santos*, “Bioinspired nanomedicines towards personalized therapy”, Bioinspired Engineering and Biomechanics

Center and School of Life Science and Technology, Xi’an Jiaotong University, 24th June 2015, Xi'an, China (invited talk). [79] H. A. Santos*, “Fabrication of nanomedicines for precisely controlled combination therapy”, Stem Cell and Regeneration

Center, The Academy of Military Medical Sciences, 19th June 2015, Beijing, China (invited talk). [78] H. A. Santos*, “Novel drug delivery technologies for biomedical applications”, 12th Annual Controlled Release

Conference, 2021 April 2015, London, UK (invited talk). [77] D. Liu, H. Zhang, B. Herranz-Blanco, M.-A. Shahbazi, C.-F. Wang, E. Mäkilä, V. Balasubramanian, S. Cito, Y. Zhang, T. M.

Sikanen, D. A. Weitz, J. Salonen, J. Hirvonen, H. A. Santos*, “Smart and multitasking nanomedicines for personalized

therapy and diagnostics: a microfluidic approach”, 4th International Conference on Multifunctional, Hybrid and

Nanomaterials (Hybrid Materials 2015), 913 March 2015, Sitges, Spain (selected oral presentation).

[76] H.A. Santos*, “Nanoparticles for drug targeting”, 3iRegeneration Tekes Project Workshop, 26-27th February 2015, Sannäsin Kartano, Porvoo, Finland (invited lecture).

[75] H.A. Santos*, Strategic planning with your own research group: case “pharmaceutical nanotechnology and nanoporous silicon

group”, Leadership Program for Academic Staff – Competence Management, 25th of November 2014, Biocenter 2, Viikinkaari 5, Faculty of Pharmacy, University of Helsinki, Finland (invited lecture).

[74] H.A. Santos*, On-chip production of nanocomposites for drug delivery applications using microfluidics, Turku University Centre

for Materials and Surfaces, 8th Annual MATSURF Seminar, 10nd October 2014, Turku, Finland (invited lecture). [73] H.A. Santos*, Smart hybrid porous silicon-based multicomposites for controlled drug delivery and combination therapy,

Laboratory of Physical Chemistry, Åbo Akademi University, 2nd October 2014, Turku, Finland (invited lecture). [72] H.A. Santos*, Smart and multitasking nanomedicines for personalized therapy, Biomedicum Helsinki, University of

Helsinki, 15th September 2014, Helsinki, Finland (invited lecture). [71] H.A. Santos*, One small particle, one giant leap forward in disease treatment and diagnosis, Viikki Biocenter Monday

Lectures Autumn 2014, University of Helsinki, 8th September 2014, Helsinki, Finland (invited lecture). [70] H.A. Santos*, Microfluidic assisted one-step fabrication of porous silicon/ acetalated dextran nanocomposites for

precisely controlled combination chemotherapy, 2nd Annual Conference on International Translational Nanomedicine

(ITNano), 25–27th July 2014, Boston, USA (keynote speaker). [69] H.A. Santos*, Advanced porous silicon-based composites for precisely controlled multi-drug delivery and targeting

applications, Institute for Microelectronics and Microsystems Unit of Naples, National Research Council, 16th June 2014, Naples, Italy (invited lecture).

[68] H.A. Santos*, Nanoporous biomaterials for pharmaceutical applications, Orion Pharma, 30th April 2014, Espoo, Finland (invited lecture).

[67] H.A. Santos*, 3iNano: targeting of drugs to heart and brain, Lammi 2014, Faculty of Pharmacy, Science Fair, 23rd April 2014, Lammi biological station, Lammi, Finland (invited lecture).

[66] H.A. Santos*, Novel nanocomposites for biomedical applications: From bench to bedside, Biocentrum Helsinki – day,

14th April 2014, Helsinki Congress Paasitorni, Finland (invited lecture). [65] H.A. Santos*, CHEM-Alumni Career Development: From University Doctoral Student to Full Professional Scientist, Career

Support– event at Aalto CHEM, Learning Hub Living Room, 24th March 2014, Department of Materials Sciences (Vuorimiehentie 2), Aalto University, Finland (invited lecture).

[64] Shahbazi M.-A., Wang C.-F., Almeida P.V., Mäkilä E., Kaasalainen M., Airaksinen A., Sarparanta M., Salonen J., J.Hirvonen, Santos H.A.* Novel porous silicon nanocomposites for cancer therapy, PSST2014, Porous Semiconductors Science and

Technology Conference, 914th March 2014, Benidorm, Spain (selected oral presentation). [63] Santos H.A. Mesoporous silicon materials for controlled drug delivery and biomedical applications. Chemistry Seminar

Series, Department of Chemistry, School of Chemistry Technology, Aalto University, 14th February 2014, Espoo, Finland (invited lecture).

[62] Santos H.A. ERC StG: Multistagemultifunctional porous silicon nanovectors for directed theranostics. The Third Annual FPTP Network Meeting – Biomedicinskt centrum BMC, 29–31 January 2014, Uppsala, Sweden (Invited speaker).

[61] Wang C.-F.*, Mäkilä E. M., Kaasalainen M. H., Salonen J. J., Hirvonen J. T., Santos H. A. Methotrexate congugated to PSi for sustain drug release and enhanced cell uptake. The Third Annual FPTP Network Meeting – Biomedicinskt centrum BMC, 29–31 January 2014, Uppsala, Sweden (short oral presentation).

[60] Pessi J.*, Miroshnyk I., Santos H., Yliruusi J., Weitz D. A., Mirza S. Microfluidic approach for preparing protein loaded polycaprolactone microspheres. The Third Annual FPTP Network Meeting – Biomedicinskt centrum BMC, 29–31 January 2014, Uppsala, Sweden (short oral presentation).

[59] Santos H.A.*, Porous silicon nanomaterials to revolutionize drug targeting and delivery, Controlled Release Society

Italian Local Chapter, 21st23rd November 2013, University of Pavia, Italy (Invited speaker). [58] Santos H.A.*, Mesoporous biomaterials in drug delivery. Controlled Release Drug Delivery Systems course, 3 cr (course

no. 59072, 3 ECTS, 18 h), Faculty of Pharmacy, University of Helsinki, 25th September 2013, Helsinki, Finland (Invited lecture).

[57] Santos H. A.*, Porous silicon as an emerging healthcare technology: How far are we?, Pharmaceutical Research

Seminars, 11th September 2013, Faculty of Pharmacy, University of Helsinki, Finland (Young Researcher’s Award Lecture). [56] Santos H. A.*, Tumor-homing peptide boosts porous silicon nanovectors accumulation in vivo. The European CLINAM &

ETPN Summit, 23-26 June 2013, Basel, Switzerland (Selected oral presentation). [55] Santos H. A.*, Nanotechnology for healthcare. Visit of H.E. Mrs. Fátima Perestrello, the Portuguese Ambassador in

Finland, to the Faculty of Pharmacy, University of Helsinki, 13th June 2013, Helsinki, Portugal (Invited lecture). [54] Santos H. A.*, Biodegradable and biocompatible nanostructured porous silicon materials for biomedical applications.

The Andalusian Centre for Nanomedicine and Biotechnology, BIONAND, 7th June 2013, Malaga, Spain (Invited lecture). [53] Santos H. A.*, Multifunctional nanovectors for personalized medicine. International Iberian Nanotechnology

LaboratoryINL, 23rd May 2013, Braga, Portugal (Invited lecture). [52] Santos H. A.*, Porous silicon nanoparticles for cancer therapy. Nanoforum (course #590297, 2 ECTS), 20-21 May 2013,

University of Helsinki, Helsinki, Finland (Invited lecture). [51] Santos H. A.*, Porous silicon nanomaterials for drug delivery applications: from concept to clinic. Department of

Pharmacology and Toxicology, University of Oulu, 15th May 2013, Oulu, Finland (Invited lecture). [50] Santos H. A.*, Peptide-modified porous silicon nanoparticles for tumor targeting. Division of Pharmaceutical Technology,

Faculty of Pharmacy, University of Helsinki, 30th April 2013, Helsinki, Finland (Invited lecture). [49] Santos H. A.*, Nanomaterials for drug delivery and personalized medicine. Department of Biology, Faculty of Medicine,

University of Azores, 10th April 2013, Ponta Delgada – Azores, Portugal (Invited lecture). [48] Santos H. A.*, Nanovectors for biomedical imaging and personalized therapy. Viikki Biocenter Monday Lectures Spring

2013, University of Helsinki, 25th March 2013, Helsinki, Finland (Invited lecture). [47] Santos H. A.*, Nanostructured porous silicon for pharmaceutical applications: safety, controlled drug delivery and

imaging. Kemian Päivät ja ChemBio Finland (Finnish Chimistry and ChemBio days), 21st March 2013, Helsinki, Finland (Invited lecture).

[46] Santos H.A.*, Advances in nanoporous silicon technology for pharmaceutical applications: from concept to brain tumour

targeting. Division of Pharmacology and Toxicology, Faculty of Pharmacy, University of Helsinki, 8th March 2013, Helsinki, Finland (Invited lecture).

[45] Santos H.A.*, Nanostructured porous silicon-lipid composites for biomedical applications. AAPS-University of Porto

Student Chapter conference: Abel Salazar Biomedical Sciences Institute/Faculty of Pharmacy, University of Porto, 17th December 2012, Porto, Portugal (Invited lecture).

[44] Santos H.A.*, Nanoporous silicon as drug delivery system for cancer therapy. Faculty of Medicine, Norwegian University

of Science and Technology, 19th November 2012, Trondheim, Norway (Invited lecture). [43] Santos H.A.*, Pharmaceutical applications of nanostructured porous silicon: Where do we stand and where do we go?

Department of Drug Sciences, Faculty of Pharmacy, University of Pavia, 25th October 2012, Pavia, Italy (Invited lecture). [42] Santos H.A.*, Nanostructured porous silicon for translational medicine. Molecular Cancer Biology Program, Faculty of

Medicine, Biomedicum, University of Helsinki, 10th October 2012, Helsinki, Finland (Invited lecture). [41] Santos H.A.*, Porous silicon and silica biomaterials for drug delivery. Controlled Release Drug Delivery Systems course,

3 cr (course no. 59072, 3 ECTS, 18 h), Faculty of Pharmacy, University of Helsinki, 1st October 2012, Helsinki, Finland (Invited lecture).

[40] Santos H.A.*, L.M. Bimbo, J. Salonen, A.J. Airaksinen, M.B. Linder, J. Hirvonen, Nanostructured Porous Silicon

Nanoparticles for Drug Delivery and Diagnostic Applications, The 9th Central European Symposium on Pharmaceutical Technology, 20-2 September 2012, Dubrovnik, Croatia (selected oral presentation).

[39] L. Bimbo*, M. Sarparanta, E. Mäkilä, T. Laaksonen, P. Laaksonen, J. Salonen, M. Linder, J. Hirvonen, A. Airaksinen, H. Santos, Surface Modified Nanoporous Silicon Particles for Improved Cell Viability, The 9th Central European Symposium on Pharmaceutical Technology, 20-2 September 2012, Dubrovnik, Croatia (selected oral presentation).

[38] Santos H.A*, Porous Silicon Nanovectors for Directed Theranostics. Faculty of Pharmacy, University of Helsinki, 14th September 2012, Helsinki, Finland (Invited keynote lecture).

[37] Santos H.A*, Nanoengineered Silicon-Based Materials for Drug Delivery Applications. Department of Polymer

Engineering, University of Minho, 26th July 2012, Braga, Portugal (Invited lecture). [36] Santos H.A*, Multifunctional Porous Silicon Nanocarriers in Preclinical Development: Moving from Bench to Bedside.

Institute of Biomedical Engineering, University of Porto, 25th July 2012, Porto, Portugal (Invited lecture). [35] Santos H.A*, Nanostructured Porous Silicon Platform for Advanced Biomedical Applications. Department of Chemistry

and Biochemistry, Faculty of Sciences, University of Porto, 24th July 2012, Porto, Portugal (Invited lecture). [34] Santos H.A*, Biomedical applications of porous silicon: drug delivery, safety and therapy. Nanoforum (course #590297,

2 ECTS), 24–25 May 2012, University of Helsinki, Helsinki, Finland (Invited lecture). [33] Santos H.A.*, Multistage–multifunctional porous silicon nanovectors for directed theranostics: porous silicon

nanovectors. ERC Starting Grant interview – Life Sciences (LS7), Covent Garden–Place Rogier, 8th of May 2012, Brussels, Belgium (Invited interview).

[32] Santos H.A.*, Nanocarriers for advanced drug delivery applications: porous silicon materials. School of Engineering and

Applied Sciences/Department of Physics, Harvard University, 10th April 2012, Cambridge, USA (Invited lecture). [31] Santos H.A.*, Bimbo L.M., Sarparanta M., Makila E., Salonen J., Laaksonen T., Linder M.B., Airaksinen A., Hirvonen J.

Hydrophobin-coated nanoporous silicon for controlled drug delivery and therapy applications. 8th International Conference, Porous Semiconductors – Science and Technology (PSST-2012), 25–30 March 2012, Malaga, Spain (Selected oral presentation).

[30] Participation in panel discussion: How to bridge the gap between engineers, clinical scientists and doctors. 3rd International Congress BioNanoMed 2012 – Nanotechnology enables Personalised Medicine, 1–2 March 2012, Krems, Austria (Invited).

[29] Santos H.A.*, Bimbo L.M., Sarparanta M., Mäkilä E., Salonen J., Linder M.B., Airaksinen A.J., Hirvonen J. Biocompatibility of nanoporous silicon materials for controlled drug release, diagnostics and therapy. 3rd International Congress BioNanoMed 2012 – Nanotechnology enables Personalised Medicine, 1–2 March 2012, Krems, Austria (Selected short oral presentation).

[28] Santos H.A.*, Nanoparticles in drug delivery. Tfy-125.4003 (5 ECTS) Nanoscience III: Molecular Nanoscience course (2 h),

15th February 2012, Aalto University, Espoo, Finland (Invited lecture). [27] Santos H.A.*, Nanotechnology research at the Viikki campus of the University of Helsinki: from the bench to the bedside.

Visit of H.E. Mr. Anibal Cavaco Silva, the President of the Portuguese Republic to Aalto University, 9th February 2012, Espoo, Finland (Invited oral presentation).

[26] Santos H.A.*/Bimbo L.M., Nanoporous silicon materials for enhanced drug release. NORDFORSK – Future Performance

Testing of Pharmaceuticals Seminar, 7th February 2012, University of Helsinki, Helsinki, Finland (Invited lecture). [25] Santos H.A.*, Porous silicon for improving drug release and drug bioavailability. Laboratory of Radiochemistry, Faculty

of Sciences, 2nd November 2011, University of Helsinki, Helsinki, Finland (Invited lecture). [24] Santos H.A.*, Nanoporous materials for controlled drug delivery. Controlled Release Drug Delivery Systems course, 3 cr

(course no. 59072, 3 ECTS, 18 h), 5th October 2011, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland (Invited lecture).

[23] Bimbo L.M.*, Sarparanta M., Mäkilä E., Laaksonen T., Peltonen L., Lehto V.-P., Salonen J., Airaksinen A.J., Hirvonen J., Santos, H.A. Mesoporous silicon particles as biocompatible drug delivery agents for enhancement of drug permeation.

5th PSSRC Symposium, 26-27 September 2011, Helsinki, Finland (Selected short oral presentation). [22] Sarparanta M., Bimbo L.M., Mäkilä E., Salonen J., Santos H.A., Laaksonen T., Hirvonen J., Lehto V.-P., Laaksonen P., Linder

M.B., Airaksinen A.J.* 18F-Radiolabeling as a tool in the evaluation of porous silicon particles for drug delivery. XX Helsinki Drug Research Congress, 19-21 September 2011, Helsinki, Finland (Selected oral presentation).

[21] Santos H.A.*, Nanoporous materials for non-invasive imaging and improving drug bioavailability. Biopharmaceutics in Pharmaceutical Product Development 2011 course, 3 cr (course no. 590278 Biofarmasia farmaseuttisessa

tuotekehityksessä, 3 ETCS, 18 h), 1st September 2011, University of Helsinki, Helsinki, Finland (Invited lecture). [20] Santos H.A.*, Nanoporous silicon materials for improved drug bioavailability. Public trial lecture for docentship (Adjunct

Professor) in Pharmaceutical Nanotechnology, 25th August 2011, University of Helsinki, Helsinki, Finland. [19] Bimbo L.M.*, Mäkilä E., Sarparanta M., Laaksonen T., Airaksinen A.J., Lehto V.-P., Salonen J., Hirvonen J., Santos H.A.,

Mesoporous silicon particles as emerging nanomedicine carriers. 3rd European Summer School in Nanomedicine, 14–19 June 2011, Wittenberg, Germany (Selected oral presentation).

[18] Bimbo L.M.*, Mäkilä E., Sarparanta M., Laaksonen T., Lehto V.-P., Airaksinen A.J., Salonen J., Hirvonen J., Santos H.A.,

Biocompatibile functionalization of silicon nanoparticles. 3rd PharmSciFair, 13–17 June 2011, Prague, Czech Republic (Invited speaker).

[17] Bimbo L.M., Sarparanta M., Mäkilä E., Laaksonen T., Lehto V.-P., Peltonen L., Airaksinen A.J., Salonen J., Hirvonen J., Santos H.A.*, Multifunctional porous silicon for therapeutic drug delivery and imaging. 3rd PharmSciFair, 13–17 June 2011, Prague, Czech Republic (Invited speaker).

[16] Santos H.A.*, Current research in mesoporous materials. Biocentrum Helsinki Networking Event – “Connecting Aalto

University and University of Helsinki Scientists”, 1st June 2011, Dipoli, Espoo-Helsinki, Finland (Short presentation). [15] Santos H.A.*, Nanoporous silicon materials as a nanomedicine platform: from drug delivery and imaging to cancer

therapy. 20th April 2011, The Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland (Invited lecture).

[14] Santos H.A.*, Multifunctional porous silicon as a nanomedicine platform for therapeutic drug delivery and imaging.

14th April 2011, Faculty of Medicine, Department of Pharmacy, University of Tartu, Tartu, Estonia (Invited lecture). [13] Santos H.A.*, Nanoporous silicon as a nanomedicine platform for imaging and delivery of therapeutics. Tumor

Progression and Metastasis Lab Biomedicum, Faculty of Medicine, University of Helsinki, 28th March 2011, Helsinki, Finland (Invited lecture).

[12] Bimbo L.M., Sarparanta M., Salonen J., Riikonen J., Mäkilä E., Airaksinen A., Lehto V.-P., Hirvonen J., Santos H.A.*, Nanoporous

silicon materials in drug delivery applications. 23rd European Conference on Biomaterials (ESB2010), 11–15 September 2010, Tampere, Finland (Keynote presentation).

[11] Sarparanta M.*, Mäkilä E., Heikkilä T., Salonen J., Lehto V.-P., Santos H.A., Hirvonen J., Airaksinen A.J. Biodistribution of 18F-labeled thermally hydrocarbonized porous silicon nanoparticles. 7th International Conference Porous

Semicondictures Science & Technology (PSST-2010), 14–19th March 2010, València, Spain (Selected oral presentation). [10] Rotko T.*, Mäkilä E., Santos H., Laaksonen T., Salonen J., Hirvonen J., Peltonen L. Tablet formulations of drug-loaded

mesoporous silicon particles: enhanced dissolution for poorly soluble drugs. 7th World Meeting on Pharmaceutics,

Biopharmaceutics, and Pharmaceutical Technology, 8–11th March 2010, Malta (Selected oral presentation). [9] Santos H.A.*, Bimbo L.M., Salonen J., Riikonen J., Mäkilä E., Laaksonen T., Peltonen L., Lehto V.-P., Hirvonen J. Towards

enhanced bioavailability and feasibility of nanoporous silicon materials as an alternative for oral drug delivery. 7th World Meeting on Pharmaceutics, Biopharmaceutics, and Pharmaceutical Technology, 8–11th March 2010, La Valletta, Malta (Selected oral presentation).

[8] Santos H.A.*, Mesoporous materials for therapeutic applications: from in vitro to animal tests. Pharmaceutical Research Seminars, Division of Pharmaceutical Technology, Faculty of Pharmacy, 3rd February 2010, University of Helsinki, Finland (Invited lecture).

[7] Santos H.A.*, PSi micro- & nanoparticles regarding drug release, drug permeability, cytotoxicity and cellular

association, 1st National MedPSi Days, 1-2.10.2009, University of Helsinki, Finland (Invited lecture). [6] Heikkilä T.*, Mäkilä E., Ojanen S., Qu H., Louhi-Kultanen M., Riikonen J., Salonen J., Kumar N., Murzin D. Y., Santos H.A.,

Laaksonen T., Peltonen L., Hirvonen J., Lehto V.-P. Effect of comminution on microparticle properties of mesoporous silicon and silica materials. European Symposium on Comminution and Classification (ESCC09), 15–18th September 2009, Helsinki University of Technology, Espoo/Otaniemi, Finland (Selected oral presentation).

[5] Santos H.A.*, Riikonen J., Heikkilä T., Salonen J., Bimbo L., Laaksonen T., Peltonen L., Lehto V.-P., Hirvonen J. Evaluation

of the cytotoxicity of meso/nanoporous silicon based materials. 2nd Pharmaceutical Sciences Fair & Exhibition (PharmSciFair), 7–12 June 2009, Nice, France (Selected oral presentation).

[4] Santos H.A.*, Nanoporous Silicon: a platform for delivery of therapeutics. Pharmaceutical Research Seminars, Division

of Pharmaceutical Technology, Faculty of Pharmacy, 22nd April 2009, University of Helsinki, Finland (Invited lecture). [3] Santos H.A.*, Nanoporous silicon/silica: an alternative for drug delivery. IX Seminar of the Faculty of Pharmacy and

Centre of Drug Research (CDR), Lammi Biological Station, 16–17th April 2009, University of Helsinki, Finland (Invited lecture).

[2] Santos H.A.*, Heikkilä T., Riikonen J., Lautenschlager T., Laaksonen T., Peltonen L., Salonen J., Kumar N., Murzin D.Y., Lehto V.-P., Hirvonen J. Investigating Cell Toxicity and Drug Dissolution Profiles Using Mesoporous Silica and Silicon Based Materials. 6th World Meeting on Pharmaceutics, Biopharmaceutics, and Pharmaceutical Technology, 7–10th April 2008, Barcelona, Spain (Selected oral presentation).

[1] Salonen J.*, Mäkilä E., Riikonen J., Heikkilä T., Santos H., Kaukonen A.-M., Peltonen L., Laaksonen T., Hirvonen J., Kilpeläinen M., Vlasova M., Herzig K.-H., Mönkäre J., Järvinen K., Lehto V.-P. Surface Chemistry Effects in Drug Delivery Applications of Porous Silicon. Porous Semicondictures Science & Technology (PSST-2008), 10–14th March 2008, Mallorca, Spain (Selected oral presentation).

Scientific Expert Positions [1] Head of the Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki (2018–

2021). [2] Head of the Preclinical Drug Formulation and Analysis Group, Faculty of Pharmacy, University of Helsinki (2016–current). [3] Head of the Nanomedicines and Biomedical Engineering Group, Faculty of Pharmacy, University of Helsinki (2009–

current). [4] Prof. responsible for the major subject Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki (2018–

current). [5] Board Member of the Leadership Group, Faculty of Pharmacy, University of Helsinki (2017–2021). [6] Board Member of the Drug Research Program, Faculty of Pharmacy, University of Helsinki (2018–2021). [7] Director of the Doctoral Programme in Drug Research, Faculty of Pharmacy, University of Helsinki (2018–2021). [8] Board Member of the Doctoral Science in Health Sciences, University of Helsinki (2018–2021). [9] FinPharmaNet Steering Group member, Finland (2018–2021). [10] Board Member of the research line of Pharmacy students, Faculty of Pharmacy, University of Helsinki (2018–2021). [11] Member of the committee for the international research assessment at the Faculty of Pharmacy, University of

Helsinki, 2018–2019. [12] Member of the organizing committee of ULLA, European University Consortium for Pharmaceutical Sciences, 2018–

2019. [13] Vice-chair of the Focus Group in Nanomedicine and Nanoscale Drug Delivery (NNDD), Controlled Release Society

(2018-Current) [14] Management Committee Member of the CA COST Action CA17140: Cancer nanomedicine - from the bench to the

bedside, Finland (2018–current). [15] Management Committee Member of the CA COST Action CA17116: International Network for Translating Research on

Perinatal Derivatives into Therapeutic Approaches, Finland (2018–current). [16] Member of the Scientific Committee of the 6th Portuguese Young Chemists Meeting, May 15-18, 2018, Setúbal,

Portugal [17] Helsinki Institute of Life Science Fellow, 2017-2020, University of Helsinki. [18] Expert panel member, Networks of Centres of Excellence (NCE) of Canada, Natural Sciences and Engineering Research

Council of Canada, 2018. [19] Expert Committee for the Agency for Assessment and Accreditation of Higher Education (A3ES; ‘Agência de Avaliação

e Acreditação do Ensino Superior) – Assessment of Master’s degree proposal for University of Algarve, Portugal (January– June 2017).

[20] European Science Foundation College of Expert Reviewers, France (2016–2019) [21] Novo Nordisk Foundation Challenge Programme Expert Committee, Denmark (January–December 2016) [22] Drug Research Programme scientific committee, Faculty of Pharmacy, University of Helsinki, Finland (January 2016–

current) [23] Word Portuguese Network Adviser for Science (December 2014–2018). [24] Journal Editor: Mesoporous Biomaterials (LinkedIn Journal's page) (March 2013–Current; journal founder), Open

Materials Science (January 2018–current; journal founder), BioMed Research International (May 2013–current), PLOS ONE (2015–current), and Journal of Healthcare Engineering (2016–current).

[25] Reviewer Editor (2018): Frontiers in Oncology; Frontiers in Materials; Frontiers in Pharmacology of Anti-Cancer; Frontiers in Bioengineering and Biotechnology.

[26] Guest Editor for the Advanced Materials (IF = 21.95). Special issue: Materials Science in Finland, Wiley: John Wiley & Sons, Inc., March–December 2017.

[27] Guest Editor for the Current Drug Metabolism. Special issue: In vitro models used in drug discovery: drug absorption and metabolism, Bentham Science Publishers Ltd., September 2010–September 2012.

[28] Guest Editor for the Current Drug Discovery Technologies. Special issue: Innovative technology for drug delivery applications: from nanocapsules and biopolymers to inorganic materials, Bentham Science Publishers Ltd., May 2010– September 2011.

[29] Book Editor: “Microfluidics for Pharmaceutical Applications: From Nano/Micro Systems Fabrication to Controlled Drug Delivery”, Elsevier. October 2018.

[30] Book Editor: “Porous Silicon for Biomedical Applications”, Elsevier. February 2014. [31] Member of the Expert Panel on Vaccines: The European Society for Translational Medicine (EUSTM). August 2013–

December 2015. [32] Guest Editor for the Biomatter. Special issue: Development of Porous Biomaterials for Tissue Engineering and Drug

Delivery Applications, Landes Bioscience, January 2012–December 2012. [33] International Editorial Advisory Board Member: Drug Delivery Letters (2011–current), Biomatter (2011–current),

Pharmaceutical Nanotechnology (2012–current), and World Journal in Pharmacology (2012–2018), International Journal of

Innovations in Biological and Chemical Sciences (2012–2014); American Journal of Digestive Disease (2013–current); AIMS Materials Science (2013–current); Journal of Biopharmaceutics and Biotechnology (2013–current); Frontiers in

Bioengineering and Biotechnology and Materials section Frontiers in Biomaterials (2015–current); Current Nanoscience (2016–current); Advances in Materials Science and Engineering (2017–current); Advances Therapeutics (2018–current); Nano Reviews & Experiments (2018–current); International Journal of Molecular Sciences — Section Board for 'Materials Science' (2018–current).

[34] Member of the organizing committee: Viikki Campus Post Doc Day. December–April 2012. [35] Organizer and chair: International Autumn School, 2–6 September 2013, Turku Finland. [36] Host and organizer of the visit of the Portuguese Ambassador in Finland to the Faculty of Pharmacy, University of

Helsinki (13.6.2013). [37] PSST2014, Porous Semiconductors Science and Technology Conference, 914th March 2014, Benidorm, Spain:

Chairman of part II of Session 6: "Medical diagnostics, imaging and therapy"; Part of the committee to select the 3 best posters of the day for the flash poster presentation.

[38] WBC 2016, World Biomaterials Congress, 17–22th May, 2016 Montreal, Canada: Chairman of 516 - General session on “Biomaterials for cancer therapy”.

[39] II International Congress in Health Sciences Research: Towards Innovation and Entrepreneurship, 17–20 May 2017, Covilhã, Portugal: Member of the Scientific and Award Committee.

[40] Member of the Scientific Committee of 6th Portuguese Young Chemists Meeting and abstract evaluator, 15–18th May 2018, Setúbal, Portugal.

[41] Organizer member of the 12th FinPharmaNet Symposium 2018, 14–15 June 2018. [42] Organizing Committee, International Conference on Nanomaterials and Nanotechnology, October 29–31, 2018, London,

UK. [43] Program Committee member, BIOMAT2019, 8-9 May 2019, Weimar, Germany. [44] Program Committee member, EUROMAT2019, 1–5 September 2019, Stockholm, Sweden.

[45] Frontiers in Delivery of Therapeutics, 21–24 August 2018, Tartu Estonia: Chairman “Nanoparticles in Drug Delivery”.

Active referee in International Journals: Peer review of manuscripts (100):

Langmuir Molecular Pharmaceutics Journal of Physical Chemistry B Springer Science + Business Media Drug Discovery Today Journal of Materials Research Journal Biomedical Chromatography European Journal of Pharmaceutics and Journal of Controlled Release Biopharmaceutics Drug Delivery Letters Clinica Chimica Acta European Journal of Pharmaceutical Sciences Journal of Chromatography B International Journal of Pharmaceutics Pharmaceutical Research Nanotoxicology Current Medicinal Chemistry Current Drug Discovery Technologies Journal of Biomedical Nanotechnology Particle and Fibre Toxicology Toxicology Research Colloids and Surfaces B: Biointerfaces RSC Advances WIREs Nanomedicine & Nanobiotechnology Therapeutic Delivery Journal of the American Chemical Society Chemical Reviews Expert Opinion on Drug Delivery Biomaterials Science Bioconjugate Chemistry Macromolecular Bioscience Journal of Nano Research Journal of Nanopharmaceutics and Drug Acta Biomaterialia Delivery Expert Opinion on Drug Metabolism & Journal of Materials Chemistry B Toxicology Dalton Transactions Small Chemical Research in Toxicology

Current Drug Delivery Chemical Engineering Journal Journal of Biomedical Materials Research Part A Biotechnology Advances Journal of Biomedical Materials Research Part B Scientific Reports ACS Applied Materials & Interfaces Industrial & Engineering Chemistry Research Biomaterials Enzyme and Microbial Technology Nanomedicine: Nanotechnology, Biology and Pharmaceutical Nanotechnology Medicine International Journal of Nanomedicine Drug Development and Industrial Pharmacy Macromolecular Rapid Communications ACS Nano European Journal of Inorganic Chemistry Porous Semiconductors-Science and Technology Elsevier: Micro and Nano Technologies Series (PSST) Conferences 2014&2016 PLOS ONE Future Science ebooks Journal of Membrane Science Chandos Publishing Frontiers in Bioengineering and Biotechnology Woodhead Publishing Silicon Nanomedicine Lab on a Chip Journal of Tissue Engineering Journal of Medicinal Chemistry Nitric Oxide: Biology and Chemistry World Biomaterials Congress – 2016 Chemistry – A European Journal Basic & Clinical Pharmacology & Toxicology Biochimica et Biophysica Acta - General Subjects Wiley-VCH (Books) Nanoscale Research Letters Molecular Therapeutics Chemical Communications Proceedings of the National Academy of Biomacromolecules Sciences Current Drug Targets Angewandte Chemie International Edition Advanced Materials Nano Today Advanced Functional Materials Chemical Science Advanced Health Materials Pharmaceutical Patent Analyst Advanced Drug Delivery Reviews Chemical Society Reviews Journal of Drug Delivery Science and Technology Oncotarget Advanced Therapeutics Particle & Particle Systems Characterization Materials Today Molecules NPG Asia Materials JOVE Theranostics ACS Applied Nano Materials Materials Horizons

Assessment of candidates for academic positions / International projects [1] Evaluation panel member: Ana Francisca Araújo (Probative year) for doctoral thesis dissertation, ICBAS, University of

Porto, 4th of April 2014, Portugal. [2] Evaluation of Assistant Professor Ester Segal’s Academic Qualifications for Promotion to the Rank of Associate Professor

with Tenure, August 2013, Department of Biotechnology and Food Engineering, Technion – Israel Institute of Technology, Haifa, Israel.

[3] Doctoral theses Grading Committee (1): Heli Paukkonen: “Nanofibrillar cellulose for encapsulation and release of pharmaceuticals”, 6th of July 2018, Faculty

of Pharmacy, University of Helsinki, Finland.

[4] Doctoral theses examiner/reviewer (20): Chiara Di Cicco: “Photo-responsive oil core based polymer nanocapsules”, November 2018, Department of Chemical,

Materials and Industrial Production Engineering, Università Degli Studi Di Napoli “Federico II”, Italy. Melissa Santi: “Modulation of nanoparticle interaction with serum proteins for targeted delivery of therapeutic

payloads”, July–August 2018, Scuola Normale Superiore of Pisa, Italy. Chen Qian: “Facile Synthesis of Hollow Porous Silica Micro- and Nanospheres Application”, July–August 2018,

Department of Chemistry and Materials Science, Aalto University, Finland. Li Kong: “Photo-activated Drug Delivery Systems”, February 2018, Leiden Institute of Chemistry, Leiden University, The

Netherlands. Sara Feola: “Optimized armed oncolytic adenoviral vaccines (PeptiCRAd) for an enhanced anti-cancer immune

response”, November 2017, Department of Molecular Medicine and Medical Biotechnology, Università Degli Studi Di Napoli “Federico II”, Italy.

Angela Langella: “Fabrication of in vitro epithelial tissues as a testing platform for drug delivery systems”, No-vember 2017, Department of Chemical Engineering, Materials and Industrial Production Engineering, Università Degli Studi Di Napoli “Federico II”, Italy.

Mubashar Rehman: “Solid Lipid Nanoparticles for Thermoresposive Drug Delivery: Fabrication and Eval-uation”, November 2017, Department of Pharmacy, Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Pakistan.

Muhammad Safdar: “Manganese oxide based catalytic micromotors: synthesis, characterization and ap plications”, September 2017, Faculty of Science and Forestry, University of Eastern Finland, Finland.

Giulia Laccarino: “Multifunctional polymer nanocapsules via layer by layer on oil based liquid templates”,

March 2017, Department of Chemical Engineering, Materials and Industrial Production, Università Degli Studi Di Napoli “Federico II”, Italy.

Eva Haartman: “Design and Evaluation of Nanoparticle-Based Theranostic Systems”, February 2017, Åbo Fac-ulty of Science and Engineering, Akademi University, Finland.

G. Gopi: “Formulation and Evaluation of Nanoparticulate Drug Delivery System Containing an Antidiabetic Drug”, Autumn 2016, Department of Pharmacy, Annamalai University, India.

K. Viveksarathi: “Formulation and Evaluation of Nanoparticles of Anti-Parkinson Drug”, Autumn 2016, De-partment of Pharmacy, Annamalai University, India.

D. Kumarasamyraja: “Study of Wound healing Activity of Some Medicinal Plants using Nanoparticle For mulation”, Spring-Summer 2016, Department of Pharmacy, Annamalai University, India.

Muhammad Imran Khan: “Development and Evaluation of Niosomal Drug Delivery System containing Antiinflammatory Drug”, Spring 2016, Department of Pharmacy, Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Pakistan.

Monica Terracciano: “Bioengineered Porous Silica Devices For Biomedical Applications”, Spring 2016, Faculty of Pharmacy, University of Naples Federico II, Italy (European PhD).

Venkateshwaran K.: “Efficient Delivery of Drugs to the Posterior Segment of Eye Using Nanoparticulate Systems”, Autumn 2015, Faculty of Technology, Anna University, India.

Fernanda Raquel da Silva Andrade: “Self-Assembled Polymeric Micelles as Powders for Pulmonary Administration of Insulin”, Spring 2015, Faculty of Pharmacy, University of Porto, Portugal (European PhD).

Ying Zhu: “Micropatterned Porous Silicon Photonic Crystal towards Microarray-based Cell Sensing”, Autumn 2014, School of Chemistry, The University of New South Wales, Australia.

Lotta Bergman: “Influence of surface functionalization on the behavior of silica nanoparticles in biological systems”, Spring 2014, Department of Natural Sciences, Åbo Akademi University, Finland.

Dibakar Mullick: “Metal Catalyzed Coupling of Amine and Alcohol Surrogates with Aryl Halides: Efficient Synthesis of Anilines and Phenols”, Autumn 2013, Department of Pharmaceutical Engineering and Technology, Bharathidasan University, India.

[5] Doctoral theses opponent (6):

I. Melissa Santi: “Modulation of nanoparticle interaction with serum proteins for targeted delivery of therapeutic payloads”, 17th September 2018, Scuola Normale Superiore of Pisa, Italy. Final decision: Honors.

II. Anne-Mari Anton Willmore: “Silver nanoparticles for cancer research”, 17th November 2017, Lab of Cancer

Biology, University of Tartu, Tartu, Estonia. Final decision: Approved. III. Nattha Kerdsakundee: “Development and Evaluation of Curcumin Raft-forming Systems for Peptic Ulcer

Treatment”, 17th October 2017, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai,

Songkla, Thailand. Final decision: Excellent. IV. Maria João Bidarra Tavares Gomes: “Modulation of drug efflux at the blood-brain barrier through targeted

siRNA delivery via nanoparticles”, 10th April 2017, Abel Salazar Biomedical Sciences Institute, University of

Porto, Portugal. Final decision: Approved. V. Lotta Bergman: “Influence of surface functionalization on the behavior of silica nanoparticles in biological

systems”, 3rd October 2014, Department of Natural Sciences, Åbo Akademi University, Finland. Final decision: Approved.

VI. José Adolfo Oliveira Ribeiro (Chemistry): “Characterization and Optimization of Electrochemical Sensors for

Biogenic Amines”, 12.4.2013, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Portugal. Final decision: Approved with honors.

[6] Master theses opponent (2):

I. Ana Francisca Araújo (Pharmacy): “Understanding the mechanism of protein intestinal permeation by using enterocyte-based in vitro co-culture cells”, 17.12.12, Instituto Superior de Ciências de Saúde - Norte, Gandra, Portugal. Final decision: Approved; Grade 19 out of 20.

II. Francisca Villanova: “Characterization and in vitro evaluation of dual drug loaded porous Si particles”,

26.10.2012, University of Pavia, Pavia, Italy. Final decision: Approved; Grade: Excellent.

[7] Evaluator for "The Daniel Shiran Memorial Research Prize 2013" in Biomedicine ($3000), Technion Israel Institute of Technology, Israel. December 2012.

[8] Evaluator of Docentship (Adjunct Professorship; Chem. Eng.) application for Dr. Jessica Rosenholm, Department of

Natural Sciences, Åbo Akademi University, Finland (October 2012). Final decision: Approved. [9] Evaluator for international research projects (99) from 34 international research foundations/institutions:

European Science Foundation (1), 10.2018: total funding evaluated of ca. +150 k€. The Icelandic Research Fund (1); September–October 2018; total funding evaluated of ca. 413.2 k€.

Cancer Research Trust, New Zealand (1); September–October 2018; total funding evaluated of ca. 150 k€.

Auckland Medical Research Foundation (1); September–October 2018; total funding evaluated of ca. 91.4 k€. Networks of Centres of Excellence (NCE) of Canada, Natural Sciences and Engineering Research Council of Canada

(1); June–August 2018; total funding evaluated of ca. 16 m€.

H2020 FETOPEN-01-2018-2019-2020 (RIA), EU (5); June–July 2018; total funding evaluated of ca. 18 m€.

Foundation for Polish Science, Poland (1); total funding evaluated of ca. 0.5 m€, May 2018.

The LEaDing Fellows Post-docs programme (1) (H2020-Marie Skłodowska-Curie COFUND Programme): Delft University of Technology, Leiden University, Erasmus University Rotterdam, Leiden University Medical Centre and Erasmus University Medical Centre; May 2018.

“la Caixa” Foundation (3), Spain; total funding evaluated of ca. 1.5 m€, April 2018.

U.S.-Israel Binational Science Foundation, Israel (1); total funding evaluated of ca. 0.2 m€, March 2018.

Swiss Cancer League, Switzerland (1); total funding evaluated of ca. 0.4 m€, March 2018.

University of Macau, Multi-Year Research Grant (MYRG) (2); total funding evaluated of ca. 1 m€, March 2018. H2020 FET-OPEN 2016–2017, EU, November–December 2017; total funding evaluated of ca. 9 m€. CÚRAM MedTrain Marie Sklodowska-Curie COFUND Fellowships, Ireland, June 2017.

Cancer Research UK, Project Grant (2); total funding evaluated of ca. 800 k€, January 2017; 2.5 m€, August 2018.

SÊR CYMRU II, Wales, Project Grant (1); total funding evaluated of ca. 300 k€, January 2017. Canada Council for the Arts–Killam, Canada, Project Grant (1); total funding evaluated of ca. 500 k€, December

2016. Wellcome Trust, UK, Project Grant (1); total funding evaluated of ca. 400 k€, November 2016.

Medical Research Council, UK, Project Grant (1); total funding evaluated of ca. 900 k€, November 2016.

Dutch Arthritis Foundation, The Netherlands, Project Grant (1); total funding evaluated of ca. 400 k€, July–August 2016.

iMed.ULisboa, Portugal, Call for Proposals (5 k€): “Academia-Industry Partnership for Collaborative Studies” (5), 2016.

Diabetes UK, Project Grant 2016 (1); total funding evaluated of ca. 177,343.00, June–July 2016. Novo Nordisk Foundation: Challenge Programme, Denmark: (10), 2016; total funding evaluated of ca. 8 m€ per

grant. Israel Science Foundation, General Individual Research Project, (1) 2016: total funding evaluated of ca. 1688192 NIS, March 2016. iMed.ULisboa, Portugal, Call for Proposals (5 k€): “Young Investigator’s Projects for Collaborative Cross-

disciplinary Studies” (7), 2015.

ARC Foundation for Cancer Research, France (1), 2015: total funding evaluated of ca. 1 630 716.00 €, April–May 2015.

Slovenian Research Agency (22), 2015–2018: total funding evaluated of ca.+1.6 m€. European Science Foundation (4), 2015&2016: total funding evaluated of ca. +500 k€. European Research Council (3):

o ERC Consolidator Grant 2015, Panel PE5 “Synthetic Chemistry and Materials” chaired by Professor Madder

o Annemieke (2nd Stage): total funding evaluated of ca. 1 560 000€ for 5 years, Spring 2015. o ERC Starting and consolidated Grants 2014, Panel LS7 “Diagnostic Tools, Therapies and Public Health”

chaired by Professor Stefanie Dimmeler (2nd Stage): total funding evaluated of ca. 3 m€ for 5 years, Summer–Autumn 2014

Life Sciences Research, Ministry of Science, Technology & Space, Israel (1): total funding evaluated of ca. 144 720 € for 2 years, June–July 2014.

The Austrian Science Fund (FWF), Austria (2): 2014&2015; total funding evaluated + 380 k€

The Netherlands Organisation for Scientific Research (NWO), The Netherlands (1): total funding evaluated of ca. 1 221 571.46 € for 5 years, December 2012.

The Swiss National Science Foundation (SNSF), Switzerland (4): 2012, 2013, 2014&2016: total funding evaluated +21 m€.

Research Foundation Flanders (FWO), Belgium (2): total funding evaluated ca. 541127€ for 4 years, Spring 2016. The Leverhulme Trust, UK (1): total funding evaluated of ca. 253 262 € for 3-years, March 2010.

Other Academic/Scientific Activities & Memberships in 2017

The Finnish Association of Pharmacy Teachers and Researchers (FOTY ry) Controlled Release Society (CRS) American Society for Nanomedicine (AENM) Finnish Society of Physical Pharmacy American Nano Society (ANS) Finnish Pharmaceutical Society European Federation for Pharmaceutical Sciences Pharmaceutical Solid State Research Cluster (PSSRC) (EUFEPS, 2012-2014) The National Doctoral Programme in Nanoscience Cancer Society of Finland Viikki Drug Discovery Program The European Society for Translational Medicine Society for Biomaterials (SFB) (EUSTM) European Society for Biomaterials (ESB) Finnish Union of University Professors European Society for Nanomedicine (ESNM) Finnish Chemical Society

Host of International Research Scientists or Public Personalities 30.6-3.7.2015 Prof. Christian Celia (Pharm.D., Ph.D.) from the Department of Pharmacy, University of Chieti – Pescara “G. d’Annunzio”, Chieti, Italy. Invited lecture: Nanotherapeutics: potential applications in therapy and future perspective. Teaching Visit to Faculty of Pharmacy, University of Helsinki, Finland. 4-5.6.2015 Prof. David E. Weitz, Harvard University, MA, USA; Prof. Tuomas Knowles, University of Cambridge, UK; Prof. Aaron Wheeler, Univerisity of Toronto, Canada; and Prof. Petra Dittrich, ETH Zurich, Switzerland. Visitors and Lecturers of MiNaPharmA workshop 2015, Faculty of Pharmacy, University of Helsinki, Finland. 1-3.3.2015 Dr. Luca de Stefano, Institute for Microelectronics and Microsystems Unit of Naples-National Research Council, Italy. Invited lecture: Hybrid Functional Interfaces: Engineering Biosensors and Biochip. Visit to Faculty of Pharmacy, University of Helsinki, Finland. 12-14.2.2015 Professor Prof. Ijeoma Uchegbu, University College London, UK. Invited lecture: Large Opportunities in Small Particles. Visit to Faculty of Pharmacy, University of Helsinki, Finland. 19.11.2014 Distinguished Professor Paul Weiss and Editor-in-Chief of ACS Nano (IF = 12.033), University of California, Los Angeles, USA. Invited lecture: Exploring the Ultimate Limits of Miniaturization. Visit to Faculty of Pharmacy, University of Helsinki, Finland. 07–18.10.2013 Dr. Michela Mori, Department of Drug Sciences, University of Pavia, Italy. Research Visit to Faculty of Pharmacy, University of Helsinki, Finland. 06–10.09.2013 Professor Carla Caramella, Department of Drug Sciences, University of Pavia, Italy. Invited lecture: Nanocarriers for drug delivery to overcome biological barriers. Teaching Visit to Faculty of Pharmacy, University of Helsinki, Finland. 06.09.2013 Distinguished Professor Erkki Ruoslahti, Sanford-Burnham Medical Research Institute in La Jolla, CA, USA. Invited lecture: Vascular zip codes in novel tumor therapies. Visit to Faculty of Pharmacy, University of Helsinki, Finland. 13.06.2013 Portuguese Ambassador in Finland, Your Excellency Dr. Fátima Prestrello; Prof. Dr. José Pereira Miguel and Prof. José Calheiros, respectively, President and Vice-preseident of the National Health Institute Doutor Ricardo Jorge (National Health Institute Doutor Ricardo Jorge); and Dr. Eva Falcão, Directorate-General of Health. 17–18.09.2012 Professor António J. Ribeiro, Center for Pharmaceutical Studies, Faculty of Pharmacy, University of Coimbra, Portugal. Invited lecture: M cell effect on intestinal uptake of insulin nanoparticle. Visit to Faculty of Pharmacy, University of Helsinki, Finland. 17–18.09.2012 Professor António J. Ribeiro, Center for Pharmaceutical Studies, Faculty of Pharmacy, University of Coimbra, Portugal. Invited lecture: M cell effect on intestinal uptake of insulin nanoparticle. Visit to Faculty of Pharmacy, University of Helsinki, Finland. 20–23.06.2012 Professor Clive Prestidge, Wark Research Institute, University of South Australia, Australia. Invited lecture: Nanostructure facilitating enhanced drug delivery. Visit to Faculty of Pharmacy, University of Helsinki, Finland. 18.04.2012 Dr. Oksana Leszczyszyn, Malvern, UK. Invited lecture: Malvern Instruments: Zetasizer Instrumentation and GPC Technologies. Visit to Faculty of Pharmacy, University of Helsinki, Finland. 04.02.2012 Prof. Mauro Ferrari, The Methodist Hospital Research Institute, USA. Invited lecture: Nanomedicine begets transport oncophysics. Visit to Faculty of Pharmacy, University of Helsinki, Finland. 13–16.10.2011 Professor Carla Caramella, Department of Drug Sciences, University of Pavia, Pavia, Italy. Invited lecture: Therapeutic platforms for the treatment of epithelial and skin ulcers, Faculty of Pharmacy, University of Helsinki, Finland. 20–24.06.2011 Professor Yeºim Aktaº, Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, 06100 Ankara, Turkey. Invited lecture: In vivo evaluation of the efficacy of brain targeted chitosan nanoparticles containing Z-DEVD-FMK on infarct volume, Faculty of Pharmacy, University of Helsinki, Finland.

Other Publishing & Information Activities, Newspapers/Radio/TV Programs & Popularizing Science

8.10.2018 Interview in newspaper and web based media (in Finnish)

Älylääke löytää tiensä syövän sisään ja vain sinne – Helsingin Viikissä kehitetään sähly­pallon näköistä

hiukkasta, johon lääkeaineet voi pakata, Helsingin Sanomat

24.9.2018 Interview in web based media (in English) My career – from start to Finnish (in English), Good News From Finland

10.9.2018 ERC PoC - ERC News (English) - ERC atribui subvenções de Prova de Conceito a quatro investigadores portugueses (Portuguese) - Quatro portugueses distinguidos entre 50 bolseiros do ERC pelo programa ‘Horizonte 2020’ (Portuguese) - Quatro portugueses distinguidos por Bruxelas recebem 150 mil euros (Portuguese) - Quatro portugueses entre os 50 bolseiros distinguidos pelo programa de investigação da União Europeia (Portuguese)

10.4.2018 Podcast on new materials: Chasing for smart materials (in English) “War against Cancer”, University of Helsinki

22.3.2018 Meilahden kampuspäivä / Meilahti Campus Day (Finnish High School event) Biomedicum, University of Helsinki

14.2.2018 Interview in web based media (in English) "Hélder Santos, the Editor-in-Chief of Open Material Sciences, Explains the Rationale Behind the Newly Launched Journal", highlighted in De Gruyter Open Access News 27.9.2017 Research news in web based media (in English) "Members of the European Parliament selected Team POCKit as the winner of the Impact Prize", highlighted in University of Helsinki News 11.9.2017 Research news in web based media (in English) "Heart-Protective Nanoparticles", highlighted in Advanced Science News (most read article of the week) 18.7.2017 Research news in web based media (in English) "Bridging the knowledge of different worlds to understand the big picture of cancer nanomedicines" (Invited Progress Report), highlighted in Advanced Science News – most downloaded and read publication of the month 9.6.2017 Research news in web based media (in Finnish) Huokoinen pii sopii ajoneuvoksi lääkemolekyyleille, highlighted in Diabetes 28.3.2017 Meilahden kampuspäivä / Meilahti Campus Day (Finnish High School event) Biomedicum, University of Helsinki 9.3.2017 Research news in web based media (in English) Prickly nanoparticles against cancer, highlighted in Advanced Science News 17.1.2017 Research news in web based media (in English) Superfast Production of Nanocomposites, highlighted in Chemistry Views 6.1.2017 Research news in web based media (in English) Porous silicon nanovaccines combat cancer, highlighted in Advanced Science News 30.12.2016 Research news in web based media (in English) Cancer immunotherapy and nanotechnology: Taking the best from two worlds, highlighted in Advanced Science News 24.11.2016 Research news in web based media Academy of Finland Video Award (in English), in Academy of Finland

“Award for Social Impact given to developer of targeted nanomedicines” 21.10.2016 Research news in web based media (in English and Finnish) PSi hits the spot: Hélder Santos’ research group is developing medicines of the future through microflows. Chasing a precise pill: Nanotechnology is making drugs more precise. But how? Hélder Santosin ryhmä kehittää mikrovirtojen pyörteissä tulevaisuuden lääkkeitä Nanotekniikka tekee lääkkeistä entistä tarkempia. Mutta miten? in University of Helsinki, Helsinki 19.4.2016 Research news in web based media (in Finnish) Nanorokotteilla syövän kimppuun in Finnish Cultural Foundation, Helsinki

22.3.2016 Meilahden kampuspäivä / Meilahti Campus Day (Finnish High School event) The invisible nano-world for treating diseases

Biomedicum, University of Helsinki 31.8.2015 Research news in web based media (in English) Oral medication for type 2 diabetes: one step closer with the help of a nanocarrier in Faculty of Pharmacy, University of Helsinki 8.4.2015 Research news in web based media (in English) Microfluidic platform produces homogenous nanoparticles with tunable properties in Faculty of Pharmacy, University of Helsinki 16.3.2015 Research news in web based media (in English) Unique technique helps building innovative nanomedicines for cancer therapy in Faculty of Pharmacy, University of Helsinki 11.3.2015 Participation in interview for radio media (in Portuguese) Portugueses pelo mundo in Radio Antena 1 20.12.2014 Participation in interview for written media (in Portuguese) Dr. Santos among the most influential portuguese working abroad!

in Jornal Expresso 27.5.2014 Participation in interview for written media (in English) Investigating Nanomedicines And Bioanalysis in Finland: Flying the flag for the research excellence, Insight Publishers Ltd 2014 9.5.2014 Participation in interview for written media (in English) Nano-medicine in Better Life - Millennium Technology Prize 10th Jubilee publication, Finland 13.4.2013 Participation in interview for written media (in Portuguese) Os emigrantes de talento, in Expresso newspaper, Portugal. December 2012 Participation in interview for written and web based media (in Finnish) Täsmälääkintää nanoteknologialla, in Apteekin Hyllyltä magazine, Finland. 26.12.2012 Participation in interview for written and web based media (in Portuguese) Um investigador português na área da nanotecnologia médica, in Mundo Português newspaper, Portugal. 10.09.2012 European Research Council (ERC) – Starting Grant 2013–2017: Research news in web Dr. HÉLDER A. SANTOS RECEIVES ERC STARTING GRANT FOR 2013-2017 (News in Finnish) Others: Faculty of Pharmacy (in Finnish) / Faculty of Pharmacy (in English) / Academy of Finland 22.05.2012 Research news in web based media (in English) Hélder A. Santos*, “Porous Silicon- Revolutionising Drug Targeting and Delivery”, NANO - the magazine for small science 2012, Issue 24, 19–22. 09.02.2012 Research news in web based media (in Finnish) Visit of H.E. Mr. Anibal Cavaco Silva, the President of the Portuguese Republic to Aalto University, Aalto University News, Finland. 08.07.2011 Research news in web based media (in English) Research Conducted at University of Helsinki Has Provided New Information about Drug Discovery, Design and Development, Therapeutics Daily News, USA. 21.01.2011 Participation in interview for written media (in Portuguese) An interview with Dr. Hélder A. Santos, Semanário Grande Porto (Regional Newspaper, in Portuguese), Portugal. 28.09.2010 Participation in interview for web based media (in Finnish/English) Portugal awards a citizen who is creating a science career in Finland / Portugali palkitsi Suomessa tutkijanuraa luovan kansalaisensa (University of Helsinki Webpage – in Finnish/English), Finland. 29.07.2010 Others (in Portuguese) – Portugal

Câmara Munincipal de Tarouca paid formal tribute to Hélder A. Santos for his Award in the 'Prémio Talento 2009' (Talent Prize in Science), Tarouca, Portugal. Others related: 1. Rádio Clube de Lamego (Participation in radio programme); 2. Secretário de Estado da Administração Local

3. MINISTÉRIO DOS NEGÓCIOS ESTRANGEIROS - Gabinete do Secretário de Estado das Comunidades Portuguesas; 4. Blog - Parliament member - Acácio Pinto

Participation in interview for written media (in Portuguese) - Local newspapers: 1. Douro Hoje; 2. Journal do Douro-1; 3. Journal do Douro-2; 4. Jornal Sempre Jovem.

23.07.2010 Participation in TV programme (in Portuguese) – Portugal Dr. Hélder A. Santos was Nominated and Winner of the “Prémio Talento 2009” (Talent Prize in Science), Attributed by the Portuguese Government, Ministry of Foreigner Affairs, State Secretary of the Portuguese Communities, Lisbon, Portugal. RTP1 video clip1 (National Public TV), RTP1 video clip2 (National Public TV)

LIST OF PUBLICATIONS Brief Summary:

Total number of publications (2003–2018): (printed, in press and submitted)

500

Theses & Monographs 3

Book Chapters 26

Books 2

Patents (granted) 3

Original research articles / Reviews / Editorials / Conference proceedings / Covers 236

Conference Abstracts (2003–2018) 229

Author’s h-index = 48 (http://www.scopus.com/authid/detail.url?authorId=9239103400; http://www.researcherid.com/rid/B-

5253-2009; http://scholar.google.fi/citations?user=K3Pj_gwAAAAJ), TOTAL CITATIONS > 5785 (4.12.2018, Scopus, Web of Knowl-edge, Scifinder, and Google Scholar).

University of Helsinki Profile: https://tuhat.halvi.helsinki.fi/portal/en/person/hsantos PubMed publications:

http://www.ncbi.nlm.nih.gov/pubmed?term=%28santos%20HA[Author]%29%20AND%20%28%222003%22[Date%20-%20Publication]%20%3A%20%223000%22[Date%20-%20Publication]%29

Publications and citations: http://www.helsinki.fi/~hsantos/publications.htm, http://www.researcherid.com/rid/B-5253-2009

and http://scholar.google.fi/citations?user=K3Pj_gwAAAAJ NOTE: The papers published since 2009 are as Principal Investigator and Group Leader.

Contents:

- Theses & Monographs Published (3) - Patents (3) - Book and Book Chapters– invited (26) - Articles in Peer-reviewed Scientific Journals (236) - Abstracts, Posters, & Oral Communications Presented in Scientific Meetings. Published in Conferences

Proceedings (229)

Theses & Monographs Published: Theses (3)

Doctoral Thesis, articles

[3] Hélder A. Santos, Improving the biomimetic properties of liquid/liquid interfaces: electrochemical and physicochemical characterisation (in English), 110 pp + 6 original article papers, (http://lib.tkk.fi/Diss/2007/isbn9789512288892/). Doctor of Science in Technology dissertation, Department of Chemical Technology, Laboratory of Physical Chemistry and Electrochemistry, Helsinki University of Technology, October 2007, Finland.

Final grade: cum laude.

Licentiate Thesis, articles

[2] Hélder A. Santos, Electrochemical and physicochemical characterisation of dextran sulfate–modified phospholipid

monolayers at soft interfaces (in English), 49 pp + 3 original article papers, (http://www.helsinki.fi/~hsantos/helder_licentiate2.pdf). Licentiate of Science in Technology thesis, Department of Chemical Technology, Laboratory of Physical Chemistry and Electrochemistry, Helsinki University of Technology, November 2005, Finland.

Final grade: cum laude.

Licentiate Thesis

[1] Hélder A. Santos, Adsorption studies of phosphatidylcholines at air–water and polarised liquid–liquid interfaces (in

Portuguese), 124 pp, (http://www.helsinki.fi/~hsantos/helder_Licentiate1.pdf). Licentiate in Chemistry thesis, Department of Chemistry, Laboratory of Analytical Chemistry and Electrochemistry, Faculty of Sciences, University of Porto, July 2003, Portugal.

Final grade: 18 out of 20 points.

Patents (3):

[1] Nadal E. G., Herranz-Blanco B., and Santos H. A. ”Plataforma reusable de ensamblaje de capilares de vidrio para micro fluidos (Reusable glass capillary microfluidic platform)”, Oficina Española de Patentes y Marcas, Spain, Patent No. ES2626263A1, 2017.

[2] Liu D., Fan J., Yin G., Santos H. A. “Nanoparticle with super high-drug loading capacity and manufacturing method thereof”,

Patent Nos. WO2017198078-A1 and CN107375238-A, 2017.

[3] Patent cooperation treaties (PCT/CN2017/083210 and PCT/CN2017/083208). Book and Book Chapters (26) – invited:

[26] Figueiredo P., Fontana F., Santos H. A.* Chapter XX: Nanomedicine Therapies. In: Handbook of In Vivo Chemistry in Mice: From Lab to Living System, Tanaka K., Vong K. (Eds.), Wiley-VCH Verlag GmbH. 2018, XX–XX. (submitted)

[25] Fontana F., Figueiredo P., Santos H. A.* Chapter XX: Advanced Nanovaccines for Immunotherapy Applications: From Concept

to Animal Test. In: Theranostic Bionanomaterials, Wenguo C., X. Zhao (Eds.), Elsevier B.V. 2018, XX–XX. (accepted) [24] Santos H.A.*, Liu D., Zhang H. (Editors) Microfluidics for Pharmaceutical Applications: From Nano/Micro Systems

Fabrication To Controlled Drug Delivery, Elsevier B.V. 2018, 1–495.

[23] Zhang Y., Liu D., Zhang H.,* Santos H. A.* Chapter 7: Microfluidic Mixing and Devices for Preparing Nanoparticulate Drug Delivery Systems. In: Microfluidics for pharmaceutical applications: from nano/micro systems fabrication to controlled drug delivery, Santos H. A., Liu D., and Zhang H. (Eds.), Elsevier B.V. 2018, 155–177.

[22] Fontana F., Ezazi N. Z., Tahir N., Santos H.A.* Chapter XX: CellNanoparticle Interactions: Toxicity and Safety Issues. In: Characterization of Pharmaceutical Nano- and Microsystems, Peltonen L. (Ed.), Wiley-VCH Verlag GmbH. 2018, XX–XX. (accepted)

[21] Zhang F., Santos H.A.* Chapter XX: Photo-Sensitive Materials for Constructing On-Demanded Drug Release Systems. In: Photoactive Inorganic Nanoparticles, Prieto J. P. and Bejar M. G. (Eds.), Elsevier B.V. 2018, XX–XX. (accepted)

[20] Figueiredo P., Bauleth-Ramos T., Hirvonen J., Sarmento B., Santos H.A.* Chapter 1: The Emerging Role of Multifunctional Theranostic Materials In Cancer Nanomedicine. In: Handbook of Nanomaterials for Cancer Theranostics, Conde J. (Ed.), Elsevier B.V. 2018, 1–31.

[19] Rahikkala A., Rosenholm J., Santos H. A.* Chapter 16: Biofunctionalized mesoporous silica nanomaterials for targeted drug

delivery. In: Biomedical Applications of Functionalized Nanomaterials, das Neves J. and Sarmento B. (Eds.), Elsevier B.V. 2018, 489–520.

[18] Martins J. M., Ferreira M. P. A., Ezazi N. Z., Hirvonen J. T., Santos H. A.* Chapter 4.1: Smart Materials With Tunable Properties for Tissue Regeneration. In: Nanotechnologies in Preventive and Regenerative Medicine, Uskokovic V. (Ed.), Elsevier B.V. 2018, 299– 349.

[17] Terracciano M.*, Rea I., De Stefano L., Santos H. A.* Chapter 9: Diatoms: A Natural Source of Nanostructured Silica for Drug Delivery. In: Diatom Nanotechnology: Progress and Emerging Applications, Losic D. (Ed.), Royal Society of Chemistry 2018, 201– 218.

[16] Decuzzi P., Coclite A., Lee A., Palange A. L., Di Mascolo D., Chiappini C., Santos H. A., Coluccio M. L., Perozziello G., Candeloro P., Di Fabrizio E., Gentile F.* Chapter 21: Nanoparticles for Biomedical Applications. In: Springer Handbook of Nanotechnology, Bhushan B. (Ed.), 4th Edition, Springer Science + Business Media 2017, 635–683.

[15] Santos H.A.* Chemotherapy with Porous Silicon. In: Handbook of Porous Silicon, Canham L. (Ed.), Springer Science + Business Media 2016, 1–15.

[14] Terracciano M., De Stefano L., Santos H.A., Martucci N.M., Ruggiero I., Rendina I., Migliaccio N., Lamberti A., Rea I. Chapter 9: Silica-based Nanovectors: from Mother Nature to Biomedical Applications. In: Algae - Organisms for Imminent Biotechnology, Thajuddin N. and Dhanasekaran D., (Ed.), InTech 2016, 211–235.

[13] Araújo F., Pereira C., Santos H.A., Granja P., Sarmento B., Functionalized Nanoparticles For Targeting the Gastrointestinal Apical Membrane Receptors. In e-book: Advances and Challenges in Oral Delivery of Macromolecules, Future Medicine Ltd. 2016, 140– 164.

[12] Shrestha N., Araújo F., Sarmento B., Hirvonen J., Santos H.A.* Chapter 3.1: Cell-based In Vitro Models for Buccal Permeability Studies. In: Concepts and Models for Drug Permeability Studies, B. Sarmento (Ed.), Elsevier Ltd. 2016, 31–40.

[11] Shahbazi M.A., Rostamizadeh K., Hamidi M., Santos H.A.* Copolymers: Drug Delivery. In: Encyclopedia of Biomedical Polymers and Polymeric Biomaterials, Ed. M.K. Mishra, Taylor & Francis 2015, 2192–2202.

[10] Ferreira M., Almeida P., Shahbazi M.-A., Correia A., Santos H.A.* Chapter 3.5: Current Trends and Developments for Nanotechnology in Cancer. In: Biomedical Chemistry: Current Trends and Developments, N Vale (Ed.), De Gruyter Open 2015, 290–342.

[9] Wang, C.-F., Santos H.A.* Copper-Free Click Chemistry Modification of Nanovectors For Integrin Targeted Cancer Therapy. In:

Integrins in Pharmacology Methods in Pharmacology and Toxicology, Y. J.s Kang and D. C. Casey (Eds.), Springer Science +

Business Media 2015, 115.

[8] Santos H.A., Bimbo L.M., Peltonen L., Hirvonen J.* Chapter 18: Inorganic Nanoparticles in Targeted Drug Delivery and Imaging. In: Targeted Drug Delivery – Concepts and Design, Sanyog J. and Devarajan P. (Eds.), Springer Science + Business Media 2015, 571–613.

[7] Santos H.A.* (Editor) Porous Silicon For Biomedical Applications, Elsevier Ltd., 2014, 1–526.

[6] Liu D., Shahbazi M.-A., Bimbo L.M., Hirvonen J., Santos H.A.* Chapter 7: Biocompatibility of Porous Silicon Materials . In: Porous Silicon For Biomedical Applications, Ed. H.A. Santos, Elsevier Ltd., 2014, 129–181.

[5] Zhang H., Shahbazi M.-A., Almeida P., Santos H.A.* Chapter 3: Mucus as a Barrier for Biopharmaceuticals and Drug Delivery Systems. In: Mucosal Delivery of Biopharmaceuticals: Biology, Challenges and Strategies. Eds. Sarmento B. and das Neves J., Springer Science + Business Media, 2014.

[4] Santos H.A.*, Mäkilä E., Bimbo L.M., Almeida P., Hirvonen J. Chapter 10: Porous Silicon Nanoparticles. In: Fundamentals of Pharmaceutical Nanoscience, Eds. I.J. Uchegbu, A.G. Schätzlein, W.P. Cheng, and A. Lalatsa, Springer Science + Business Media, 2013, 235–275.

[3] Santos H.A.*, Salonen J., and Bimbo L.M. Porous Silicon for Drug Delivery. In: Encyclopedia of Metalloproteins, Eds. R.H. Kretsinger, V.N. Uversky, E.A. Permyakov, and Springer Science+Business Media, 2013, New York, 1773-1781.

[2] Lehto V.-P.*, Salonen J., Santos H.A. and Riikonen J. Chapter 15: Nanostructured Silicon Based Materials as a Drug Delivery System for Insoluble Drugs. In: Drug Delivery Strategies for Poorly Water-Soluble Drugs, Eds. D. Douroumis and A. Fahr.

Wiley-Blackwell, 2013, 477508

[1] Santos H.A., Bimbo L.M., das Neves J., Sarmento B.* Chapter 9: Nanoparticulate Targeted Drug Delivery Using Peptides and

Proteins. In: Nanomedicine: Technologies and Applications, Ed. J.T. Webster, Elsevier Ltd., 2012, No. 49, 236301.

Articles in Peer-reviewed Scientific Journals:

2019 (1) [236] Pereira S. A. P., Passos M. L. C., Correia A., Mäkilä E., Salonen J., Araujo A. R. S. T., Santos H. A., Saraiva M. L. M. F. S.* Automatic

Methodologies to Perform Loading and Release Assays of Anticancer Drugs from Mesoporous Silicon Nanoparticles. Talanta 2019, 196, 277–283. (IF = 4.244, 2017). Publisher: Elsevier B.V.

2018 (48) Editorial [235] Santos, H. A.* Materials Science in Finland (Special Issue), Adv. Mater. 2018, 30(24), 1802557 (IF = 19.7, 2016). Publisher: Wiley-

VCH. (Invited Editorial) [234] Santos, H. A.* Cover Picture – Materials Science in Finland: (Adv. Mater. 24/2018) (Special Issue), Adv. Mater. 2018, 30(24),

1870167 (IF = 19.7, 2016). Publisher: Wiley-VCH. (Invited Editorial) Conference articles [233] Shahbazi M.-A.*, Sedighi M., Bauleth-Ramos T., Kant K., Correia A., Poursina N., Sarmento B., Hirvonen J., Santos H. A.* Targeted

reinforcement of macrophage reprogramming towards M2 polarization by IL-4 loaded hyaluronic acid particles. ACS Omega 2018, 3(12), 18444–18455 (OA, ISSN: 2470-1343). Publisher: American Chemistry Society.

[232] Martins J. P.*, Liu D., Fontana F., Ferreira M. P. A., Correia A., Valentino S., Kemell M., Moslova K., Mäkilä E., Salonen J., Hirvonen

J., Sarmento B., Santos H. A.* Microfluidic nanoassembly of bioengineered chitosan-modified fcrn-targeted porous silicon nanoparticles @ hypromellose acetate succinate for oral delivery of anti-diabetic peptides. ACS Appl. Mater. Interfaces 2018, 10(51), 44354–44367 (IF = 8.097, 2017). Publisher: American Chemistry Society.

[231] Li W., Mäkilä E., Salonen J., Saarma M., Sidorova Y., Santos H. A.*, GDNF mimetics delivery by porous silicon nanoparticles for

improved Parkinson’s disease management. Nanomedicine: NBM 2018, 14(5), 1848 (IF = 6.500, 2017). Publisher: Elsevier B.V. Refereed journal articles and reviews [230] Fontana F., Martins J. P., Torrieri G., Santos H. A., “Nuts and Bolts: Microfluidics for the Production of Biomaterials”, Adv. Mater.

Technol. 2018, XX, XXX (ISSN: 2365-709X). Publisher: Wiley-VCH. (Invited Review) (accepted). [229] Yan Y., Sun T., Zhang H., Ji X., Sun Y., Zhao X., Deng L., Qi J.*, Cui W.*, Santos H. A.*, Zhang H.*, “Euryale ferox seed-inspired

super-lubricated nanoparticles for treatment of osteoarthritis”, Adv. Funct. Mater. 2018. (IF = 13.3, 2017). Publisher: Wiley-VCH. (in press).

[228] Qi S., Zhang P., Ma M.*, Yao M., Wu J., Mäkilä E., Salonen J., Ruskoaho H., Xu Y., Santos H. A*, Zhang H.*, “Cellular internalization-

induced aggregation of porous silicon nanoparticles for ultrasound imaging and protein-mediated protection of stem cells”, Small 2018, XX(XX), XXX (IF = 9.59, 2017). Publisher: Wiley-VCH. (in press).

(Hot topic in Drug Delivery, Wiley) [227] Imlimthan S., Otaru S., Keinänen O., Correia A., Lintinen k. S., Santos H. A., Airaksinen A. J., Kostiainen M. A., Sarparanta M.*,

Radiolabeled Molecular Imaging Probes for the in Vivo Evaluation of Cellulose Nanocrystals for Biomedical Applications, Biomacromul. 2018, XXX, XX–XX. (IF = 5.738, 2017). Publisher: American Chemical Society. (in press).

[226] Liu Z., Li Y., Li W.*, Lian W., Kemell M., Hietala S., Figueiredo P., Li L., Mäkilä E., Ma M., Salonen J., Hirvonen J. T., Liu D., Zhang

H.*, Deng X.*, Santos H. A.*, Close-loop dynamic nanohybrids on collagen-ark with in-situ gelling transformation capability for bio-mimetically stage specific diabetic wound healing, Mater. Horiz. 2018, XXX, XX–XX. (IF = 13.1, 2017). Publisher: Royal Society of Chemistry. (in press).

[225] Mao X., Cheng R., Zhang H., Bae J., Cheng L., Zhang L., Deng L., Cui W.*, Zhang Y.*, Santos H. A.*, Sun X.*, Self-healing and

injectable hydrogel for matching skin flap regeneration, Adv. Sci. 2018. (IF = 12.441, 2017). Publisher: Wiley-VCH. (in press). [224] Zhu Y., Zhang H., Zhang Y., Wu H., Wei L., Zhou G., Zhang Y., Deng L., Cheng Y.*, Li M.*, Santos H. A.*, Cui* W., Cell-Nanoparticle

interactions at sub(nanometer) resolution analysed by electron microscopy and correlative coherent anti-stokes raman scattering, Biotechnol. J. 2018. (ISSN: 1860-7314). Publisher: Wiley-VCH. (in press).

[223] Zhu Y., Zhang H., Zhang Y., Wu H., Wei L., Zhou G., Zhang Y., Deng L., Cheng Y.*, Li M.*, Santos H. A.*, Cui, W.*, Endovascular

metal devices for the treatment of cerebrovascular diseases, Adv. Mater. 2018. (IF = 21.95, 2017). Publisher: Wiley-VCH. (Invited Review) (in press).

[222] Bertoni S., Liu Z., Correia A., Martins J. P., Rahikkala A., Fontana F., Kemell M., Liu D., Albertini B., Passerini N.*, Li W.*, Santos H

A.*, pH And reactive oxygen species-sequential responsive nano-in-micro composite for targeted therapy of inflammatory bowel disease, Adv. Funct. Mater. 2018, 28(50), 1806175 (IF = 13.3, 2017). Publisher: Wiley-VCH.

[221] Bertoni S., Liu Z., Correia A., Martins J. P., Rahikkala A., Fontana F., Kemell M., Liu D., Albertini B., Passerini N.*, Li W.*, Santos H

A.*, Drug delivery: pH And reactive oxygen species‐sequential responsive nano‐in‐micro composite for targeted therapy of inflammatory bowel disease (Adv. Funct. Mater. 50/2018), Adv. Funct. Mater. 2018, 28(50), 1870353 (IF = 13.3, 2017). Publisher: Wiley-VCH. (Issue's Front Cover Page)

[220] Ding Y.*, Li W., Zhang F., Liu Z., Zanjanizadeh Ezazi N., Liu D., Santos H A.*, Electrospun fibrous architectures for drug delivery,

tissue engineering and cancer therapy, Adv. Funct. Mater. 2018. (IF = 13.3, 2017). Publisher: Wiley-VCH. (Invited Review) (in press).

(Hot topic in Drug Delivery, Wiley)

[219] Li W., Li Y., Liu Z., Kerdsakundee N., Zhang M., Zhang F., Liu X., Bauleth-Ramos T., Lian W., Mäkilä E., Kemell M., Ding Y., Sarmento

B., Wiwattanapatapee R., Salonen J., Zhang H., Hirvonen J. T., Liu D.*, Deng X.*, Santos H. A.*, Hierarchical structured and programmed vehicles deliver drugs locally to inflamed sites of intestine. Biomaterials 2018, 185, 322–332 (IF = 8.387, 2015). Publisher: Elsevier B.V.

[218] Sun X., Zhang H., He J., Cheng R., Cao Y., Che K., Cheng L., Zhang L., Pan G., Ni P., Deng L., Zhang Y.*, Santos H. A.*, Cui W.*

Adjustable hardness of hydrogel for promoting vascularization and maintaining stemness of stem cells in skin flap regeneration. Appl. Mater. Today 2018, 13, 5463. (ISSN: 2352-9407). Publisher: Wiley-VCH.

[217] Liu X., Zhang H., Cheng R., Gu Y., Yin Y., Sun Z., Pan G., Deng Z., Yang H., Deng L., Cui W.*, Santos H. A.*, Shi Q.* Immunological

electrospun scaffold for tumor imprison killing and healthy tissue regeneration. Mater. Horiz. 2018, 5, 1082–1091. (IF = 13.1, 2017). Publisher: Royal Society of Chemistry.

[216] Xia G., Zhang H., Cheng R., Wang H., Song Z., Deng L., Huang X., Santos H. A.*, Cui W.* Localized controlled delivery of

gemcitabine via microsol electrospun fibers to prevent pancreatic cancer recurrence. Adv. Healthcare Mater. 2018, 7(18), 1800593. (IF = 5.609, 2017). Publisher: Wiley-VCH.

[215] Ji J., Ma F., Zhang H., Liu F., He J., Li W., Xie T., Zhong D., Zhang T., Tian M.,* Zhang H.,* Santos H. A.,* Zhou M.* Light-activatable

assembled nanoparticles to improve tumor penetration and eradicate metastasis in triple negative breast cancer. Adv. Funct. Mater. 2018, 28(33), 1870238. (IF = 12.12, 2016). Publisher: Wiley-VCH.

[214] Ji J., Ma F., Zhang H., Liu F., He J., Li W., Xie T., Zhong D., Zhang T., Tian M.,* Zhang H.,* Santos H. A.,* Zhou M.* Front cover

Cancer therapy: Light-activatable assembled nanoparticles to improve tumor penetration and eradicate metastasis in triple negative breast cancer (Adv. Funct. Mater. 33/2018). Adv. Funct. Mater. 2018, 28(33), 1870228. (IF = 12.12, 2016). Publisher: Wiley-VCH. (Issue's Front Cover Page)

[213] Martins C., Araújo, Gomes M. J., Fernandes C., Nunes R., Li W., Santos H. A., Borges F., Sarmento B*. Using microfluidic plat-

forms to develop CNS-targeted polymeric nanoparticles for HIV therapy. Eur. J. Pharm. Biopharm. 2018, XXX, XXX-XXX 348 (IF = 4.159, 2016). Publisher: Elsevier B.V. (in press)

[212] Liu D., Lipponen K., Quan P., Wan X., Zhang H., Mäkilä E. M., Salonen J. J., Kostiainen R., Hirvonen J. J., Kotiaho T., Santos H. A.*

Impact of pore size and surface chemistry of porous silicon particles and structure of phospholipids on their interactions. ACS Biomater. Sci. Eng. 2018, 4(7), 2308–2313 (IF = 3.234, 2016). Publisher: American Chemical Society.

[211] Martins J. P., D'Auria R., Liu D., Fontana F., Ferreira M. P. A., Correia A., Kemell M., Moslova K., Mäkilä E., Salonen J. Casettari L.,

Hirvonen J., Sarmento B., Santos H. A.* Engineered multifunctional albumin-decorated porous silicon nanoparticles for FcRn translocation of insulin. Small 2018, 14(27), 1800462 (IF = 9.59, 2017). Publisher: Wiley-VCH.

[210] Zhang F., Kong Li, Liu D., Li W., Mäkilä E., Correia A., Lindgren R., Salonen J., Hirvonen J. T., Zhang H., Kros A., Santos H. A.*

Sequential antifouling surface for efficient modulation of the nanoparticle-cell interactions in protein-rich environment. Adv. Ther. 2018, 1(1), 1800013. Publisher: Wiley-VCH.

[209] Ding Y., Li W., Correia A., Yang Y., Zheng K., Liu D., Schubert D. W., Boccaccini A. R., Santos H. A.*, Roether J. A.* Electrospun

PHB/PCL/Sol-gel derived silica hybrid scaffolds with drug releasing function for bone tissue engineering applications. ACS Appl. Mater. Interfaces 2018, 10(17), 14540–14548 (IF = 7.504, 2016). Publisher: American Chemical Society.

[208] Kinnunen S. M., Tölli M., Välimäki M. J., Gao E., Szabo Z., Rysä J., Ferreira M. P. A., Ohukainen P., Serpi R., Correia A., Mäkilä E.,

Salonen J., Hirvonen J., Santos H. A., Ruskoaho H.* Cardiac actions of a small molecule inhibitor targeting GATA4–NKX2-5 interaction, Sci. Rep. 2018, 8(1), 4611 (IF = 4.259, 2016). Publisher: Nature Publishing Group.

[207] Fontana F.*, Albertini S., Correia A., Kemell M., Lindgren R., Mäkilä E., Salonen J., Hirvonen J. T., Ferrari F., Santos H. A.*

Bioengineered porous silicon nanoparticles@macrophages cell membrane as composite platforms for rheumatoid arthritis. Adv. Funct. Mater. 2018, 28(22), 1801355 (IF = 12.12, 2016). Publisher: Wiley-VCH.

[206] Liu Z., Li Y., Xiao C., Liu D., Dong C., Zhang M., Mäkilä E., Kemell M., Salonen J., Hirvonen J. T., Zhang H.*, Zhou D.*, Deng X.*,

Santos H.A.* Multifunctional nanohybrid based on porous silicon nanoparticles, gold nanoparticles and acetalated dextran for

liver regeneration and acute liver failure theranostics. Adv. Mater. 2018, 30(24), 1703393 (IF = 19.7, 2016). Publisher: Wiley-VCH.

[205] Liu Z., Li Y., Xiao C., Liu D., Dong C., Zhang M., Mäkilä E., Kemell M., Salonen J., Hirvonen J. T., Zhang H.*, Zhou D.*, Deng X.*,

Santos H.A. Inside Front Cover – Nanohybrids: Multifunctional Nanohybrid Based on Porous Silicon Nanoparticles, Gold Nanoparticles, and Acetalated Dextran for Liver Regeneration and Acute Liver Failure Theranostics (Adv. Mater. 24/2018). Adv. Mater. 2018, 30(24), 1870168 (IF = 19., 2016). Publisher: Wiley-VCH. (Issue's Inside Front Cover Page)

[204] Ferreira M. P. A. *, Talman V., Torrieri G., Liu D., Marques G., Moslova K., Liu Z., Pinto J. P., Hirvonen J.*, Ruskoaho H.*, Santos H.

A.* Dual-drug delivery using dextran-functionalized nanoparticles targeting cardiac fibroblasts for cellular reprogramming. Adv. Funct. Mater. 2018, 28(15), 1705134 (IF = 12.12, 2016). Publisher: Wiley-VCH.

[203] Liu D., Chen J., Jiang T., Li W., Huang Y., Lu X., Liu Z., Zhang W., Zhou Z., Ding Q., Santos H. A.,* Yin G.,* Fan J.* Biodegradable

Spheres Protect Traumatically Injured Spinal Cord by Alle-viating the Glutamate-Induced Excitotoxicity. Adv. Mater. 2018, 30(14), 1706032 (IF = 19.8, 2016). Publisher: Wiley-VCH.

[202] Liu D., Chen J., Jiang T., Li W., Huang Y., Lu X., Liu Z., Zhang W., Zhou Z., Ding Q., Santos H. A.,* Yin G.,* Fan J.* Inside Front Cover

– Neuroprotection: Biodegradable Spheres Protect Traumatically Injured Spinal Cord by Alleviating the Glutamate‐Induced Excitotoxicity (Adv. Mater. 14/2018). Adv. Mater. 2018, 30(14), 1870095 (IF = 19.8, 2016). Publisher: Wiley-VCH. (Issue's Inside Front Cover Page)

[201] Balasubramanian V., Poillucci A., Correia A., Zhang H., Celia C.,* Santos H. A.* Cell membranes based nanoreactor to mimic the

bio-compart-mentalization strategy of a cell. ACS Biomater. Sci. Eng. 2018, 4(4), 1471–1478 (IF = 3.234, 2016). Publisher: American Chemical Society.

[200] Zhang H., Zhu Y., Qu L., Wu H., Kong H., Yang Z., Chen D., Mäkilä E., Salonen J. J., Santos H. A., Hai M.*, Weitz A. A.* Gold nanorods conjugated porous silicon nanoparticles encapsulated in calcium alginate nano hydrogels using microemulsion templates. Nano Lett. 2018, 18(2), 1448–1453 (IF = 12.71, 2016). Publisher: American Chemical Society.

[199] Cenev Z., Zhang H.*, Sariola V., Rahikkala A., Liu D., Santos H. A.*, Zhou Q.* Manipulating superparamagnetic microparticles

with an electromagnetic needle. Adv. Mater. Technol. 2018, 3(1), 1700177 (ISSN: 2365-709X). Publisher: Wiley-VCH. [198] Ezazi N. Z., Shahbazi M.-A., Shatalin Y. V., Nadal E., Mäkilä E., Salonen J., Kemell M., Correia A., Hirvonen J., Santos H. A.*

Conductive vancomycin-loaded mesoporous silica polypyrrole-based scaffolds for bone regeneration. Int. J. Pharm. 2018, 536(1), 241–250. (IF = 3.649, 2016). Publisher: Elsevier B.V.

Refereed reviews in scientific journal

[197] Shahbazi M.-A. Bauleth-Ramos, Santos H. A.* DNA hydrogel assemblies: bridging synthesis principles to biomedical

applications. Adv. Ther. 2018, 1(4), 1800042 (ISSN: 2366-7478, 2016). Publisher: Wiley-VCH. (Invited Review) Highlighted in Advanced Science News

[196] Rahikkala A., Pereira S. A. P., Figueiredo P., Passos M. L. C., Araújo A. R. T. S., Saraiva M. L. M. F. S.*, Santos H. A.* Mesoporous

silica nanoparticles for targeted and stimuli-responsive delivery of chemotherapeutics: a review. Adv. Biosys. 2018, 2(7), 1800020 (ISSN: 2366-7478, 2016). Publisher: Wiley-VCH. (Invited Review)

(Hot topic in Drug Delivery, Wiley) (Hot topic in Mesoporous Materials, Wiley)

[195] Fontana F., Figueiredo P., Zhang P., Hirvonen J. T., Liu D., Santos H. A.* Production of pure drug nanocrystals and nano co-crystals

by confinement methods. Adv. Drug Deliv. Rev. 2018, 131, 321 (IF = 11,764, 2016). Publisher: Elsevier B.V. (Invited Review) [194] Liu D.*, Zhang H., Fontana F., Hirvonen J. T., Santos H. A..* Current developments and applications of microfluidic technology

toward clinical translation of nanomedicines. Adv. Drug Deliv. Rev. 2018, 128, 54–83 (IF = 11,764, 2016). Publisher: Elsevier B.V. (Invited Review)

[193] Li W., Liu Z., Fontana F., Ding Y., Liu D., Hirvonen J. T.*, Santos H. A.* Tailoring porous silicon for biomedical applications: from

drug delivery to cancer immunotherapy. Adv. Mater. 2018, 30(24), 1703740 (IF = 19.7, 2016). Publisher: Wiley-VCH. (Invited Review) (Hot topic in Drug Delivery, Wiley)

[192] Fontana F., Figueiredo P., Bauleth-Ramos T., Correia A., Santos H. A.*. Immunostimulation and immunosuppression:

Nanotechnology on the brink. Small Methods 2(5), 1700347 (ISSN: 2366-9608, 2016). Publisher: Wiley-VCH. (Invited Review) [191] Balasubramanian V.*, Liu Z., Hirvonen J., Santos, H. A.*. Bridging the knowledge of different worlds to understand the big pic-

ture of cancer nanomedicines. Adv. Healthcare Mater. 2018, 7(1), 1700432 (IF = 5.760, 2015). Publisher: Wiley-VCH. (Invited Progress report)

Cover Highlighted in Advanced Science News (http://www.advancedsciencenews.com/): http://www.advancedsciencenews.com/ coverart-biomaterials-cancer-nanomedicine-macroporous-hydrogels/

Article highlighted in Advanced Science News (http://www.advancedsciencenews.com/) on 18.17.2017: most downloaded and read

publication of the month [190] Balasubramanian V.*, Liu Z., Hirvonen J., Santos, H. A.*. Inside back cover - Nanomedicine: Bridging the knowledge of different

worlds to understand the big picture of cancer nanomedicines (Adv. Healthcare Mater. 1/2018). Adv. Healthcare Mater. 2018, 7(1), 1870005 (IF = 5.760, 2015). Publisher: Wiley-VCH. (Invited Progress report) (Issue's Inside Back Cover Page)

[189] Figueiredo P.*, Lintinen K., Hirvonen J. T., Kostiainen M. A., Santos H. A.* Properties and chemical modifications of lignin:

towards lignin-based nanomaterials for biomedical applications. Prog. Mater. Sci. 2018, 93, 233–269. (IF = 31.14, 2016). Publisher: Elsevier B.V. (Review)

[188] Martins J. P.*, Torrieri G., Santos H. A.* The importance of microfluidics for the preparation of nanoparticles as advanced drug

delivery systems. Exp. Opin. Drug Deliv. 2018, 15(5), 469-479. (IF = 4.84, 2016). Publisher: Taylor and Francis Group. (Invited Review)

2017 (40) Refereed journal articles [187] Figueiredo P.*, Ferro C., Kemell M., Liu Z., Kiriazis A., Lintinen K., Florindo H. F., Yli-Kauhaluoma J., Hirvonen J., Kostiainen M. A.,

Santos H. A.* Functionalization of carboxylated lignin nanoparticles for targeted and pH-responsive delivery of anticancer drugs. Nanomedicine (Lond.) 2017, 12(21), 2581–2596. (IF = 4.889, 2015). Publisher: Future Medicine Ltd.

[186] Zhang H., Qu X., Chen H., Ding R., Chen D., Zhang W., Zhang X., Pei H., Santos H. A., Hai M.*, Weitz D. A.* Fabrication of calcium

phosphate-based nanocomposites containing DNA origami, gold nanorods and drugs for synergistic anticancer applications. Adv. Healthcare Mater. 2017, 6(20), 1700664 (IF = 5.760, 2015). Publisher: Wiley-VCH.

[185] Kerdsakundee N., Li Wei,* Martins J. P., Liu Z., Zhang F., Kemell M., Correia A., Airavaara M., Hirvonen J., Wiwattanapatapee R.,

Heìlder A. Santos.* Multifunctional nanotube-mucoadhesive poly(methyl vinyl ether-co-maleic acid)@hydroxypropyl methylcellulose acetate succinate composite for site specific oral drug delivery. Adv. Healthcare Mater. 2017, 6(20), 1700629 (IF = 5.760, 2015). Publisher: Wiley-VCH.

[184] Bauleth-Ramos T., Shahbazi M.-A.*, Liu D., Fontana F., Correia A., Figueiredo P., Zhang H., Martins J. P., Hirvonen J. T., Granja P., Sarmento B.*, Santos H. A.* Nutlin-3a and cytokine co-loaded spermine-modified acetalated dextran nanoparticles for cancer chemo-immunotherapy. Adv. Funct. Mater. 2017, 27(42), 1703303 (IF = 12.12, 2016). Publisher: Wiley-VCH.

[183] Bauleth-Ramos T., Shahbazi M.-A.*, Liu D., Fontana F., Correia A., Figueiredo P., Zhang H., Martins J. P., Hirvonen J. T., Granja P.,

Sarmento B.*, Santos H. A.* Front cover - Cancer Therapy: Nutlin-3a and cytokine co-loaded spermine-modified acetalated dextran nanoparticles for cancer chemo-immunotherapy (Adv. Funct. Mater. 42/2017). Adv. Funct. Mater. 2017, 27(42) (IF = 12.12, 2016). Publisher: Wiley-VCH.

[182] Nayab Tahir, Asadullah Madni*, Vimalkumar Balasubramanian, Mubashar Rehman, Alexandra Correia, Prince Muhammad Kashif,

Ermei Mäkilä, Jarno Salonen, Heìlder A. Santos*. Development and optimization of methotrexate-loaded lipid-polymer hybrid nanoparticles for controlled drug delivery applications. Int. J. Pharm. 2017, 533(1), 156–168 (IF = 3.994, 2015). Publisher: Elsevier B.V.

[181] Auvinen H., Zhang H., Nonappa, Kopilow A., Niemelä E. H., Nummelin S., Correia A., Santos H. A., Linko V.*, Kostiainen M. A.*

Protein coating of DNA nanostructures for enhanced delivery, stability and immunocompatibility. Adv. Healthcare Mater. 2017, 6(18) (IF = 5.760, 2015). Publisher: Wiley-VCH.

[180] Auvinen H., Zhang H., Nonappa, Kopilow A., Niemelä E. H., Nummelin S., Correia A., Santos H. A., Linko V.*, Kostiainen M. A.*

Front Cover - Nanobiomedicine: Protein Coating of DNA Nanostructures for Enhanced Stability and Immunocompatibility (Adv. Healthcare Mater. 18/2017). Adv. Healthcare Mater. 2017, 6(18), 1700692 (IF = 5.760, 2015). Publisher: Wiley-VCH.

[179] Ferreira M. P. A.*, Ranjan S., Kinnunen S., Correia A., Talman V., Mäkilä E., Barrios-Lopez B., Kemell M., Balasubramanian V.,

Salonen J., Hirvonen J., Ruskoaho H.*, Airaksinen A. J.*, Santos H. A.* Drug-loaded multifunctional nanoparticles targeted to the endocardial layer of the injured heart modulate hypertrophic signaling. Small 2017, 13(33), 1701276 (IF = 8.315, 2015). Publisher: Wiley-VCH.

[178] Ferreira M. P. A.*, Ranjan S., Kinnunen S., Correia A., Talman V., Mäkilä E., Barrios-Lopez B., Kemell M., Balasubramanian V.,

Salonen J., Hirvonen J., Ruskoaho H.*, Airaksinen A. J.*, Santos H. A.* Front Cover – Drug Delivery: Drug-loaded multifunctional nanoparticles targeted to the endocardial layer of the injured heart modulate hypertrophic signaling. Small 2017, 13(33) (IF = 8.315, 2015). Publisher: Wiley-VCH.

[177] Guo J., Liu D., Filpponen I.*; Johansson L.-S., Malho J.-M., Quraishi S., L. Falk, Santos H. A., Rojas O. J. Photoluminescent hybrids

of cellulose nanocrystals and carbon quantum dots as cytocompatible probes for in vitro bio-imaging. Biomacromol. 2017, 18(7), pp 2045–2055 (IF = 5.583, 2015). Publisher: American Chemical Society.

[176] Reuter L. J., Shahbazi M.-A., Mäkilä E. M., Salonen J. J., Saberianfar R., Menassa R., Santos H. A., Joensuu J. J., Ritala A.* Coating

nanoparticles with plant-produced transferrin-hydrophobin fusion protein enhances their uptake in cancer cells. Bioconj. Chem. 2017, 28(6), 1639–1648 (IF = 4.500, 2015). Publisher: American Chemical Society.

[175] Almeida P.V.*, Shahbazi M.-A., Correia A., Mäkilä E., Kemell M., Salonen J., Hirvonen J., Santos H. A.* Multifunctional nano-in-

nanocomplex composite designed for enhanced cell uptake, fast endosomal escape and cancer theranostics. Nanomedicine (Lond.) 2017, 12(12), 1401–1420. (IF = 4.889, 2015). Publisher: Future Medicine Ltd.

[174] Zhang H.*, Liu D., Wang L., Liu Z., Wu R., Janoniene A., Ma M., Pan G., Baranauskiene L., Zhang L., Cui W., Petrikaite V., Matulis

D., Zhao H., Pan J.*, Santos H.A.* Microfluidic encapsulation of prickly zinc-doped copper oxide nanoparticles with VD1142 modified spermine acetalated dextran for efficient cancer therapy. Adv. Healthcare Mater. 2017, 6(11), 1601406 (IF = 5.760, 2015). Publisher: Wiley-VCH.

[173] Janoniene A., Liu Z., Baranauskiene L., Mäkilä E., Ma M., Salonen J., Hirvonen J., Zhang H.*, Petrikaite V.*, Santos H. A.* A versatile

carbonic anhydrase ix targeting ligand functionalized porous silicon nanoplatform for dual hypoxia cancer therapy and imaging. ACS Appl. Mater. Interfaces 2017, 9(16), 13976–13987 (IF = IF = 7.145, 2015). Publisher: American Chemical Society.

[172] Ollikainen E., Liu D., Kallio A., Mäkilä E., Zhang H., Salonen J., Santos H. A., Sikanen T.* The impact of porous silicon nanoparticles

on human cytochrome p450 metabolism in human liver microsomes in vitro. Eur. J. Pharm. Sci. 2017, 104, 124–132 (IF = 3.773, 2015). Publisher: Elsevier B.V.

[171] Kääriäinen T. O., Kemell M., Kääriäinen M.-L., Correia A., Santos H. A., Bimbo L. M., Hirvonen J., Hoppu P., George S. M., Cameron

D. C., Ritala M., Leskelä M. Surface modification of acetaminophen particles by atomic layer deposition. Int. J. Pharm. 2017, 525(1), 160–174 (IF = 3.994, 2015). Publisher: Elsevier B.V.

[170] Saarinen J.*, Sözeri E., Fraser S., Peltonen L., Santos H.A., Isomäki A., Strachan C. J. Insights into Caco-2 cell culture structure

using coherent anti-Stokes Raman scattering (CARS) microscopy. Int. J. Pharm. 2017, 523(1), 270–280 (IF = 3.994, 2015). Publisher: Elsevier B.V.

[169] Zhang F., Correia A., Mäkilä E., Li W., Salonen J. J., Hirvonen J. J., Zhang H.*, Santos H. A.* Receptor-mediated surface charge

inversion platform based on porous silicon nanoparticles for efficient cancer cell recognition and combination therapy. ACS Appl. Mater. Interfaces 2017, 9(11), 10034–10046 (IF = 7.145, 2015). Publisher: American Chemical Society.

[168] Balasubramanian V.*, Correia A., Zhang H., Fontana F., Mäkilä E., Salonen J., Hirvonen J., Santos H. A.* Biomimetic engineering

using cancer cell membranes for designing compartmentalized nanoreactors with organelle-like functions. Adv. Mater. 2017, 29(11), 1605375 (IF = 18.96, 2015). Publisher: Wiley-VCH.

[167] Balasubramanian V.*, Correia A., Zhang H., Fontana F., Mäkilä E., Salonen J., Hirvonen J., Santos H. A.* Nanoreactors: Biomimetic engineering using cancer cell membranes for designing compartmentalized nanoreactors with organelle-like functions (Adv. Mater. 11/2017). Adv. Mater. 2017, 29(11 (IF = 18.96, 2015). Publisher: Wiley-VCH.

[166] Liu D.*, Bernuz C. R., Fan J., Li W., Correia A., Hirvonen J., Santos H. A.* A nano-in-nano vector: merging the best of polymeric

nanoparticles and drug nanocrystals. Adv. Funct. Mater. 2017, 27(9), 1604508 (IF = 11.382, 2015). Publisher: Wiley-VCH. [165] Liu D.*, Bernuz C. R., Fan J., Li W., Correia A., Hirvonen J., Santos H. A.* Back Covver – Drug Delivery: nano-in-nano vector:

merging the best of polymeric nanoparticles and drug nanocrystals. Adv. Funct. Mater. 2017, 27(9), (Issue's Back Cover Page) (IF = 11.382, 2015). Publisher: Wiley-VCH.

[164] Ullah H., Badshah M., Mäkilä E., Salonen J., Shahbazi M.-A., Santos H. A.*, Khan T.* Fabrication, characterization and evaluation

of bacterial cellulose-based capsule shells for oral drug delivery. Cellulose 2017, 24(3) 1445–1454 (IF = 3.195, 2015). Publisher: Springer Science+Business Media.

[163] Liu D.*, Zhang H., Cito S., Fan J., Mäkilä E., Salonen J., Hirvonen J., Sikanen T. M., Weitz D. A., Santos H. A.* Core/shell

nanocomposites produced by superfast sequential microfluidic nanoprecipitation. Nano Lett. 2017, 17(2), 606–614 (IF = 13.779, 2015). Publisher: American Chemical Society.

Article highlighted in Chemistry Views (http://www.chemistryviews.org/) on 17.1.2017:

http://www.chemistryviews.org/details/news/10371541/Superfast_Production_of_Nanocomposites.html [162] Fontana F.*, Shahbazia M.-A., Liu D., Zhang H., Mäkilä E., Salonen J., Hirvonen J. T., Santos H. A.* Multistaged nanovaccines based

on porous silicon@acetalated dextran@cancer cell membrane for cancer immunotherapy. Adv. Mater. 2017, 29(7), 1603239 (IF = 18.96, 2015). Publisher: Wiley-VCH.

Article highlighted in Advanced Science News (http://www.advancedsciencenews.com/) on 6.1.2017:

http://www.advancedsciencenews.com/porous-silicon-nanovaccines-combat-cancer/ [161] Fontana F.*, Shahbazia M.-A., Liu D., Zhang H., Mäkilä E., Salonen J., Hirvonen J. T., Santos H. A.* Isuue back cover page -

Nanovaccines: ultistaged nanovaccines based on porous silicon@acetalated dextran@cancer cell membrane for cancer immunotherapy. Adv. Mater. 2017, 29(7) (IF = 18.96, 2015). Publisher: Wiley-VCH.

[160] Liu Z., Balasubramanian V., Bhat C., Vahermo M., Mäkilä E., Kemell M., Fontana F., Vegytë A., Petrikaite V., Salonen J., Yli-

Kauhaluoma J., Hirvonen J., Zhang H.*, Santos H. A.* Quercetin-based modified porous silicon nanoparticles for enhanced inhibition of doxorubicin-resistant cancer cells. Adv. Healthcare Mater. 2017, 6(3), 1601009 (IF = 5.760, 2015). Publisher: Wiley-

VCH. [159] Shahbazi M.-A.,* Almeida P. V., Correia A., Herranz-Blanco B., Shrestha N., Mäkilä E., Salonen J., Hirvonen J., Santos H. A.*

Intracellular responsive dual delivery by endosomolytic polyplexes carrying DNA anchored porous silicon nanoparticles. J. Control. Release 2017, 249, 111–122 (IF = 7.441, 2015). Publisher: Elsevier B.V.

[158] Vale B.*, Correia A., Silva S., Figueiredo P., Mäkilä E., Salonen J., Hirvonen J., Pedrosa J., Santos H. A., Fraga A.. Preparation and

biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. 2017, 27(3), 403–405 (IF = 2.486, 2015). Publisher: Elsevier B.V.

[157] Sun X., Lang Q., Zhang H., Cheng L., Zhang Y., Pan G., Zhao X., Cheng R., Zhang Y.*, Santos H. A.*, Cui W.* Electrospun

photocrosslinkable hydrogel fibrous scaffolds for rapid in vivo vascularized skin flap regeneration. Adv. Funct. Mater. 2017, 27(2), 1604617 (IF = 11.382, 2015). Publisher: Wiley-VCH.

[156] Sun X., Lang Q., Zhang H., Cheng L., Zhang Y., Pan G., Zhao X., Cheng R., Zhang Y.*, Santos H. A.*, Cui W.* Front Cover Picture –

Cell Scaffolds: Electrospun photocrosslinkable hydrogel fibrous scaffolds for rapid in vivo vascularized skin flap regeneration. Adv. Funct. Mater. 2017, 27(2), 1604617 (IF = 11.382, 2015). Publisher: Wiley-VCH.

[155] Li W., Liu D., Zhang H., Correia A., Mäkilä E., Salonen J., Hirvonen J., Santos H.A.* Microfluidic assembly of a nano-in-micro dual

drug delivery platform composed of halloysite nanotubes and a pH-responsive polymer for colon cancer therapy. Acta Biomater. 2017, 48, 238–246 (IF = 6.008, 2015). Publisher: Elsevier B.V.

[220] Figueiredo P.,* Lintinen K., Kiriazis A., Hynninen V., Liu Z., Bauleth Ramos T., Rahikkala A., Correia A., Kohout T., Sarmento B., Yli-

Kauhaluoma J., Hirvonen J., Ikkala O., Kostiainen M. A., Santos H. A.* In vitro evaluation of biodegradable lignin-based nanoparticles for drug delivery and enhanced antiproliferation effect in cancer cells. Biomaterials 2017, 121, 97–108 (IF = 8.387, 2015). Publisher: Elsevier B.V.

[153] Herranz-Blanco B., Ginestar E., Zhang H., Hirvonen J., Santos, H. A.* Microfluidics platform for glass capillaries and its

application in droplet and nanoparticle fabrication. Int. J. Pharm. 2017, 516(1–2), 100–105 (IF = 3.994, 2015). Publisher: Elsevier B.V.

Refereed reviews in scientific journal [152] Madni A.*, Rahem M. A., Tahir N., Sarfraz M., Jabar J., Rehman M., Kashif P. M., Badshah S. F., Khan K. U., Santos H. A.* Non-

invasive strategies for targeting the posterior segment of eye. Int. J. Pharm. 2017, 530(1–2), 326–345 (IF = 3.994, 2015). Publisher: Elsevier B.V. (Review)

[151] Araújo F., das Neves J., Martins J. P., Granja P. L., Santos H. A., Sarmento B. Functionalized materials for multistage platforms in the oral delivery of biopharmaceuticals. Prog. Mater. Sci. 2017, 89, 306–344 (IF = 31.083, 2015). Publisher: Elsevier B.V. (Review)

[150] Liu D.*, Zhang H., Fontana F., Hirvonen J., Santos H.A.* Microfluidic-assisted fabrication of carriers for controlled drug

delivery. Lab Chip 2017, 17(11), 1856–1883 (IF = 5.586, 2015). Publisher: Royal Society of Chemistry. (Invited Review) [149] Fontana F., Liu D., Hirvonen J., Santos H.A.* Issue inside cover page – Delivery of therapeutics with nanoparticles: what’s new

in cancer immunotherapy?. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2017, 9(1), e1459 (IF = 4.095, 2015). Publisher: Wiley-VCH.

Article highlighted in Advanced Science News (http://www.advancedsciencenews.com/) on 30.12.2016:

http://www.advancedsciencenews.com/cancer-immunotherapy-nanotechnology-taking-best-two-worlds/ [148] Fontana F., Liu D., Hirvonen J., Santos H.A.* Delivery of therapeutics with nanoparticles: what’s new in cancer

immunotherapy?. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2017, 9(1), e1421 (IF = 4.095, 2015). Publisher: Wiley-VCH. (Invited Review)

2016 (35) Journal Editorial [147] Kennedy E., Canham L., Santos H.A. Mesoporous biomaterials: a lexicon and structured bibliography of reviews. Mesoporous

Biomater. 2016, 3(1), 1–14 (ISSN 2300-2271). Publisher: De Gruyter Open. (Editorial)

Refereed journal articles [146] Mäkilä E., Kivelä H., Shrestha N., Correia A., Kaasalainen M., Kukk E., Hirvonen J., Santos H.A., Salonen J. J.* Influence of surface

chemistry on ibuprofen adsorption and confinement in mesoporous silicon microparticles. Langmuir 2016, 32(49), 13020– 13029 (IF = 3.993, 2015). Publisher: American Chemical Society.

[145] Kong F., Zhang H., Qu X., Zhang X., Chen D., Ding R., Mäkilä E., Salonen J., Santos H. A., Mingtan Hai.* Frontispiece Cover – rug

Delivery: Gold nanorods, DNA origami and porous silicon nanoparticles functionalized biocompatible double emulsion for versatile targeted therapeutics and antibody combination therapy (Adv. Mater. 46/2016). Adv. Mater. 2016, 28(46), 10194 (IF = 18.960, 2015). Publisher: Wiley-VCH.

[144] Kong F., Zhang H., Qu X., Zhang X., Chen D., Ding R., Mäkilä E., Salonen J., Santos H. A., Mingtan Hai.* Gold nanorods, DNA origami

and porous silicon nanoparticles functionalized biocompatible double emulsion for versatile targeted therapeutics and antibody combination therapy. Adv. Mater. 2016, 28(46), 10195–10203 (IF = 18.960, 2015). Publisher: Wiley-VCH.

[143] Ora A., Järvihaavisto E., Zhang H., Auvinen H., Santos H. A., Kostiainen M. A.*, Linko V.* Cellular delivery of enzyme-loaded

DNA origami. Chem. Commun. 2016, 52(98), 14161‒14164 (IF = 6.567, 2015). Publisher: Royal Society of Chemistry. [142] Jäppinen L.,* Jalkanen T., Sieber B., Addad A., Heinonen M., Kukk E., Radevici I., Paturi P., Peurla M., Shahbazi M.-A., Santos H.

A., Boukherroub R., Santos H., Lastusaari M., Salonen J. Enhanced photoluminescence in acetylene-treated ZnO nanorods. Nanoscale Res. Lett. 2016, 11(1), 413–423 (IF = 2.584, 2015). Publisher: Springer Science+Business Media.

[141] Yuryev M.*, Ferreira M. P. A., Balasubramanian V., Correia A. M. R., Mäkilä E. M., Jokinen V., Andriichuk L., Kemell M., Salonen J.

J., Hirvonen J. T., Santos H. A.*, Rivera C.* Active diffusion of nanoparticles of maternal origin within the embryonic brain. Nanomedicine (Lond.) 2016, 11(19), 2471–2481 (IF = 4.889, 2015). Publisher: Future Medicine Ltd.

[140] Wu R., Zhang H., Pan J.,* Zhu H., Ma Y., Cui W., Santos H.A.*, Pan G.* Spatio-design of multi-dimensional prickly zn-doped cuo

nanoparticle for efficient bacterial killing. Adv. Mater. Interfaces 2016, 3(18), 1600472 (IF = 3.365, 2015). Publisher: Wiley-VCH. Article highlighted in the 2016 Advent Calendar of Advanced Science News (http://www.advancedsciencenews.com/) on 5.12.2016:

http://www.advancedsciencenews.com/december-5-spatio-design-of-multidimensional-prickly-zn-doped-cuo-nanoparticle-for-efficient-bacterial-killing-published-in-advanced-materials-interfaces/

[139] Wu R., Zhang H., Pan J.,* Zhu H., Ma Y., Cui W., Santos H.A.*, Pan G.* Issue front cover page – Spatio-design of multi-dimensional

prickly zn-doped cuo nanoparticle for efficient bacterial killing. Adv. Mater. Interfaces 2016, 3(18), 1600472 (IF = 3.365, 2015). Publisher: Wiley-VCH.

[138] Kong F., Zhang H., Zhang X., Liu D., Chen D., Zhang W., Zhang L., Santos H.A., Hai M.* Issue inside front cover page – Drug Co-

Delivery: Biodegradable Photothermal and pH Responsive Calcium Carbonate@Phospholipid@Acetalated Dextran Hybrid Platform for Advancing Biomedical Applications (Adv. Funct. Mater. 34/2016). Adv. Funct. Mater. 2016, 26(34), 6138 (IF = 11.382, 2015). Publisher: Wiley-VCH.

[137] Kong F., Zhang H., Zhang X., Liu D., Chen D., Zhang W., Zhang L., Santos H.A., Hai M.* Biodegradable photothermal and pH

responsive calcium carbonate@phospholipid@acetalated dextran hybrid platform for advancing biomedical applications. Adv. Funct. Mater. 2016, 26(34), 6158–6169 (IF = 11.382, 2015). Publisher: Wiley-VCH.

[136] Herranz-Blanco B.*, Shahbazi M.-A., Correia A.R., Balasubramanian V., Hirvonen J., Santos H.A.* Issue inside front cover page –

Targeted Cancer Therapy: pH-Switch Nanoprecipitation of Polymeric Nanoparticles for Multimodal Cancer Targeting and Intracellular Triggered Delivery of Doxorubicin (Adv. Healthcare Mater. 15/2016). Adv. Healthcare Mater. 2016, 5(15), 1834 (IF = 5.760, 2015). Publisher: Wiley-VCH.

[135] Herranz-Blanco B.*, Shahbazi M.-A., Correia A.R., Balasubramanian V., Hirvonen J., Santos H.A.* pH-Switch nanopricipitation of

polymeric nanoparticles for multimodal cancer targeting and triggered intracellular delivery of doxorubicin. Adv. Healthcare Mater. 2016, 5(15), 1904–1916 (IF = 5.760, 2015). Publisher: Wiley-VCH.

[134] Figueiredo P., Balasubramanian V.*, Shahbazi M.-A., Correia A., Wu D., Palivan C.G., Hirvonen J.T., Santos H.A.* Angiopep2-

functionalized polymersomes for targeted doxorubicin delivery to glioblastoma cells. Int. J. Pharm. 2016, 511(2), 794–803 (IF = 3.994, 2015). Publisher: Elsevier B.V.

[133] Hui Guo, Dongmei Liu, Bin Gao, Xiaohui Zhang, Minli You, Hui Ren, Hongbo Zhang, Hélder A. Santos, Feng Xu.* Antiproliferative

activity and cellular uptake of evodiamine and rutaecarpine based on 3D tumour models. Molecules 2016, 21(7), 954 (IF = 2.465, 2015). Publisher: MDPI AG.

[132] Paaver U., Laidmäe I., Santos H.A., Yliruusi J., Aruväli J., Kogermann K., Heinämäki J.* Development of a novel electrospun

nanofibrous delivery system for poorly water-soluble -sitosterol. Asian J. Pharm. Sci. 2016, 11(4), 500–506 (ISSN: 1818-0876). Publisher: Elsevier B.V.

[131] Liu D., Jiang T., Cai W., Chen J., Zhang H., Hietala S., Santos H.A.*, Yin G.*, Fan J.* An in situ gelling drug delivery system for

improved recovery after spinal cord injury. Adv. Healthcare Mater. 2016, 5(12), 1513–1521 (IF = 5.760, 2015). Publisher: Wiley-VCH.

[130] Araújo F., Shrestha N., Gomes M J.J., Liu D., Hirvonen J.J., Granja P. L., Santos H.A., Sarmento B.* In vivo dual-delivery of GLP-1

and DPP4 inhibitor through composites prepared by microfluidics for diabetes therapy. Nanoscale 2016, 8(20), 10706–10713 (IF = 7.760, 2015). Publisher: Royal Society of Chemistry.

[129] Shrestha N.*, Araújo F., Shahbazi M.-A., Mäkilä E., Gomes M.J., Herranz-Blanco B., Lindgren R., Granroth S., Kukk E., Salonen J.,

Hirvonen J., Sarmento B., Santos H.A.* Issue inside front cover page – Drug Delivery: Thiolation and cell-penetrating peptide surface functionalization of porous silicon nanoparticles for oral delivery of insulin (Adv. Funct. Mater. 20/2016). Adv. Funct. Mater. 2016, 26(20), 3374 (IF = 11.382, 2015). Publisher: Wiley-VCH.

[128] Shrestha N.*, Araújo F., Shahbazi M.-A., Mäkilä E., Gomes M.J., Herranz-Blanco B., Lindgren R., Granroth S., Kukk E., Salonen J.,

Hirvonen J., Sarmento B., Santos H.A.* Thiolation and cell-penetrating peptide surface functionalization of porous silicon nanoparticles for oral delivery of insulin. Adv. Funct. Mater. 2016, 26(20), 3405–3416 (IF = 11.382, 2015). Publisher: Wiley-VCH.

[127] Shrestha N.*, Araújo F., Shahbazi M.-A., Mäkilä E., Gomes M. J., Airavaara M., Kauppinen E. I., Raula J., Salonen J., Hirvonen J.,

Sarmento B., Santos H.A.* Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model. J. Control. Release 2016, 232, 113–119 (IF = 7.441, 2015). Publisher: Elsevier B.V.

[126] Ferreira M. P. A.*, Correia A. M. R., Mäkilä E. M., Kinnunen S. M., Zhang H., Shahbazi M.-A., Almeida P. V., Salonen J. J., Ruskoaho

H. J., Hirvonen J. T.*, Santos H. A.* In vitro and in vivo assessment of heart-homing nanoparticles. Biomaterials 2016, 94, 93– 104 (IF = 8.387, 2015). Publisher: Elsevier B.V.

[125] Lopes M., Shrestha N., Correia A., Shahbazi M.-A., Sarmento B., Hirvonen J., Veiga F., Seiça R., Ribeiro A.*, Santos. H.A.* Dual

chitosan/albumin-coated alginate/dextran sulfate nanoparticles for enhanced oral delivery of insulin. J. Control. Release 2016, 232, 29–41 (IF = 7.441, 2015). Publisher: Elsevier B.V.

[124] Chen H., Jia P., Kang H., Zhang H., Liu Y., Yang P., Yan Y., Zuo G., Guo L., Jiang M., Qi J., Liu Y.*, Cui W.*, Santos H.A.*, Deng L.*

Issue cover picture – Upregulating Hif-1á by hydrogel nanofibrous scaffolds for rapidly recruiting angiogenesis relative cells in diabetic wound (Adv. Healthcare Mater. 8/2016). Adv. Healthcare Mater. 2016, 5(8), 856 (IF = 5.760, 2015). Publisher: Wiley-VCH.

[123] Chen H., Jia P., Kang H., Zhang H., Liu Y., Yang P., Yan Y., Zuo G., Guo L., Jiang M., Qi J., Liu Y.*, Cui W.*, Santos H.A.*, Deng L.*

Upregulating Hif-1á by hydrogel nanofibrous scaffolds for rapidly recruiting angiogenesis relative cells in diabetic wound. Adv. Healthcare Mater. 2016, 5(8), 907–918 (IF = 5.760, 2015). Publisher: Wiley-VCH.

[122] Fontana F., Mori M., Riva F., Mäkilä F., Liu D., Salonen J., Nicoletti G., Hirvonen J., Caramella C.*, Santos H.A.* Platelet lysate-

modified porous silicon microparticles for enhanced cell proliferation in wound healing applications. ACS Appl. Mater. Interfaces 2016, 8(1), 988−996 (IF = 7.145, 2015). Publisher: American Chemical Society.

[121] Vale N.*, Correia A., Figueiredo P., Santos H.A. Multinuclear NMR analysis of the antitubercular drug ethionamide. J. Mol.

Struct. 2016, 1105, 286–292 (IF = 1.780, 2015). Publisher: Elsevier B.V. Refereed reviews in scientific journal [120] Ranjan S.*, Fontana F., Ullah H., Hirvonen J., Santos H.A.* Microparticles for enhancing delivery of drugs and growth factors to

wound sites. Ther. Deliv. 2016, 7(10), 711–732 (ISSN = 2041-6008). Publisher: Future Science. (Review) [119] Balasubramanian V.*, Herranz-Blanco B., Almeida P.V., Hirvonen J., Santos H.A.* Multifaceted polymersome platforms: spanning

from self-assembly to drug delivery and protocells. Prog. Polym. Sci. 2016, 60, 51–85 (IF = 27.184, 2015). Publisher: Elsevier B.V. (Review)

[118] Ullah H., Santos H.A.*, Khan T.* Applications of bacterial cellulose in food, cosmetics and drug delivery. Cellulose 2016, 23(4) 2291–2314 (IF = 3.195, 2015). Publisher: Springer Science+Business Media. (Review)

[117] Fontana F., Ferreira M.P.A., Correia A., Hirvonen J., Santos H.A.* Microfluidics as a cutting-edge technique for drug delivery

applications. J. Drug Deliv. Sci. Technol. 2016, 34, 76–87 (IF = 0.620, 2015). Publisher: Elsevier B.V. (Review) [116] Ullah H., Wahid F., Santos H.A.*, Khan T.* Advances in biomedical and pharmaceutical applications of functional bacterial

cellulose-based nanocomposites. Carbohyd. Polym. 2016, 150, 330–352 (IF = 4.219, 2015). Publisher: Elsevier B.V. (Review) [115] Martins J.P., Kennedy P.J., Santos H.A., Barrias C., Sarmento B.* A comprehensive review of the neonatal Fc Receptor and its

application in drug delivery. Pharmacol. Ther. 2016, 161, 22–39 (IF = 11.000, 2015). Publisher: Elsevier B.V. (Review) Refereed conference abstract [114] Araújo F., Shrestha N., Gomes M. J., Liu D., Herranz-Blanco B., Hirvonen J., Granja P. L., Santos H. A., Sarmento B. Multifunctional

tailorable composite system as a dual peptide-drug delivery system. Front. Bioeng. Biotechnol. 2016 (ISSN: 2296-4185). Publisher: Frontiers Media S.A.

[113] Santos H. A. Preclinical development of porous silicon nanocomposites for translational biomedical applications. Front.

Bioeng. Biotechnol. 2016 (ISSN: 2296-4185). Publisher: Frontiers Media S.A.

2015 (29) Journal Editorial [112] Canham L., Santos H.A., Palestino G. Mesoporous biomaterials – multifunctional materials for future medical therapies and

bioanalysis. Mesoporous Biomater. 2015, 2(1), 1–2 (ISSN 2300-2271). Publisher: De Gruyter Open. (Editorial) Refereed conference publication [111] Terracciano M., Lamberti A., Santos H.A., Martucci N.M., Shahbazi M.A., Correira A., Ruggiero I., Rendina I., De Stefano L., Rea I.

Diatomite nanoparticles as potential drug delivery systems. 3rd International Conference BioPhotonics 2015, 1–3. Publisher: IEEE Xplore. (Conference proceedings)

Refereed reviews in scientific journal [110] Santos, H.A.* Microfluidics technique to revolutionize the drug delivery field: current developments and applications. Curr.

Drug Deliv. 2015, 12(6), 643–644 (IF = 1.446, 2015). Publisher: Bentham Science Publishers Ltd. (Opinion Paper) [109] Ferreira M.P.A., Balasubramanian V., Hirvonen J., Ruskoaho H., Santos H.A.* Advanced nanomedicines for the treatment and

diagnosis of myocardial infarction and heart failure. Curr. Drug Targets 2015, 16(14), 1682–1697 (IF = 3.029, 2015). Publisher: Bentham. (Review)

[108] Fonte P., Araújo F., Silva C., Pereira C., Reis S., Santos H.A., Sarmento B.* Polymeric nanoparticles for oral insulin delivery:

revisited approaches. Biotechnol. Adv. 2015, 33(6), 1342–1354 (IF = 9.848, 2015). Publisher: Elsevier B.V. (Review) [107] Araújo F., Shrestha N., Granja P.L., Hirvonen J., Santos H.A., Sarmento B.* Safety and toxicity concerns of orally delivered

nanoparticles as drug carriers. Expert Opin. Drug Metab. Toxicol. 2015, 11(3), 381–393 (IF = 2.598, 2015). Publisher: Taylor & Francis (Review)

[106] Shahbazi M.-A., Santos H.A.* Revolutionary impact of nanovaccines in immunotherapy. New Horiz. Transl. Med. 2015, 2(2),

44– 50 (ISSN: 2307-5023). Publisher: Elsevier B.V. (Review) Refereed journal articles [105] Shahbazi M.-A.*, Mäkilä E., Shrestha N., Salonen J., Hirvonen J., Santos H.A.* Controlled shape and nucleation switching of

interfacially polymerizable nanoassemblies by methyl substitution. Chem. Mater. 2015, 27(23), 8170–8178 (IF = 9.407, 2015). Publisher: American Chemical Society.

[104] Terracciano M., Shahbazi M.-A., Correia A., Rea I., Lamberti A., De Stefano L.*, Santos H.A.* Surface bioengineering of diatomite

based nanovectors for superior intracellular localization and drug delivery. Nanoscale 2015, 7(47), 20063–20074 (IF = 7.760, 2015). Publisher: Royal Society of Chemistry.

[103] Xu W., Thapa R., Liu D., Nissinen T., Granroth S., Närvänen A., Suvanto M., Santos H.A., Lehto V.-P.* Smart porous silicon

nanoparticles with polymeric coatings for sequential combination therapy. Mol. Pharmaceutics 2015, 12(11), 4038–4047 (IF = 4.342, 2015). Publisher: American Chemical Society.

[102] Correia A., Shahbazi M.-A., Mäkilä E., Almeida S., Salonen J., Hirvonen J., Santos H.A.* Cyclodextrin-modified porous silicon

nanoparticles for efficient sustained drug delivery and proliferation inhibition of breast cancer cells. ACS Appl. Mater. Interfaces 2015, 71(41), 23197–23204 (IF = 7.145, 2015). Publisher: American Chemical Society.

[101] Darville N., Saarinen J., Isomäki A., Khriachtchev L., Cleeren D., Sterkens P., van Heerden M., Annaert P., Peltonen L., Santos H.A.,

Strachan C.J., Van den Mooter G.* Multimodal non-linear optical imaging for the investigation of drug nano-/microcrystal-cell interactions. Eur. J. Pharm. Biopharm. 2015, 96, 338–348 (IF = 3.975, 2015). Publisher: Elsevier B.V.

[100] Araújo F., Shrestha N., Shahbazi M.-A., Liu D., Herranz-Blanco B., Mäkilä E., Salonen J., Hirvonen J., Granja P.L., Sarmento B.*,

Santos H.A.* Microfluidic assembly of a multifunctional composite system designed for site specific combined oral delivery of peptide drugs. ACS Nano 2015, 9(8) 8291–8302 (IF = 13.334, 2015). Publisher: American Chemical Society.

[99] Shrestha N., Shahbazi M.-A., Araújo F., Mäkilä E., Raula J., Kauppinen E. I., Salonen J., Sarmento B., Hirvonen J., Santos H.A.*

Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: A controlled dual protein- drug delivery system. Biomaterials 2015, 68, 9–20 (IF = 8.387, 2015). Publisher: Elsevier B.V.

[98] Vasiliauskas R., Liu D., Cito S., Zhang H., Shahbazi M.-A., Sikanen T., Mazutis L.*, Santos H.A.* Simple microfluidic approach to

fabricate monodisperse hollow microparticles for multidrug delivery. ACS Appl. Mater. Interfaces 2015, 7(27), 14822–14832 (IF = 7.145, 2015). Publisher: American Chemical Society.

[97] Roine J.*, Kaasalainen M., Peurla M., Correia A., Araújo F., Santos H.A., Murtomaa M., Salonen J. Controlled dissolution of

griseofulvin solid dispersions from electrosprayed enteric polymer micromatrix particles: physicochemical characterization and in vitro evaluation. Mol. Pharmaceutics 2015, 12(7), 2254–2264 (IF = 4.342, 2015). Publisher: American Chemical Society.

[96] Kong F., Zhang Xu, Zhang H., Qu X., Chen D., Servos M., Mäkilä E., Salonen J., Santos H.A., Hai M.*, Weitz D.A.* Inhibition of

multidrug resistance of cancer cells by co-delivery of DNA nanostructures and drugs using porous silicon nanoparticles@giant liposomes. Adv. Funct. Mater. 2015, 25(22), 3330–3340 (IF = 11.382, 2015). Publisher: Wiley-VCH.

[95] Shahbazi M.-A.*, Shrestha N., Mäkilä E., Araújo F., Correia A., Ramos T., Sarmento B., Salonen J., Hirvonen J., Santos H.A.* A

prospective cancer chemo-immunotherapy approach mediated by synergistic CD326 targeted porous silicon nanovectors. Nano Res. 2015, 8(5), 1505–1521 (IF = 8.893, 2015). Publisher: Springer

[94] Liu D.*, Cito S., Zhang Y., Wang C.-F., Sikanen T.M., Santos H.A.* Microfluidics: A Versatile and robust microfluidic platform

towards high throughput synthesis of homogeneous nanoparticles with tunable properties (Issue’s Front Cover Page). Adv. Mater. 2015, 27(14), 2269 (IF = 18.960, 2015). Publisher: Wiley-VCH.

[93] Liu D.*, Cito S., Zhang Y., Wang C.-F., Sikanen T.M., Santos H.A.* A versatile and robust microfluidic platform towards high

throughput synthesis of homogeneous nanoparticles with tunable properties. Adv. Mater. 2015, 27(14), 2298–2304 (IF = 18.960, 2015). Publisher: Wiley-VCH.

[92] Wang C.-F.*, Mäkilä E.M., Kaasalainen M.H., Hagström M.V., Salonen J.J., Hirvonen J.T., Santos H.A.* Dual-drug delivery by porous silicon nanoparticles for improved cellular uptake, sustained release, and combination therapy. Acta Biomater. 2015, 16, 206–214 (IF = 6.008, 2015). Publisher: Elsevier B.V.

[91] Herranz-Blanco B.*, Liu D., Mäkilä E., Shahbazi M.-A., Ginestar E., Zhang H., Aseyev V., Balasubramanian V., Salonen J., Hirvonen

J., Santos H.A.* Drug delivery: On-chip self-assembly of a smart hybrid nanocomposite for antitumoral applications (Issue’s Back Cover Page). Adv. Funct. Mater. 2015, 25(10), 1612 (IF = 11.382, 2015). Publisher: Wiley-VCH.

[90] Herranz-Blanco B.*, Liu D., Mäkilä E., Shahbazi M.-A., Ginestar E., Zhang H., Aseyev V., Balasubramanian V., Salonen J., Hirvonen

J., Santos H.A.* On-chip self-assembly of a smart hybrid nanocomposite for antitumoral applications. Adv. Funct. Mater. 2015, 25(10), 1448–1497 (IF = 11.382, 2015). Publisher: Wiley-VCH.

[89] Riikonen J., Correia A., Kovalainen M., Näkki S., Lehtonen M., Leppänen J., Rantanen J., Xu W., Araújo F., Hirvonen J., Järvinen K.,

Santos H.A., Lehto V.-P. Systematic in vitro and in vivo study on nanostructured porous silicon to improve oral bioavailability of celecoxib. Biomaterials 2015, 52, 44–55 (IF = 8.387, 2015). Publisher: Elsevier B.V.

[88] Näkki S., Rytkönen J., Nissinen T., Florea C., Riikonen J., Ek P., Zhang H., Santos H.A., Närvänen A., Xu W.*, Lehto V.-P. Improved

stability and biocompatibility of nanostructured silicon drug carrier for intravenous administration. Acta Biomater. 2015, 13, 207–215 (IF = 6.008, 2015). Publisher: Elsevier B.V.

[87] Wang C.-F.*, Mäkilä E., Bonduelle C., Rytkonen J., Raula J., Almeida S., Närvänen A., Salonen J., Lecommandoux S., Hirvonen J.,

Santos H.A.* Functionalization of alkyne-terminated thermally hydrocarbonized porous silicon nanoparticles with targeting peptides and antifouling polymers: effect on the human plasma protein adsorption. ACS Appl. Mater. Interfaces 2015, 7(3), 2006–2015 (IF = 7.145, 2015). Publisher: American Chemical Society.

[86] Wang C.-F., Sarparanta M., Mäkilä E., Hyvönen M.L.K., Laakkonen P.M., Salonen J., Hirvonen J.T., Airaksinen A.J.*, Santos H.A.*

Multifunctional porous silicon nanoparticles for cancer theranostics. Biomaterials 2015, 48, 108–118 (IF = 8.387, 2015). Publisher: Elsevier B.V.

[85] Nyström S.*, Roine J., Murtomaa M., Sankaran R.M., Santos H.A., Salonen J. Solid state transformations in consequence of

electrospraying – a novel polymorphic form of piroxicam. Eur. J. Pharm. Biopharm. 2015, 89, 182–189 (IF = 3.975, 2015). Publisher: Elsevier B.V.

[84] Liu D.*, Zhang H., Mäkilä E., Fan J., Herranz-Blanco B., Wang C.-F., Rosa R., Ribeiro A.J., Salonen J., Hirvonen J., Santos H.A.*

Microfluidic assisted one-step fabrication of porous silicon@acetalated dextran nanocomposites for precisely controlled combination chemotherapy. Biomaterials 2015, 39, 249–259 (IF = 8.387, 2015). Publisher: Elsevier B.V.

2014 (21) Refereed reviews in scientific journal [83] Pereira C., Araújo F., Granja P., Santos H.A., Sarmento B.* Targeting membrane transporters and receptors as a mean to optimize

orally delivered biotechnological based drugs through nanoparticle delivery systems. Curr. Pharm. Biotechnol. 2014, 15(7), 650658 (IF = 1.802, 2015). Publisher: Bentham. (Review)

[82] Araújo F., Shrestha N., Granja P.L., Hirvonen J., Santos H.A.*, Sarmento B.* Antihyperglycemic potential of incretins delivered

via nano and microsystems and subsequent glucoregulatory effects. Curr. Pharm. Biotechnol. 2014, 15(7), 609619 (IF = 1.802, 2015). Publisher: Bentham. (Review)

[81] Shrestha N., Araújo F., Sarmento B., Hirvonen J., Santos H.A.* Gene based therapy for type 1 diabetes mellitus: Viral and non-

viral vectors. Diabetes Manag. 2014, 4(4), 367380 (IF = 2.179, 2015). Publisher: Future Medicine (Review) [80] Santos H.A., Mäkilä E., Airaksinen A.J., Bimbo L.M., Hirvonen J.* Porous silicon nanoparticles for nanomedicine: Preparation and

biomedical applications. Nanomedicine (Lond.) 2014, 9(4), 535554 (IF = 4.889, 2015). Publisher: Future Medicine Ltd. (Review) Refereed journal articles [79] Mori M., Almeida P.V., Cola M., Anselmi G., Mäkilä E., Correia A., Salonen J., Hirvonen J., Caramella C.*, Santos H.A.* In vitro

assessment of biopolymer-modified porous silicon microparticles for wound healing applications. Eur. J. Pharm. Biopharm. 2014, 88(3), 635–642 (IF = 3.975, 2015). Publisher: Elsevier.

[78] Fussell A.L., Mah P.T., Offerhaus H.*, Niemi S.-M., Salonen J., Santos H.A., Strachan C. Coherent anti-Stokes Raman scattering

microscopy driving the future of drug loaded MCM-41 ordered mesoporous silica imaging. Acta Biomater. 2014, 10(11), 4870– 4877 (IF = 6.008, 2015). Publisher: Elsevier B.V.

[77] Shahbazi M.-A.*, Fernández T.D., Mäkilä E., Le Guével X., Mayorga C., Kaasalainen M., Salonen J., Hirvonen J., Santos H.A.*

Surface chemistry dependent immunostimulative potential of porous silicon nanoplatforms. Biomaterials 2014, 35(33), 9224–9235 (IF = 8.387, 2015). Publisher: Elsevier B.V.

[76] Araújo F, Shrestha N., Shahbazi M.-A., Fonte P., Mäkilä E.M., Salonen J.J., Hirvonen J.T., Granja P.L., Santos H.A.*, Sarmento B.*

The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium. Biomaterials

2014, 35(33), 9199–9207 (IF = 8.387, 2015). Publisher: Elsevier B.V. [75] Almeida P.V., Shahbazi M.-A., Mäkilä E., Kaasalainen M., Salonen J., Hirvonen J., Santos H.A.* Amine-modified hyaluronic acid-

functionalized porous silicon nanoparticles for breast cancer targeting. Nanoscale 2014, 6(17), 10377–10387 (IF = 7.760, 2015). Publisher: Royal Society of Chemistry.

[74] Kallinen A.M., Sarparanta M.P., Liu D., Mäkilä E.M., Salonen J.J., Hirvonen J.T., Santos H.A.*, Airaksinen A.J.* In vivo evaluation

of porous silicon and porous silicon solid lipid nanocomposites for passive targeting and imaging. Mol. Pharmaceutics 2014, 11(8), 2876–2886 (IF = 4.342, 2015). Publisher: American Chemical Society.

[73] Tölli M.A., Ferreira M.P.A., Kinnunen S.M., Rysä J., Mäkilä E.M., Szabó Z., Serpi R.E., Ohukainen P.J., Välimäki M.J., Correia A.M.R.,

Salonen J.J., Hirvonen J.T, Ruskoaho H.J.*, Santos H.A.* In vivo biocompatibility of porous silicon biomaterials for drug delivery to the heart. Biomaterials 2014, 35(29), 8394–8405 (IF = 8.387, 2015). Publisher: Elsevier B.V.

[72] Zhang H.*, Liu D., Shahbazi M.-A., Mäkilä E., Herranz-Blanco B., Salonen J., Hirvonen J., Santos H.A* Fabrication of a

multifunctional nano-in-micro drug delivery platform by microfluidic templated encapsulation of porous silicon in polymer matrix. Adv. Mater. 2014, 26(26), 4497–4503 (IF = 18.960, 2015). Publisher: Wiley-VCH.

[71] Pessi J.,* Santos H.A., Miroshnyk I, Yliruusi J., Weitz D.A., Mirza S.* Microfluidic-assisted engineering of polymeric microcapsules

with high encapsulation efficiency for protein drug delivery. Int. J. Pharm. 2014, 472(1–2), 82–87 (IF = 3.994, 2015). Publisher: Elsevier B.V.

[70] Shahbazi M.-A.*, Almeida P.V., Mäkilä E.M., Kaasalainen M.H., Salonen J.J., Hirvonen J.T., Santos H.A.* Augmented cellular

trafficking and endosomal escape of porous silicon nanoparticles via zwitterionic bilayer polymer surface engineering. Biomaterials 2014, 35(26), 7488–7500 (IF = 8.387, 2015). Publisher: Elsevier B.V.

[69] Shrestha N., Shahbazi M.-A., Araújo F., Zhang H., Mäkilä E.M., Kauppila J., Sarmento B., Salonen J., Hirvonen J., Santos H.A.*

Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers. Biomaterials 2014, 35(25), 7172–7179 (IF = 8.387, 2015). Publisher: Elsevier B.V.

[68] Liu D., Zhang H., Herranz-Blanco B., Mäkilä E., Lehto V.-P., Salonen J., Hirvonen J., Santos H.A.* Microfluidic assembly of

monodisperse multistage pH-responsive polymer/porous silicon composites for precisely controlled multi-drug delivery. Small 2014, 10(10), 2029–2038 (IF = 8.315, 2015). Publisher: Wiley-VCH.

[59] Shahbazi M.-A.*, Almeida P.V., Mäkilä E., Correia A., Ferreira M.P.A., Kaasalainen M., Salonen J., Hirvonen J., Santos H.A.*

Poly(methyl vinyl ether-alt-maleic acid) functionalized porous silicon nanoparticles for enhanced stability and cellular internalization. Macromol. Rapid Comm. 2014, 35(6), 624629 (IF = 4.638, 2015). Publisher: Wiley-VCH.

[66] Mäkilä E., Ferreira M.P.A., Kivelä H., Niemi S.-M., Correia A., Shahbazi M.-A., Kauppila J., Hirvonen J., Santos H.A., Salonen J.*

Confinement effects on drugs in thermally hydrocarbonized porous silicon. Langmuir 2014, 30(8), 2196–2205 (IF = 3.993, 2015). Publisher: American Chemical Society.

[65] Wang C.-F.,* Auriola S., Hirvonen J., Santos H.A.* Conjugation of peptides to antisense interleukin-6 via click chemistry. Curr.

Med. Chem. 2014, 21(10), 1247–1254 (IF = 3.455, 2015). Publisher: Bentham. [64] Herranz-Blanco B., Arriaga L.R., Mäkilä E., Correia A., Shrestha N., Mirza S., Weitz D.A., Salonen J., Hirvonen J.T., Santos H.A.*

Microfluidic assembly of multistage porous silicon/lipid vesicles for controlled drug release. Lab Chip 2014, 14(6), 1083–1086 (IF = 5.586, 2015). Publisher: Royal Society of Chemistry.

(One of the Lab On a Chip 2014 Most Accessed Article) [63] Wang C.-F., Mäkilä E.M., Kaasalainen M.H., Liu D., Sarparanta M.P., Airaksinen A.J., Salonen J.J.,. Hirvonen J.T, Santos H.A.*

Copper-free azide–alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for enhanced intracellular uptake and drug delivery. Biomaterials 2014, 35(4), 1257–1266 (IF = 8.387, 2015). Publisher: Elsevier B.V.

2013 (17) Refereed journal articles [62] Santos H.A., Peltonen L., Limnell T., Hirvonen J.* Mesoporous materials and nanocrystals for enhancing the dissolution behavior of

poorly water-soluble drugs. Curr. Pharm. Biotechnol. 2013, 14(10), 926–938 (IF = 1.802, 2015). Publisher: Bentham. (Review) [61] Liu D., Herranz-Blanco B., Mäkilä E., Arriaga L.R., Mirza S., Weitz D.A., Sandler N., Salonen J., Hirvonen J., Santos H.A.* Microfluidic

templated mesoporous silicon−solid lipid microcomposites for sustained drug delivery. ACS Appl. Mater. Interfaces 2013, 5(22), 12127–12134 (IF = 7.145, 2015). Publisher: American Chemical Society.

[60] Zhang H., Shahbazi M.-A., Mäkilä E.M., da Silva T.H., Reis R.L., Salonen J.J., Hirvonen J.T., Santos H.A.* Diatom silica microparticles

for sustained release and permeation enhancement following oral delivery of prednisone and mesalamine. Biomaterials 2013, 34(36), 9210–9219 (IF = 8.387, 2015). Publisher: Elsevier B.V.

[60] Kinnari P.J., Hyvönen M., Mäkilä E.M., Kaasalainen M.H., Rivinoja A., Salonen J.J., Hirvonen J.T., Laakkonen P.M., Santos H.A.*

Tumour homing peptide-functionalized porous silicon nanovectors for cancer therapy. Biomaterials 2013, 34(36), 9134–9141 (IF = 8.387, 2015). Publisher: Elsevier B.V.

[58] Bimbo L.M., Denisova O.V., Mäkilä E., Kaasalainen M., De Brabander J.K., Hirvonen J., Salonen J., Kakkola L., Kainov D., Santos

H.A.* Inhibition of influenza A virus infection in vitro by saliphenylhalamide loaded porous silicon nanoparticles. ACS Nano 2013, 7(8), 6884–6893 (IF = 13.334, 2015). Publisher: American Chemical Society.

[57] Shahbazi M.-A., Hamidi M., Mäkilä E., Zhang H., Almeida P., Kaasalainen M., Salonen J., Hirvonen J., Santos H.A.* The mechanisms

of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility. Biomaterials 2013, 34(31), 7776–7789 (IF = 8.387, 2015). Publisher: Elsevier B.V.

Unrefereed scientific article [56] Santos H.A.* Drug Delivery with Nanostructured Porous Silicon Nanoparticles. SPIE Nwesroom 2013. Publisher: SPIE. Refereed journal articles [55] Liu D.,* Bimbo L.M., Mäkilä E., Villanova F., Kaasalainen M., Herranz B., Caramella C.M., Lehto V.-P., Salonen J., Herzig K.-H.,

Hirvonen J., Santos H.A.* Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. J. Control. Release 2013, 170(2), 268–278 (IF = 7.441, 2015). Publisher: Elsevier B.V.

[54] Liu D., Mäkilä E., Zhang H., Herranz B., Kaasalainen M., Kinnari P.J., Salonen J., Hirvonen J., Santos H.A.* Nanostructured porous

silicon-solid lipid nanocomposite: towards enhanced cytocompatibility and stability, reduced cellular association and prolonged drug release. Adv. Funct. Mater. 2013, 23(15), 1893–1902 (IF = 11.382, 2015). Publisher: Wiley-VCH.

[53] Mori M., Airaksinen A.J., Hirvonen J., Santos H.A.*, Caramella C.* Evaluation of physicochemical and biopharmaceutical

properties of fluoro-indomethacin. Curr. Drug Metab. 2013, 14(1), 80–89 (IF = 2.847, 2015). Publisher: Bentham Science Publishers Ltd.

Refereed reviews in scientific journal [52] Santos H.A.*, Bimbo L.M., Herranz B., Shahbazi M.-A., Hirvonen J., Salonen J. Nanostructured porous silicon in preclinical

imaging: moving from bench to bed side. J. Mater. Res. 2013, 28(2), 152–164 (IF = 1.579, 2015). Publisher: Materials Research Society. (Review)

[51] Vale N., Gomes P., Santos H.A.* Metabolism of the antituberculosis drug ethionamide. Curr. Drug Metab. 2013, 14(1), 151–

158 (IF = 2.847, 2015). Publisher: Bentham Science Publishers Ltd. (Review) [50] Shahbazi M.-A. and Santos H.A.* Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal

models and rational fabrication. Curr. Drug Metab. 2013, 14(1), 28–56 (IF = 2.847, 2015). Publisher: Bentham Science Publishers Ltd. (Review)

Journal Editorial [49] Santos H.A.* Non-Animal Models Used in Drug Discovery: Drug Absorption and Metabolism. Curr. Drug Metab. 2013, 14(1), 2–

3 (IF = 2.847, 2015). Publisher: Bentham Science Publishers Ltd. (Editorial)

Article in conference publication (refereed) [48] Zhang H., Shahbazi M.-A., Mäkilä E., Silva T. H., Reis R. L., Salonen J. J., Hirvonen J., Santos H.A. Sustained release of prednisone

and mesalamine from diatom exoskeletons: bioinspiration for the development of safe oral drug delivery devices to tackle gastrointestinal diseases. J. Tissue Eng. Regen. Med. 2013, 7(S1), S33 (IF = 4.71, 2015). Publisher: Wiley-VCH.

[47] Kallinen A., Liu D.F., Mäkilä E., Sarparanta M., Salonen J., Hirvonen J., Santos, H.A., Airaksinen A.J. F-18-radiolabeled solid lipid

nanocomposite porous silicon nanoparticles for studying the tumour accumulation of the particles. J. Labelled Comp. Rad. 2013, 56(S1), S252 (IF = 1.532, 2015). Publisher: Wiley-VCH.

[46] Sarparanta M., Bimbo L.M., Rytkönen J.J., Mäkilä E., Salonen J., Santos H.A., Laaksonen T., Hirvonen J., Lehto V.-P., Laaksonen P.,

Linder M.B., Airaksinen A.J. Effects of hydrophobin-biofunctionalization on the in vivo behavior of F-18-radiolabeled porous silicon drug delivery systems. J. Labelled Comp. Rad. 2013, 56(S1), S251 (IF = 1.532, 2015). Publisher: Wiley-VCH.

2012 (13) Journal Editorial [45] Santos H.A. and Hirvonen J.* Nanostructured porous silicon materials: potential candidates for improving drug delivery.

Nanomedicine (Lond.) 2012, 7(9), 1281–1284 (IF = 4.889, 2015). Publisher: Future Medicine Ltd. (Editorial) [44] Santos H.A.* Porous-based biomaterials for tissue engineering and drug delivery applications. Biomatter 2012, 2(4), 237–238

(ISSN 21592535). Publisher: Landes Bioscience. (Editorial)

Refereed review in scientific journal [43] Bimbo L.M.*, Peltonen L., Hirvonen J., Santos H.A.* Toxicological profile of therapeutic nanodelivery systems. Curr. Drug

Metab. 2012 13(8), 1068–1086 (IF = 2.847, 2015). Publisher: Bentham Science Publishers Ltd. (Review) Refereed journal articles [42] Shahbazi M.-A., Herranz B., Santos H.A.* Nanostructured porous Si-based nanoparticles for targeted drug delivery. Biomatter

2012, 2(4), 296–312 (ISSN 21592535). Publisher: Taylor & Francis. (Review) [41] Araújo F., Fonte P., Santos H.A., Sarmento B.* Oral delivery of GLP-1 and analogs: alternatives for diabetes control? J. Diabetes

Sci. Tech. 2012 6(6), 1486–1497 (ISSN 19322968). Publisher: Diabetes Technology Society. (Review) [40] Mäkilä E., Bimbo L.M., Kaasalainen M., Herranz B., Airaksinen A.J., Heinonen M., Kukk E., Hirvonen J., Santos H.A., Salonen J.*

Amine-modification of thermally carbonized porous silicon with silane coupling chemistry. Langmuir 28(39), 14045–14054 (IF = 3.993, 2015). Publisher: American Chemical Society.

[39] Shevchenko A.*, Bimbo L.M., Miroshnyk I., Jelínková K., Haarala J., van Veen B., Santos H.A., Yliruusi J. A new cocrystal and salts

of itraconazole: comparison of solid-state properties, stability and dissolution behavior. Int. J. Pharm. 2012, 436(1–2), 403–409 (IF = 3.994, 2015). Publisher: Elsevier B.V.

[38] Vale V.*, Mäkilä E., Salonen J., Gomes P., Hirvonen J., Santos H.A.* New times, new trends for ethionamide: In vitro studies of thermally carbonized porous silicon microparticles. Eur. J. Pharm. Biopharm. 2012, 81(2), 314–323 (IF = 3.975, 2015). Publisher: Elsevier B.V.

[37] Bimbo L.M.*, Sarparanta M., Mäkilä E., Laaksonen T., Laaksonen P., Salonen J., Linder M.B., Hirvonen J., Airaksinen A.J., Santos

H.A.* Cellular interactions of surface modified nanoporous silicon particles. Nanoscale 2012, 4(10), 3184–3192 (IF = 7.760, 2015). Publisher: Royal Society of Chemistry.

[36] Sarparanta M.*, Bimbo L.M., Mäkilä E., Laaksonen T.J., Laaksonen P.H., Nyman M., Salonen J., Linder M.B., Hirvonen J., Santos H.A., Airaksinen A.J. Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution. Mol. Pharmaceutics 2012, 9(3), 654–663 (IF = 4.342, 2015). Publisher: American Chemical Society.

[35] Sarparanta M.P.*, Bimbo L.M., Mäkilä E.M., Salonen J.J., Laaksonen P.H., Helariutta A.M.K., Linder M.B., Hirvonen J.T., Laaksonen T.J.,

Santos H.A., Airaksinen A.J.* The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems. Biomaterials 2012, 33(11), 3353–3362 (IF = 8.387, 2015). Publisher: Elsevier B.V.

[34] Tahvanainen M.*, Rotkoa T., Mäkilä E., Santos H.A., Neves D., Laaksonen T., Kallonen A., Hämäläinen K., Peura M., Serimaa R.,

Salonen J., Hirvonen J., Peltonen L. Tablet preformulations of indomethacin-loaded mesoporous silicon microparticles. Int. J. Pharm. 2012, 422(3), 125–131 (IF = 3.994, 2015). Publisher: Elsevier B.V.

Unreferred scientific article [33] Santos H.A.*, Porous silicon revolutionising drug targeting and delivery, NANO the magazine for small science 2012, Issue

24, 19–22 (ISSN 1757-2517). (Featured Article invited)

2011 (13) Journal Editorial [32] Santos H.A.* Innovative technologies for drug delivery applications: from biopolymers and nanocapsules to inorganic

materials. Curr. Drug Discov. Technol. 2011, 8(3), 155–156 (ISSN 1570-1638). Publisher: Bentham Science Publishers Ltd. (Editorial) Refereed journal articles [31] Sarparanta M.*, Mäkilä E., Heikkilä T., Salonen J.J., Kukk E., Lehto V.-P., Santos H.A., Hirvonen J., Airaksinen A.J.* 18F-Labeled

modified porous silicon particles for investigation of drug delivery carrier distribution in vivo with positron emission tomography. Mol. Pharmaceutics 2011, 8(5), 1799–1806 (IF = 4.342, 2015). Publisher: American Chemical Society.

[30] Bimbo L.M.*, Mäkilä E., Raula J., Laaksonen T., Laaksonen P., Strommer K., Kauppinen E.I., Salonen J., Linder M.B., Hirvonen J.,

Santos H.A.* Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles. Biomaterials 2011, 32(34), 9089–9099 (IF = 8.387, 2015). Publisher: Elsevier B.V.

[29] Limnell T.*, Heikkilä T.*, Santos H.A., Sistonen S., Ojanen S., Laaksonen T., Peltonen L., Kumar N., Murzin D. Y., Louhi-Kultanen

M., Salonen J., Hirvonen J., Lehto V.-P. Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles. Int. J. Pharm. 2011, 416(1), 242–251 (IF = 3.994, 2015). Publisher: Elsevier B.V.

[28] Kinnari P., Mäkilä E., Heikkilä T., Salonen J., Hirvonen J., Santos H.A.* Comparison of mesoporous silicon and non-ordered

mesoporous silica materials as drug carriers for itraconazole. Int. J. Pharm. 2011, 414(1–2), 148–156 (IF = 3.994, 2015). Publisher: Elsevier B.V.

[27] Limnell T.*, Santos H.A., Mäkilä E., Heikkilä T., Salonen J., Murzin D.Y., Kumar N., Laaksonen T., Peltonen L., Hirvonen J. Drug

delivery formulations of ordered and non-ordered mesoporous silica: Comparison of three drug loading methods. J. Pharm. Sci. 2011, 100(8), 3294–3306 (IF = 2.59, 2015). Publisher: Wiley-VCH.

Refereed reviews in scientific journal [26] Santos H.A.*, Bimbo L.M., Lehto V.-P., Airaksinen A.J., Salonen J., Hirvonen J. Multifunctional porous silicon for therapeutic drug

delivery and imaging. Curr. Drug Discov. Tech. 2011, 8(3), 228–249 (ISSN 1570-1638). Publisher: Bentham Science Publishers Ltd. (Review)

[25] Santos H.A., Salonen J., Bimbo L.M., Lehto V.-P., Peltonen L., Hirvonen J.* Mesoporous materials as controlled drug delivery

formulations. J. Drug Deliv. Sci. Technol. 2011, 21(2), 139155 (IF = 0.620, 2015). Publisher: Elsevier B.V. (Review) Refereed journal article [24] Bimbo L.M.*, Mäkilä E., Laaksonen T., Lehto V.-P., Salonen J., Hirvonen J., Santos H.A.* Drug permeation across intestinal

epithelial cells using porous silicon nanoparticles. Biomaterials 2011, 32(10), 26252633 (IF = 8.387, 2015). Publisher: Elsevier B.V.

Article in conference publication (refereed) [23] Sarparanta M.*, Bimbo L.M., Mäkilä E., Salonen J., Santos H.A., Laaksonen T., Hirvonen J., Lehto V.P., Laaksonen P., Linder M.B.,

Airaksinen A.J. Fluorine-18 radiolabeling as a tool to evaluate novel porous silicon based nano- and microcarriers for drug delivery. J. Labelled Comp. Rad. 2011, 54(S1), S538 (IF = 1.532, 2015). Publisher: Wiley-VCH.

[22] Limnell T., Mäkilä E., Heikkilä T., Salonen J., Murzin D.Y., Kumar N., Laaksonen T., Peltonen L., Hirvonen J., Santos H.A.*

Preparation and characterization of drug formulations of ordered and nonordered mesoporous silica microparticles. Eur. J. Pharm. Sci. 2011, 44 (S1), S125–S126 (IF = 3.773, 2015). Publisher: Elsevier B.V.

[21] Bimbo L. M.*, Sarparanta M., Mäkilä E., Laaksonen T., Peltonen L., Lehto V.-P., Airaksinen A.J., Salonen J., Hirvonen J., Santos H.A.

Mesoporous silicon particles as biocompatible drug delivery agents. Eur. J. Pharm. Sci. 2011, 44(S1), S129–S130 (IF = 3.773, 2015). Publisher: Elsevier B.V.

[20] Kinnari P.*, Mäkilä E., Heikkilä T., Salonen J., Hirvonen J., Santos H.A. Stability studies of itraconazole-loaded mesoporous silicon

and non-ordered mesoporous silica microparticles. Eur. J. Pharm. Sci. 2011, 44(S1), S131–S132 (IF = 3.773, 2015). Publisher: Elsevier B.V.

2010 (6) Article in conference publication (refereed) [19] Santos H.A.*, Bimbo L.M., Salonen J., Lehto V.-P., Hirvonen J. Tailoring in vitro cell responses of porous silicon micro- and

nanoparticles. Control. Release Soc. Newslett. 2010, 27(1), 10–11. Publisher: Controlled Release Society. (Scientifically speaking - invited)

Refereed journal articles [18] Bimbo L.M., Sarparanta M., Santos H.A.*, Airaksinen A.J., Mäkilä E., Laaksonen T., Peltonen L., Lehto V.-P., Hirvonen J., Salonen

J.* Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano 2010, 4(6), 3023–3032 (IF = 13.334, 2015). Publisher: American Chemical Society.

[17] Pinto V.V.*, Ferreira M.J., Silva R., Santos H.A., Silva F., Pereira C.M.* Long time effect on the stability of silver nanoparticles in

aqueous medium: The effect of synthesis and storage conditions. Colloids Surf. A 2010, 364(1–3), 19–25 (IF = 3.902, 2015). Publisher: Elsevier B.V.

[16] Santos H.A.*, Riikonen J., Salonen J., Heikkilä T., Mäkilä E., Laaksonen T., Peltonen L., Lehto V.-P., Hirvonen J. In vitro cytotoxicity

of porous silicon microparticles: effect of the particle concentration, surface chemistry and size. Acta Biomater. 2010, 6(7), 2721–2731 (IF = 6.008, 2015). Publisher: Elsevier B.V.

[15] Heikkilä T.*, Santos H.A., Kumar N., Murzin D.Y., Salonen J., Laaksonen T., Peltonen L., Hirvonen J., Lehto V.-P. Cytotoxicity of

ordered mesoporous silica MCM-41 and SBA-15 microparticles. Eur. J. Pharm. Biopharm. 2010, 74(34), 483–494 (IF = 3.975, 2015). Publisher: Elsevier B.V.

Refereed review in scientific journal [14] Santos H.A.*, García-Morales V., Pereira C.M. Electrochemical properties of phospholipid monolayers at liquid–liquid

interfaces. ChemPhysChem 2010, 11(1), 28–41 (IF = 3.138, 2015). Publisher: Wiley-VCH. (Review)

2008 (3)

Refereed review in scientific journal [13] Hirvonen J.*, Laaksonen T., Peltonen L., Santos H., Lehto V.-P., Heikkilä T., Riikonen J., Mäkilä E., Salonen J. Feasibility of silicon-

based mesoporous materials for oral drug delivery applications. Dosis 2008, 24(2), 129–149 (ISSN 0783-4233). Publisher: The Finnish Pharmacists' Association. (Review)

Article in conference publication (refereed) [12] Santos H.A.*, Riikonen J., Heikkilä T., Salonen J., Peltonen L., Mäkilä E., Laaksonen T., Kumar N., Murzin D., Lehto V.-P., Hirvonen

J. Biocompatibility of mesoporous silicon microparticles. Eur. J. Pharm. Sci. 2008, 34(1), S36–S37 (IF = 3.773, 2015). Publisher: Elsevier B.V.

[11] Laaksonen T.*, Limnell T., Santos H., Heikkilä T., Riikonen J., Salonen J., Peltonen L., Lehto V.-P., Hirvonen J. Drug dissolution

studies on mesoporous silicon particles – a theoretical approach. Eur. J. Pharm. Sci. 2008, 34(1), S35 (IF = 3.773, 2015). Publisher: Elsevier B.V.

2007 (6) Refereed journal articles [10] Laaksonen T.*, Santos H., Vihola H., Salonen J., Riikonen J., Heikkilä T., Peltonen L., Kumar N., Murzin D.Y., Lehto V.-P., Hirvonen

J. Failure of MTT as a toxicity testing agent for mesoporous silicon microparticles. Chem. Res. Toxicol. 2007, 20(12), 1913–1918 (IF = 3.025, 2015). Publisher: American Chemical Society.

[9] Santos H.A.*, Ferreira E.S., Pereira E.J., Pereira C.M.*, Kontturi K., Silva F. Adsorption–penetration studies of glucose oxidase

into phospholipid monolayers at the 1,2–dichloroethane/water interface. ChemPhysChem 2007, 8(10), 1540–1547 (IF = 3.138, 2015). Publisher: Wiley-VCH.

[8] Santos H.A.*, Manzanares J.A., Mortumäki L., Kontturi K.* Thermodynamic analysis of binding between drugs and

glycosaminoglycans by isothermal titration calorimetry and fluorescence spectroscopy. Eur. J. Pharm. Sci. 2007, 32(2), 105–114 (IF = 3.773, 2015). Publisher: Elsevier B.V.

[7] Santos H.A.*, Carlsson S., Murtomäki L., Kontturi K.* Effect of gramicidin on phospholipid monolayers and on ion transfer at a

liquid–liquid interface. ChemPhysChem 2007, 8(6), 913–920 (Journal’s issue cover picture, p. 769) (IF = 3.138, 2015). Publisher: Wiley-VCH.

[6] Martins M.C., Pereira C.M.*, Santos H.A., Dabirian R., Silva F., García-Morales V., Manzanares J.A. Analysis of adsorption of

phospholipids at the 1,2-dichloroethane/water interface by electrochemical impedance spectroscopy: a study of the effect of the saturated alkyl chain. J. Electroanal. Chem. 2007, 599(2), 367–375 (IF = 2.822, 2015). Publisher: Elsevier B.V.

[5] Santos H.A.*, García-Morales V., Manzanares J.A., Murtomäki L., Kontturi K.* Preparation of nanostructures composed of

dextran-sulfate ruthenium nanoparticles and their interaction with phospholipid monolayers at a liquid–liquid interface. J. Electroanal. Chem. 2007, 599(2), 194–202 (IF = 2.822, 2015). Publisher: Elsevier B.V.

2005 (3) [4] Santos H.A.*, Chirea M., García-Morales V., Silva F., Manzanares J.A., Kontturi K.* Electrochemical study of interfacial composite

nanostructures: polyelectrolyte/gold nanoparticle multilayers assembled on phospholipid/dextran sulfate monolayers at a liquid–liquid interface. J. Phys. Chem. B 2005, 109(43), 20105–20114 (IF = 3.187, 2015). Publisher: American Chemical Society.

[3] Santos H.A., García-Morales V., Roozeman R.-J., Manzanares J.A., Kontturi K.* Interfacial interaction between dextran sulfate

and lipid monolayers: an electrochemical study. Langmuir 2005, 21(12), 5475–5484 (IF = 3.993, 2015). Publisher: American Chemical Society.

[2] Santos H.A., Pereira C.M. *, Silva F. Ion transfer through DPPC films. Port. Electrochim. Acta 2005, 23(2), 263–274 (ISSN 0872-

1904). Publisher: Portuguese Society of Electrochemistry. 2003 (1) [1] Fernandes P.A., Carvalho A.T.P., Marques A.T., Pereira A.L.F., Madeira A.P.S., Ribeiro A.S.P., Carvalho A.F.R., Ricardo E.T.A., Pinto

F.J.V., Santos H.A., Mangericão H.D.G., Martins H.M., Pinto H.D.B., Santos H.R.R., Moreira I.S., Azeredo M.J.V., Abreu R.P.S., Oliveira R.M.S., Sousa S.F.M., Silva R.J.A.M., Mourão Z.S., Ramos M.J.* New designs for MRI contrast agents. J. Comput.-Aided Mol. Design 2003, 17, 463–473 (IF = 3.199, 2015). Publisher: Springer.

Abstracts, Posters, & Oral Communications Presented in Scientific Meetings. Published in Conferences Proceedings: 2018 (30) [229] E. Mäkilä, C.-F. Wang, O. M. Keinänen, M. Kaasalainen, A. J. Airaksinen, S. Lecommandoux, H. A. Santos, J. Salonen, "Click

chemistry on hydrolytically stable porous silicon", 12th Annual MatSurf Seminar, 5 November 2018, Turku, Finland. (Abstract + Poster Presentation).

[228] S. A. P. Pereira, A. Rahikkala, P. Figueiredo, M. L. C. Passos, H. A. Santos, M. L. M. F. S. Saraiva and A. R. T. S. Araujo, "Mesoporous

silica nanoparticles for targeted delivery of chemotherapeutic drugs", NanoMedicine 2018, 23–25 October 2018, Venice, Italy. (Abstract + Poster Presentation).

[227] N. Z. Ezazi, M. Kemell, H. Ruskoaho, J. Hirvonen, H. A. Santos, "Biofunctionalization of biodegradable conductive patch for

myocardial infarction treatment", 5th TERMIS World Congress, 4–7 September 2018, Kyoto, Japan. (Abstract + Poster Presentation).

[226] P. Figueiredo, K. Lintinen, A. Kiriazis, T. Kohout, J. Yli-Kauhaluoma, J. Hirvonen, M. A. Kostiainen, H. A. Santos, "In vitro evaluation

of lignin-based nanoparticles for drug delivery to cancer cells", CLINAM 2018, 2–5 September 2018, Basel, Switzerland. (Abstract + Poster Presentation).

[225] G. Torrieri, V. Talman, M. P.A. Ferreira, L. Pohjolainen, Z. Liu, J. Hirvonen, H. Ruskoaho, H. A. Santos, "Acetalated dextran

nanoparticles for cardiomyocytes proliferation", CLINAM 2018, 2–5 September 2018, Basel, Switzerland. (Abstract + Poster Presentation).

[224] F. Fontana, C. Capasso, M.-A. Shahbazi, D. Liu, M. Fusciello, S. Feola, H. Zhang, E. Mäkilä, J. Salonen, J. Hirvonen, V. Cerullo, H. A.

Santos, "Development of biohybrid multistage nanovaccines for melanoma", CLINAM 2018, 2–5 September 2018, Basel, Switzerland. (Abstract + Oral Presentation).

[223] J. P. Martins, D. Liu, F. Fontana, M. Kemell, M. P. A. Ferreira, A. Correia, S. Valentino, M. Kemell, K. Moslova, E. Mäkilä, J. Salonen,

J. Hirvonen, B. Sarmento, H. A. Santos, “Microfluidic nanoassembly of pH-sensitive FcRn-targeted nanoparticles for oral delivery of GLP-1”, Drug Delivery - Using nano and microtechnologies Summer School, 13-24 August 2018, Technical University of Denmark – DTU, Lyngby, Denmark. (Poster presentation)

[222] Z. Liu, Y. Li, W. Li, C. Xiao, D. Liu, C. Dong, M. Zhang, E. Mäkilä, M. Kemmel, J. Salonen, J. T. Hirvonen, H. Zhang, D. Zhou, X. Deng,

H. A. Santos, "Porous silicon based nanohybrids for liver regeneration and acute liver failure theranostics", 45th Annual Meeting & Exposition of the Controlled Release Society, 22–24 July 2018, New York, USA. (Abstract + Poster Presentation).

[221] S. Bertoni, W. Li, Z. Liu, A. Correia, J.P. Martins, A. Rahikkala, F. Fontana, M. Kemell, B. Albertini, N. Passerini, H. A. Santos,

"Reactive oxygen species-responsive nano-in-micro composite for targeted therapy of inflammatory bowel disease", Nanomedicine Rome 2018, 18-20 June 2018, Rome, Italy. (Abstract + Oral Presentation).

[220] N. Z. Ezazi, M.-A. Shahbazi, Y. V. Shatalin, E. Nadal, E. Mäkilä, J. Salonen, M. Kemell, A. Correia, J. Hirvonen, H. A. Santos,

"Conductive vancomycin-loaded porous silica bone scaffolds", Finland-Japan Workshop: The next generation medical engineering in biomaterials, 17-21 June 2018, Oulu, Finland. (Poster Presentation).

[219] N. Z. Ezazi, M.-A. Shahbazi, Y. V. Shatalin, E. Nadal, E. Mäkilä, J. Salonen, M. Kemell, A. Correia, J. Hirvonen, H. A. Santos,

"Conductive vancomycin-loaded mesoporous silica polypyrrole-based scaffolds for bone regeneration", 12th FinPharmaNet Symposium 2018, 14-15 June 2018, Espoo, Finland. (Poster Presentation).

[218] Z. Liu, Y. Li, W. Li, C. Xiao, D. Liu, C. Dong, M. Zhang, E. Mäkilä, M. Kemmel, J. Salonen, J. T. Hirvonen, H. Zhang, D. Zhou, X. Deng,

H. A. Santos, "Porous silicon based nanohybrids for liver regeneration and acute liver failure theranostics", 12th FinPharmaNet Symposium 2018, 14-15 June 2018, Espoo, Finland. (Poster Presentation).

[217] J. P. Martins, D. Liu, F. Fontana, M. Kemell, E. Mäkilä, J. Salonen, J. Hirvonen, B. Sarmento, H. A. Santos, “Microfluidic-assisted

fabrication of pH-sensitive FcRn-targeted nanoparticles for insulin delivery via oral administration”, 12th FinPharmaNet Symposium 2018, 14-15 June 2018, Espoo, Finland. (Poster presentation)

[216] P. Figueiredo, K. Lintinen, A. Kiriazis, T. Kohout, J. Yli-Kauhaluoma, J. Hirvonen, M. A. Kostiainen, H. A. Santos, "Lignin-based

nanoparticles for cancer therapy: in vitro evaluation", 12th FinPharmaNet Symposium 2018, 14-15 June 2018, Espoo, Finland. (Poster Presentation).

[215] M. P.A. Ferreira, V. Talman, G. Torrieri, D. Liu, G. Marques, K Moslova, Z. Liu, J. F. Pinto, J. Hirvonen, H. Ruskoaho, H. A. Santos,

"Dual-drug delivery using dextran-functionalized nanoparticles targeting cardiac fibroblasts for cellular reprogramming", 12th FinPharmaNet Symposium 2018, 14-15 June 2018, Espoo, Finland. (Poster Presentation).

[214] F. Zhang, L. Kong, D. Liu, W. Li, E. Mäkilä, A. Correia, R. Lindgren, J. Salonen, J. J. Hirvonen, H. Zhang, A. Kros, H. A. Santos,

"Sequential antifouling surface for efficient modulation of thenanoparticle–cell interactions in protein-rich environments", 12th FinPharmaNet Symposium 2018, 14-15 June 2018, Espoo, Finland. (Poster Presentation).).

[213] F. Fontana, C. Capasso, C. Groeneveldt, M. Fusciello, J. Chiaro, S. Feola, Z. Liu, E. Mäkilä, J. Salonen, J. Hirvonen, V. Cerullo, H. A. Santos, "Cancer nanovaccines: biohybrid nanoparticles and combo with immmune checkpoint inhibitors", 12th FinPharmaNet Symposium 2018, 14-15 June 2018, Espoo, Finland. (Poster Presentation).

[212] J.P. Martins, R. D'Auria, D. Liu, F. Fontana, M. P. A. Ferreira, A. Correia, M. Kemell, E. Mäkilä, J. Salonen, L. Casettari, J. Hirvonen,

B. Sarmento, H. A. Santos, "Engineered multifunctional albumin-decorated porous silicon nanoparticles for FcRn translocation of insulin", Advances in Diabetes and Insulin Therapy 2018, 15-17 April 2018, Dubrovnik, Croatia. (Abstract + Poster Presentation).

[211] S. Imlimthan, A. Correia, V. Balasubramanian, P. Figueiredo, K. Lintinen, A. J. Airaksinen, M. A. Kostiainen, H. A. Santos, M.

Sarparanta, "In vitro cellular interactions of multimodal cellulose nanocrystal and lignin nanoparticles for drug delivery applications", Society For Biomaterials 2018 Annual Meeting and Exposition, 11–14 April 2018, Atlanta, USA. (Abstract + Poster Presentation).

[210] F. Fontana, C. Capasso, M.-A. Shabazi, D. Liu, M. Fusciello, S. Feola, H. Zhang, E. Mäkila, J. Salonen, J. T. Hirvonen, V. Cerullo, H. A.

Santos, "Biohybrid multistage nanovaccines based on acetalated dextran-coated pSi nanoparticles: development of an innovative formulation", Porous Semiconductors-Science and Technology 2018, 11-16 March 2018, La Grande Motte, France. (Abstract + Oral Presentation).

[209] E. Mäkilä, H. Kivelä, A. Correia, H. A. Santos, J. Salonen, "Influence of surface chemistry on adsorption and confinement of drug

in porous silicon", Porous Semiconductors-Science and Technology 2018, 11-16 March 2018, La Grande Motte, France. (Abstract + Poster Presentation).

[208] Z. Liu, Y. Li, W. Li, C. Xiao, D. Liu, C. Dong, M. Zhang, E. Mäkilä, M. Kemmel, J. Salonen, J. T. Hirvonen, H. Zhang, D. Zhou, X. Deng,

H. A. Santos, "Porous silicon based nanohybrids for liver regeneration and acute liver failure theranostics", Porous Semiconductors-Science and Technology 2018, 11-16 March 2018, La Grande Motte, France. (Abstract + Poster Presentation).

[207] M. P. A. Ferreira, S. Ranjan, S. Kinnunen, A. Correia, V. Talman, E. Mäkilä, B. Barrios-Lopez, M. Kemell, V. Balasubramanian, J.

Salonen, J. Hirvonen, H. Ruskoaho, A. J. Airaksinen, H. A. Santos, "Targeting the heart with multifunctional porous silicon nanoparticles", Porous Semiconductors-Science and Technology 2018, 11-16 March 2018, La Grande Motte, France. (Abstract + Poster Presentation).

[206] J. P. Martins, D. Liu, F. Fontana, M. Kemmel, E. Mäkilä, J. Salonen, J. Hirvonen, B. Sarmento, H. A. Santos, "Microfluidic-assisted

fabrication of pH-sensitive FcRN-targeted nanoparticles for insulin delivery via oral administration", Porous Semiconductors-Science and Technology 2018, 11-16 March 2018, La Grande Motte, France. (Abstract + Poster Presentation).

[205] N. Z. Ezazi, M.-A. Shahbazi, Y. V. Shatalin, E. Nadal, E. Mäkilä, J. Salonen, M. Kemell, A. Correia, J. Hirvonen, H. A. Santos,

"Conductive vancomycin-loaded mesoporous silica polypyrrole-based scaffolds for bone regeneration", Porous Semiconductors-Science and Technology 2018, 11-16 March 2018, La Grande Motte, France. (Abstract + Poster Presentation).

[204] F. Gütter, J. Saarinen, L. Peltonen, H. A. Santos, C. J. Strachan, R. Scherlie, "Understanding nano-bio interactions by

characterisation of nanocrystal-cell relations", CRS Local Chapter Germany, 1-2 March 2018, Martin-Luther-Universität Halle-Wittenberg, Germany. (Abstract + Poster Presentation).

[203] M.A. Shahbazia, P. Almeida, A. Correia, E. Mäkilä, J. Salonen, J. Hirvonen, H.A. Santos, " Intracellular responsive dual delivery by

porous silicon@endosomolytic polyplex nanoparticles", Proceedings of the 7th International Conference on Nanostructures

(ICNS7) 27 February 1 March 2018, Tehran, Iran. (Abstract + Poster Presentation).

[202] P. Quan [...], H. A. Santos, "Roles of penetration enhancers in transdermal patches", Northern Pharma Network Meeting 2018,

29-31 January 2018, University of Southern Denmark, Odense, Denmark. (Abstract + Oral Presentation). [201] D. Liu [...], H. A. Santos, "Microfluidic assisted fabrication of drug crystals-encapsulated nanovectors for controlled drug

delivery", Northern Pharma Network Meeting 2018, 29-31 January 2018, University of Southern Denmark, Odense, Denmark. (Abstract + Oral Presentation).

[200] C. Martins, F. Araújo, M. J. Gomes, C. Fernandes, R. Nunes, W. Li, H. A. Santos, F. Borges, B. Sarmento, "Using microfluidic

platforms to develop CNS-targeted polymeric nanoparticles for HIV therapy", XII Spanish-Portuguese Conference on Controlled Drug Delivery - Tailoring drug delivery systems to the patients’ needs, 14-16 January 2018, Coimbra, Portugal. (Abstract + Poster Presentation).

2017 (27) [199] F. Fontana, C. Capasso, M. Fusciello, S. Feola, E. Mäkilä, J. Salonen, J. T. Hirvonen, V. Cerullo, H. A. Santos, "Biohybrid nanovaccines

in murine melanoma: efficacy and synergistic combo therapy with immune checkpoint inhibitor", 4th SFN (French Society of Nanomedicine) Congress, 5–7 December 2017, Bordeaux, France. (Oral Presentation).

[198] M. Ferreira, et al., H. A. Santos, "Multifunctional nanoparticles for targeted drug delivery and imaging to the ischemic

myocardial injury", Faculty of Pharmacy Symposium 2017, 22–23 November 2017, Lammi, Finland. (Oral Presentation). [197] F. Fontana, et al., H. A. Santos, "Development of Biohybrid Nanovaccines for Cancer Immunotherapy", Faculty of Pharmacy

Symposium 2017, 22–23 November 2017, Lammi, Finland. (Oral Presentation).

[123] P. V. Almeida, M.-A. Shahbazi, A. Correia, E. Mäkilä, J. Salonen, J. Hirvonen, H. A. Santos, "Multifunctional nanocomplexes for cancer theranostics and combined drug delivery", DKFZ Postdoctoral Fellowships Symposium 2017, 14th November 2017, Heidelberg, Germany. (Oral Presentation).

[195] D. Liu, C. R. Bernuz, W. Li, A. Correia, J. Hirvonen, H. A. Santos, "Merging the best of two worlds: drug crystals-encapsulated

nanovectors for controlled drug delivery", The 6th International Symposium on Surface and Interface of Biomaterials, 16–19th October 2017, Chengdu, China (Abstract + Oral Presentation).

[194] W. Li, Y. Li, Z. Liu, X. Deng, H. A. Santos, "Multistage oral drug delivery system for inflammatory bowel disease therapy", The

6th International Symposium on Surface and Interface of Biomaterials, 16–19th October 2017, Chengdu, China (Abstract + Oral Presentation).

[193] P. V. Almeida, M.-A. Shahbazi, A. Correia, E. Mäkilä, J. Salonen, J. Hirvonen, H. A. Santos, “Multifunctional nanocomplex designed

for enhanced cell uptake, endosomal escape and improved cancer therapeutic effect”, International Conference on Nanomedicine and Nanobiotechnology, 25-27th September 2017, Barcelona, Spain (Abstract + Oral Presentation)

[192] J. P. Martins, D. Liu, F. Fontana, M. Kemell, E. Mäkilä, J. Salonen, J. Hirvonen, B. Sarmento, H. A. Santos, “Microfluidic-assisted

fabrication of pH-sensitive FcRn-targeted nanoparticles for insulin delivery via oral administration”, 15th International Nanomedicine & Drug Delivery Symposium (NanoDDS 2017), 22-24th September 2017, University of Michigan, Ann Arbor, Michigan, USA (Abstract + Poster presentation).

[191] S. Imlimthan, A. Correia, D. E. Lumén, V. Balasubramanian, M. Vehkamäki, M. A. Kostiainen, H. A. Santos, A. J. Airaksinen, M.

Sarparanta, "Development of a multimodality molecular imaging probe for the in vitro and in vivo evaluation of a cellulose nanocrystal drug delivery system", The World Molecular Imaging Congress (WMIC), 13–16th September 2017, Philadelphia Pennsylvania, USA (Abstract + Poster presentation).

[190] V. Balasubramanian, A. Correia, H. Zhang, F. Fontana, E. Mäkilä, J. Salonen, J. Hirvonen, H. A. Santos, “Towards a bio-nanoreactor

by engineering inorganic nanoparticles with cancer cell membranes”, YUCOMAT 2017, 4–8 September 2017, Herceg Novi, Montenegro (Abstract + Poster presentation).

[189] V. Balasubramanian, A. Correia, H. Zhang, F. Fontana, E. Mäkilä, J. Salonen, J. Hirvonen, H. A. Santos, “Biomimetics: from nature

to nanotechnology”, ICONN 2017, 9–11th August 2017, SRM University, Chennai, India (Abstract + Oral presentation). [188] T. Bauleth-Ramos, M.-A. Shahbazi, D. Liu, F. Fontana, A. Correia, P. Ferreira, H. Zhang, P. Granja, H. A. Santos, B. Sarmento, “Spermine-modified acetalated dextran nanoparticles for cancer chemoimmunotherapy”, 44th Annual Meeting & Exposition of the

Controlled Release Society, 16–19 July 2017, Boston, USA (Abstract + Short oral presentation). [187] J. P. Martins, D. Liu, M. Kemell, E. Mäkilä, J. Hirvonen, B. Sarmento, H. A. Santos, “pH-Sensitive FcRn-targeted porous silicon

nanoparticles for oral delivery of insulin”, ULLA Summer School 2017, 8–15th July 2017, University of Leuven, Leuven, Belgium (Abstract + Poster presentation).

[186] P. Figueiredo, K. Lintinen, A. Kiriazis, Z. Li, T. Bauleth Ramos, A. Rahikkala, A. Correia, T. Kohout, J. Yli-Kauhaluoma, J. Hirvonen, M.

A. Kostiainen, H. A. Santos, “In vitro evaluation of lignin-based nanoparticles for drug delivery to cancer cells”, ULLA Summer School 2017, 8–15th July 2017, University of Leuven, Leuven, Belgium (Abstract + Poster presentation).

[185] Z. Liu, Y. Li, W. Li, C. Xiao, D. Liu, C. Dong, M. Zhang, E. Mäkilä, M. Kemmel, J. Salonen, J. T. Hirvonen, H. Zhang, D. Zhou, X. Deng, H. A.

Santos, “Porous silicon based nanohybrids for liver regeneration and acute liver failurer thernostics”, ULLA Summer School

2017, 8–15th July 2017, University of Leuven, Leuven, Belgium (Abstract + Poster presentation). [184] A. Janoniene, Z. Liu, L. Baranauskiene, E. Mäkilä, M. Ma, J. Salonen, J. Hirvonen. Zhang, V. Petrikaite, H. A. Santos, “Porous silicon

based nanoplatform targeting hypoxic cancer cells”, 3rd International Conference "Current Trends of Cancer Theranostics", 25– 29th June 2017, Pakruojis, Lithuania (Abstract + Poster presentation).

[183] A. Janoniene, Z. Liu, L. Baranauskiene, E. Mäkilä, M. Ma, J. Salonen, H. Zhang, V. Petrikaite, H. A. Santos, “Modified porous silicon

nanoparticles for cancer targeting via carbonic anhydrase IX”, International Conference Nanotechnology and Innovation in the

Baltic Sea Region, 14–16th June 2017, Kaunas, Lithuania (Abstract + Poster presentation). [182] J. Saarinen, F. Gütter, S. Fraser-Miller, A. Isomäki, O. Antikainen, R. Scherließ, E. Jokitalo, H. A. Santos, L. Peltonen, C. J. Strachan,

“Correlative light-electron microscopy (CLEM) of drug nano-/microcrystal cellular uptake with coherent anti-stokes raman scattering (CARS)”, CRS Nordic Chapter Meeting, 11-13th June 2017, Kuopio, Finland (Abstract + Poster + Short oral presentation).

[181] P. V. Almeida, M.-A. Shahbazi, A. Correia, E. Mäkilä, M. Kemell, J. Salonen, J. Hirvonen, H. A. Santos, “Multifunctional

nanocomplex designed for enhanced cell uptake, endosomal escape and improved cancer therapeutic effect”, CLINAM 10/2017, 7-10 May 2017, Basel, Switzerland (Abstract + Poster + Short oral presentation).

[180] F. Fontana, M. A. Shahbazi, D. Liu, H. Zhang, E. Mäkilä, J. Salonen, J. Hirvonen, H. A. Santos, “Development of multistaged

nanoparticles as cancer vaccines”, International School of Nanomedicine – Course: New Trends In Nanomedicine, 8−13th April 2017, Erice-Sicily (Abstract + Oral presentation).

[179] M.P.A. Ferreira, S. Ranjan, S. Kinnunen, A. Correia, V. Talman, E. Mäkilä, B. Barrios-Lopez, M. Kemell, V. Balasubramanian, J.

Salonen, J. Hirvonen, H. Ruskoaho, A.J. Airaksinen, H. A. Santos, “Targeting the heart with multifunctional porous silicon nanoparticles”, International School of Nanomedicine – Course: New Trends In Nanomedicine, 8−13th April 2017, Erice-Sicily

(Abstract + Oral presentation). [178] V. Balasubramanian, A. Correia, H. Zhang, F. Fontana, E. Mäkilä, J. Salonen, J. Hirvonen, H. A. Santos, "Biomimetic engineering:

designing biocompartmentalized nanoreactors as artificial organelles", 28th Symposium of the Finnish Society of Physical Pharmacy, 9th February 2017, Turku, Finland (Abstract + Poster presentation).

[177] M. P. A. Ferreira, S. Ranjan1, A. M. R. Correia, E. M. Mäkilä, S. M. Kinnunen, H. Zhang, M.-A. Shahbazi, P. V. Almeida, J. J. Salonen, H. J.

Ruskoaho, A. J. Airaksinen, J. T. Hirvonen, H. A. Santos, "Heart-homing porous silicon nanoparticles for therapy of heart diseases", 28th Symposium of the Finnish Society of Physical Pharmacy, 9 February 2017, Turku, Finland (Abstract + Poster presentation).

[176] N. Zanjanizadeh Ezazi, M.-A. Shahbazi, Y. Shatalin, E. Nadal, E. Mäkilä, J. Salonen, M. Kemell, A. Correia, J. Hirvonen , H. A. Santos,

"Drug loaded composite scaffold for bone regeneration", 28th Symposium of the Finnish Society of Physical Pharmacy, 9 February 2017, Turku, Finland (Abstract + Poster presentation).

[175] F. Fontana, M. A. Shahbazi, D. Liu, H. Zhang, E. Mäkilä, J. Salonen, J. Hirvonen, H. A. Santos, "Nanovaccines for cancer therapy: a

multistage approach for personalized medicine", 28th Symposium of the Finnish Society of Physical Pharmacy, 9 February 2017, Turku, Finland (Abstract + Oral presentation).

[174] M. P. A. Ferreira, S. Ranjan, S. Kinnunen, A. Correia, V. Talman, E. Mäkilä, B. Barrios-Lopez, M. Kemell, V. Balasubramanian, J.

Salonen, J. Hirvonen, H. Ruskoaho, A. J. Airaksinen, H. A. Santos, "Targeting the heart with porous silicon nanoparticles", 6th Northern Pharma Network Meeting, 13 January 2017, Tartu, Estonia (Abstract + Oral presentation).

[173] P. Figueiredo, K. Lintinen, A. Kiriazis, Z. Liu, T. B. Ramos, A. Rahikkala, A. Correia, T. Kohout, J. Yli-Kauhaluoma, J. Hirvonen, M. A.

Kostiainen, H. A. Santos, "In vitro evaluation of biodegradable lignin-based nanoparticles for drug delivery and enhanced antiproliferation effect in cancer cell", 6th Northern Pharma Network Meeting, 13 January 2017, Tartu, Estonia (Abstract + Oral presentation).

2016 (33) [172] M. Terracciano, L. De Stefano, A. Lamberti, H.A. Santos, I. Rea. Engineered natural porous silica nanoparticles as drug delivery

systems, Materials 2016, 12‒16 December 2016, Catania, Italy (Abstract + Oral presentation). [171] T. O. Kääriäinen, M. Kemell, A. Correia, H. A. Santos, L. M. Bimbo, J. T. Hirvonen, M-L. Kääriäinen, P. Hoppu, S. M. George, M.

Ritala, M. Leskelä. Atomic layer deposition on active pharmaceutical particles, 2016 AAPS Annual Meeting and Exposition, 13– 17 November 2016, Denver, USA (Abstract + Poster presentation).

[170] W. Li, E. Mäkilä, J. Salonen, M. Saarma, Y. Sidorova, H. A. Santos. improved Parkinson’s disease management.

ChinaNanomedicine GDNF mimetics delivery by porous silicon nanoparticles for 2016, 18–21 October 2016, Wuhan, China (Abstract + Oral presentation).

[169] F. Fontana, M.-A. Shahbazi, D. Liu, H. Zhang, E. Mäkilä, J. Salonen, J. Hirvonen, H. A. Santos. Development of innovative multistage nanovectors for cancer immunotherapy. International Conference On Nanomedicine And Nanobiotechnology – ICONAN 2016, 28–30 September 2016, Paris, France (Abstract + Oral presentation).

[168] V. Balasubramanian, A. Correia, H. Zhang, F. Fontana, E. Mäkilä, J. Salonen, J. Hirvonen, H. A. Santos. Biomimetic

compartmentalization approach in designing nanoreactors with organelle-like function. International Conference On Nanomedicine And Nanobiotechnology – ICONAN 2016, 28–30 September 2016, Paris, France (Abstract + Oral presentation).

[167] S. Ranjan, M. P.A. Ferreira, S. M. Kinnunen, V. Balasubramanian, B. Barrios-Lopez, A. M. Correia, E. Mäkilä, V. Talman, J. Salonen,

J. T. Hirvonen, H. J. Ruskoaho, H. A. Santos, A. J. Airaksinen. SPECT/CT imaging, ex vivo biodistribution and autoradiographic quantification of peptide modified 111In-labelled silicon nanoparticles in a rat model of myocar-dial infarction. 2016 World Molecular Imaging Congress, 7–10 September 2016, New York, USA (Abstract + Poster presentation).

[166] U. Jakobsson, E. Mäkilä, A. Airaksinen, O. Alanen, A. Etilé, J. Ikonen, U. Köster, S. Ranjan, J. Salonen, H. A. Santos, K. Helariutta.

Metal-implanted mesoporous silicon nanoparticles as novel drug carriers for radiation theranostics. 9th International Conference on Nuclear and Radiochemistry – NRC9, 29 August–2 September 2016, Helsinki, Finland (Abstract + Poster presentation).

[165] S. Ranjan, M. P.A. Ferreira, S. M. Kinnunen, V. Balasubramanian, B. Barrios-Lopez, A. M. Correia, E. Mäkilä, V. Talman, J. Salonen,

J. T. Hirvonen, H. J. Ruskoaho, H. A. Santos, A. J. Airaksinen. Evaluation of 111In-labelled peptide functionalized silicon nanoparticles in a rat model of myocardial infarction. 9th International Conference on Nuclear and Radiochemistry – NRC9, 29 August–2 September 2016, Helsinki, Finland (Abstract + Poster presentation).

[164] A. Fraga, A. Correia, P. Figueiredo, E. Mäkilä, J. Salonen, J. Hirvonen, J. Pedrosa, H. A. Santos, N. Vale. Activity of ethionamide-

mesoporous silicon nanoparticles against Mycobacterium tuberculosis. EFMC-ISMC 2016, XXIV EFMC International Symposium on Medicinal Chemistry, 28 August–1 September 2016, Manchester, UK (Abstract + Poster presentation).

[163] E. Ollikainen, D. Liu, A. Kallio, E. Mäkilä, J. Salonen, H. A. Santos, T. Sikanen. Effects of pharmaceutical polymers and nanoparticles

on cytochrome P450 metabolism. 21st International Mass Spectrometry Conference (IMSC 2016), 20–26 August 2016, Toronto, Canada (Abstract + Poster presentation).

[162] F. Araújo, N. Shrestha, M. J. Gomes, D. Liu, J. Hirvonen, P. L. Granja, H. A. Santos, Bruno Sarmento. In vivo dual-delivery of GLP-

1 and DPP4 inhibitor through composites prepared by microfluidics for diabetes therapy. The 43rd Annual Meeting & Exposition of the Controlled Release Society, Washington State Convention Center – Seattle, 17–20 July 2016, Washington, USA (Abstract + Poster presentation).

[161] F. Araújo, N. Shrestha, M. J. Gomes, D. Liu, B. Herranz-Blanco, J. Hirvonen, P. L. Granja, H. A. Santos, B. Sarmento. Multifunctional

tailorable composite system as a dual peptide-drug delivery system. 10th World Biomaterials Congress (WBC2016), 1722th May 2016, Montreal, Canada (Abstract + Poster presentation).

[160] H. A. Santos. Preclinical development of porous silicon nanocomposites for translational biomedical applications. 10th World

Biomaterials Congress (WBC2016), 1722th May 2016, Montreal, Canada (Abstract + Oral presentation). [159] A. Correia, M.-A. Shahbazi, E. Mäkilä, S. Almeida, J. Salonen, J. Hirvonen, H. A. Santos. Cyclodextrin-conjugated nanoparticles for

sustained drug delivery and enhanced anti-proliferation in cancer cells. 5th Portuguese Young Chemists Meeting and 1st

European Young Chemists Meeting, 2629th April 2016, GuimarãesCentro Cultural Vila Flor, Portugal (Abstract + Poster presentation).

[158] J. Saarinen, F. Gütter, S. Fraser, A. Isomäki, O. Antikainen, R. Scherließ, L. Peltonen, H. A. Santos, C. J. Strachan. Visualisation of

un-labeled drug nanocrystals in cells using coherent anti-Stokes Raman scattering (CARS) microscopy combined to multivariate data-analysis. 2nd Symposium of the Bridging Nordic Imaging Network and the 1st Cellular Imaging workshop, 1415th April 2016, Gothenburg, Sweden (Abstract + Poster presentation).

[157] P. Figueiredo, V. Balasubramanian, M.-A. Shahbazi, A. Correia, D. Wu, C. G. Palivan, J. T. Hirvonen, H. A. Santos. Angiopep2-

functionalized polymersomes for targeted doxorubicin delivery to glioblastoma. 7th International Congress Nanotechnology in

Biology & Medicine, 68th April 2016, Krems, Austria (Abstract + Poster presentation). [156] P.V. Almeida, M.-A. Shahbazi, A. Correia, E. Mäkilä, J. Salonen, J. Hirvonen, H. A. Santos. Theranostic potential of a nano-in-nano

multifunctional nanocomplex. 7th International Congress Nanotechnology in Biology & Medicine, 68th April 2016, Krems, Austria (Abstract + Poster presentation).

[155] M. P. A. Ferreira, S. Ranjan, A. M. R. Correia, E. M. Mäkilä, S. M. Kinnunen, H. Zhang, M.-A. Shahbazi, P. V. Almeida, J. J. Salonen,

H. J. Ruskoaho, A. J. Airaksinen, J. T. Hirvonen, H. A. Santos. In vitro and in vivo assessment of heart-homing nanoparticles. 7th

International Congress Nanotechnology in Biology & Medicine, 68th April 2016, Krems, Austria (Abstract + Oral presentation). [154] F. Gütter, J. Saarinen, R. Scherließ, H. Steckel, C. Strachan, H. A. Santos, L. Peltonen, C. J. Strachan. Production of auto-fluorescent

nanocrystals and uptake studies in Caco-2 cells. 10th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical

Technology, 47th April 2016, SECC, Glasgow, UK (Abstract + Poster presentation). [153] J. Saarinen, F. Gütter, S. Fraser, A. Isomäki, O. Antikainen, R. Scherließ, L. Peltonen, H. A. Santos, C. J. Strachan. Multiplex coherent

anti-Stokes Raman scattering (CARS) microscopy as a visualisation technique to probe drug nanocrystal–cell interactions. 10th

World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 47th April 2016, SECC, Glasgow, UK (Abstract + Poster presentation).

[152] F. Araújo, N. Shrestha, M.J. Gomes, D. Liu, J.T. Hirvonen, P.L. Granja, H.A. Santos, B. Sarmento. Sistemas de entrega particulares

para entrega dupla de GLP-1 e DPP4 inibidor para a terapia da Diabetes Mellitus Tipo 2, 12º Congresso Português de Diabetes,

17–20th March 2016, Vilamoura, Portugal (Abstract + Oral presentation). [151] E. Mäkilä, C.-F. Wang, O. M. Keinänen, M. Kaasalainen, A. J. Airaksinen, S. Lecommandoux, H. A. Santos, J. Salonen. Click chemistry

on hydrolytically stable porous silicon. PSST-2016, Porous Semiconductors – Science and Technology Conference, 6–11th March 2016, Tarragona, Spain (Abstract + Oral presentation).

[150] M. Terracciano, L. De Stefano, H. A. Santos, A. Lamberti, N. M. Martucci, M.-A. Shahbazi, A. Correia, I. Ruggiero, N. Migliaccio, I.

Rea. Diatomite nanoparticles: an innovative natural porous silica nanovectors. PSST-2016, Porous Semiconductors – Science

and Technology Conference, 6–11th March 2016, Tarragona, Spain (Abstract + Poster presentation). [149] E. Mäkilä, A. A. Cavallaro, H.A. Santos, N.H. Voelcker, J. Salonen. Plasma polymerization of porous silicon microparticles. The

27th Annual Symposium of the Finnish Society of Physical Pharmacy, 21th22nd January 2016, Biomedicum–University of Helsinki, Helsinki, Finland (Abstract + Poster presentation).

[148] J. Saarinen, F. Gütter, S. Fraser, A. Isomäki, O. Antikainen, R. Scherließ, L. Peltonen, H. A. Santos, C. J. Strachan. Multiplex coherent

anti-Stokes Raman scattering (CARS) microscopy with multivariate data-analysis as a visualisation tool for probing un-labeled

drug nanocrystals in cells. The 27th Annual Symposium of the Finnish Society of Physical Pharmacy, 21th22nd January 2016, Biomedicum–University of Helsinki, Helsinki, Finland (Abstract + Poster presentation).

[147] D. Liu, S. Cito, Y. Zhang, C.-F. Wang, T. M. Sikanen, H. A. Santos. High throughput production of nanoparticles with homogeneous

size distribution through fast microfluidic mixing. Northern Pharma Network meeting, 19th21st January 2016, Biomedicum– University of Helsinki, Helsinki, Finland (Abstract + Oral presentation).

[146] M.-A. Shahbazi, E. Mäkilä, N. Shrestha, J. Salonen, J. Hirvonen, H. A. Santos. Effect of methyl substitution on the structure and

biological responses of aniline nanostructures. Northern Pharma Network meeting, 19th21st January 2016, Biomedicum– University of Helsinki, Helsinki, Finland (Abstract + Oral presentation).

[145] M. P. A. Ferreira, S. Ranjan, S. Kinnunen, V. Balasubramanian, A. Correia, E. Mäkilä, V. Talman, B. Barrios-Lopez, J. Salonen, J.

Hirvonen, H. Ruskoaho, A. J. Airaksinen, H. A. Santos. In vivo assessment of the biodistribution of heart-targeted porous silicon

nanoparticles in a myocardial infarction model. Northern Pharma Network meeting, 19th21st January 2016, Biomedicum– University of Helsinki, Helsinki, Finland (Abstract + Oral presentation).

[144] B. Herranz-Blanco, D. Liu, E. Mäkilä, M-A. Shahbazi, E. Ginestar, H. Zhang, V. Aseyev, V. Balasubramanian, J. Salonen, J. Hirvonen,

H. A. Santos. Microfluidic fabrication of a stimulus responsive hybrid nanocomposite for antitumoral applications. Northern

Pharma Network meeting, 19th21st January 2016, Biomedicum–University of Helsinki, Helsinki, Finland (Abstract + Oral presentation).

[143] P. Figueiredo, V. Balasubramanian, M.-A. Shahbazi, A. Correia, C. G. Palivan, J. T. Hirvonen, H. A. Santos. Angiopep2-

functionalized polymersomes for doxorubicin delivery to glioblastoma treatment. Northern Pharma Network meeting,

19th21st January 2016, Biomedicum–University of Helsinki, Helsinki, Finland (Abstract + Oral presentation). [142] J. Saarinen, F. Gütter, S. Fraser, A. Isomäki, O. Antikainen, R. Scherließ, L. Peltonen, H. A. Santos, C. J. Strachan. Visualisation of

nanocrystal-cell interactions using coherent-anti Stokes Raman scattering (CARS) microscopy combined to multivariate data-

analysis. Northern Pharma Network meeting, 19th21st January 2016, Biomedicum–University of Helsinki, Helsinki, Finland (Abstract + Poster + Oral presentation).

[141] N. Shrestha, M.-A. Shahbazi, F. Araújo, E. Mäkilä, J. Raula, B. Sarmento, J. Salonen, J. Hirvonen, H. A. Santos. pH-Responsive dual

peptide-drug delivery system for type 2 diabetes mellitus therapy. Northern Pharma Network meeting, 19th21st January 2016, Biomedicum–University of Helsinki, Helsinki, Finland (Abstract + Poster presentation).

[140] F. Fontana, M. Mori, F. Riva, E. Mäkilä, J. Salonen, G. Nicoletti, J. Hirvonen, C. Caramella, H. A. Santos. Platelet lysate-modified

porous silicon microparticles for wound healing applications. Northern Pharma Network meeting, 19th21st January 2016, Biomedicum–University of Helsinki, Helsinki, Finland (Abstract + Poster presentation).

2015 (24) [139] J. Saarinen, F. Gütter, N. Darville, A. Isomäki, G. Van den Mooter, L. Peltonen, H.A. Santos, C.J. Strachan. Visualisation of itraconazole

nanocrystal cell uptake using coherent anti-Stokes Raman scattering (CARS) microscopy. 75th FIP World Congress of Pharmacy and

Pharmaceutical Sciences 2015, 29 September3 October 2015, Düsseldorf, Germany (Abstract + Poster presentation). [138] Terraccianoa M., De Stefano L., Lamberti A., Santos H.A., Martucci N.M., Shahbazi M.-A., Correira A., Ruggiero I., Rendina I., Rea

I. Biosilica nanovectors for imaging and therapeutic applications. 6th European Optical Society Topical Meetings 2015, 17-19 September 2015, Capri, Italy (Abstract + Oral presentation).

[137] Saarinen J., Darville N., Sözeri E., Isomäki A., Van den Mooter G., Peltonen L., Santos H.A., Strachan C.J. Coherent anti-stokes

raman scattering (CARS) microscopy in cell imaging with drug nanocrystals. 6th BBBB Conference on Pharmaceutical Sciences, 10-12 September 2015, Helsinki, Finland (Abstract + Poster presentation).

[136] Saarinen J., Darville N., Isomäki A., Van den Mooter G., Peltonen L., Santos H.A., Strachan C.J. Exploration of nanocrystal cell

uptake using coherent anti-Stokes Raman scattering (CARS) microscopy. 9th Annual Symposium of Pharmaceutical Solid State Research Cluster (PSSRC), 16-17 September 2015, Faculty of Pharmaceutical Sciences, Ghent University, Belgium (Abstract + Poster presentation).

[135] Araújo F., Shrestha N., Shahbazi M.-A., Liu D., Herranz-Blanco B., Mäkilä E., Salonen J., Hirvonen J., Granja P. L., Sarmento B.,

Santos, H.A. Co-deliver of glucagon-like peptide-1 and dipeptidyl peptidase 4 inhibitor for treatment of type 2 diabetes. 27th European Conference on Biomaterials, 29 August3 September 2015, Kraków, Poland (Abstract + Oral presentation).

[134] Herranz-Blanco B., Liu D., Mäkilä E., Shahbazi M.-A., Ginestar E., Zhang H., Aseyev V., Balasubramanian V., Salonen J., Hirvonen J.,

Santos H.A. Microfluidic nanoprecipitation of a stimuli responsive hybrid nanocomposite for antitumoral applications. 42nd Annual Meeting & Exposition of the Controlled Release Society, 2629 July 2015, Edinburgh, Scotland-UK (Abstract + Research Highlight Talk + Poster presentation).

[133] Zhang H., Hai M., Liu D., Balasubramanian V., Herranz-Blanco B., Feng K., Qu X., Shahbazi M.-A., Almeida P.V., Mäkilä E., Salonen

J., Hirvonen J., Weitz D.A., Santos H.A. Droplet based microfluidics for drug delivery applications. 42nd Annual Meeting & Exposition of the Controlled Release Society, 2629 July 2015, Edinburgh, Scotland-UK (Abstract + Poster presentation).

[132] Terracciano M., Shahbazi M.-A., Correia A., Rea I., De Stefano L., Santos H.A. PEGylation and CPP-bioconjugation of diatomite

nanoparticles for enhanced stability, biocompatibility and cellular internalization in cancer cells. 42nd Annual Meeting & Exposition of the Controlled Release Society, 2629 July 2015, Edinburgh, Scotland-UK (Abstract + Poster presentation).

[131] Shahbazi M.-A., Shrestha N., Hirvonen J., Santos H.A. Effect of methyl substitution on the redox response and biological

impact of aniline based nanostructures used for cancer therapy. 42nd Annual Meeting & Exposition of the Controlled Release Society, 2629 July 2015, Edinburgh, Scotland-UK (Abstract + Poster presentation).

[130] Vasiliauskas R., Liu D., Zhang H., Mazutis L., Santos H.A. Multidrug encapsulation using PDMS microfluidic devices for pulmonary

drug delivery. 42nd Annual Meeting & Exposition of the Controlled Release Society, 2629 July 2015, Edinburgh, Scotland-UK (Abstract + Poster presentation).

[129] Liu D., Cito S., Zhang Y., Wang C.-F., Sikanen T.M., Santos H.A. Mass production of nanoparticles through a versatile and robust

microfluidic platform for drug delivery. 42nd Annual Meeting & Exposition of the Controlled Release Society, 2629 July 2015, Edinburgh, Scotland-UK (Abstract + Poster presentation).

[128] Araújo F., Shrestha N., Shahbazi M.-A., Liu D., Herranz-Blanco B., Mäkilä E., Salonen J., Hirvonen J., Granja P.L., Sarmento B.,

Santos H.A. A multisystem to orally co-deliver glucagon-like peptide-1 and dipeptidyl peptidase 4 inhibitor for type 2 diabetes

mellitus therapy. 42nd Annual Meeting & Exposition of the Controlled Release Society, 2629 July 2015, Edinburgh, Scotland-UK (Abstract + Poster presentation).

[127] Shrestha N., Shahbazi M.-A., Araújo F., Mäkilä E., Raula J., Sarmento B., Salonen J., Hirvonen J., Santos H.A. Co-loading of

glucagon-like peptide-1 and dipeptidyl peptidase 4 inhibitor in pH sensitive polymer/porous silicon nanomatrix for type 2

diabetes mellitus therapy. 42nd Annual Meeting & Exposition of the Controlled Release Society, 2629 July 2015, Edinburgh, Scotland-UK (Abstract + Poster presentation).

[126] Ferreira M.P.A., Ranjan S., Kinnunen S., Balasubramanian V., Correia A., Mäkilä E., Talman V., Barrios-Lopez B., Salonen J.,

Hirvonen J., Ruskoaho H., Airaksinen A.J., Santos H.A., In vivo assessment of the biodistribution of peptide functionalized porous silicon nanoparticles in a myocardial infarction rat model. ULLA Summer School 2015, 6–10 July 2015, Université Paris-Sud, Paris, France (Abstract + Poster presentation).

[125] Almeida P.V., Balasubramanian V., Correia A., Mäkilä E., Ferreira M.P.A., Kaasalainen M., Jiang H., Salonen J., Ruokolainen J.,

Hirvonen J., Santos H.A., Fabrication of a hybrid nanoplatform by encapsulation of porous silicon nanoparticles into self-assembling polymersomes for cancer theranostics. ULLA Summer School 2015, 6–10 July 2015, Université Paris-Sud, Paris, France (Abstract + Poster presentation).

[124] Saarinen J., Darville N., Sözeri E., Isomäki A., Van den Mooter G., Peltonen L., Santos H., Strachan C., Coherent anti-Stokes Raman

scattering (CARS) microscopy on the way of imaging oral drug absorption. ULLA Summer School 2015, 6–10 July 2015, Université Paris-Sud, Paris, France (Abstract + Poster presentation).

[123] Araújo F., Shrestha N., Shahbazi M.-A., Liu D., Herranz-Blanco B., Mäkilä E., Salonen J., Hirvonen J., Granja P.L., Sarmento B.,

Santos H.A., Co-deliver of glucagon-like peptide-1 and dipeptidyl peptidase 4 inhibitor for treatment of type 2 diabetes. The Nano/Medicine Interface, 29 June–3 July 2015, Porto, Portugal (Abstract + Poster presentation).

[122] Almeida P.V., Balasubramanian V., Correia A., Mäkilä E., Ferreira M.P.A., Kaasalainen M., Jiang H., Salonen J., Ruokolainen J.,

Hirvonen J., Santos H.A., A multifunctional hybrid nanoplatform fabricated by encapsulation of porous silicon nanoparticles into self-assembling polymeric nanossomes for cancer therapy. CLINAM 8/2015, 28 June–2 July 2015, Basel, Switzerland (Abstract + Poster presentation).

[121] Balasubramanian V., Almeida P.V., Correia A., Mäkilä E., Ramos T., Jiang H., Salonen J., Ruokolainen J., Hirvonen J., Santos H.A. A

Multistage and Multifunctional Nanocarrier For Cancer Therapy, Gordon Research Conference 2015: Nanomedicines from Laboratory to Clinical Reality, 28 June-3 July 2015, Mount Snow West Dover, USA (Abstract + Poster presentation).

[120] Ranjan S., Ferreira M., Kinnunen S., Balasubramanian V., Muje S., Correia A., Mäkilä E., Talman V., Salonen J., Hirvonen J.,

Ruskoaho H., Santos H., Airaksinen A. J. SPECT/CT imaging and ex vivo biodistribution of peptide modified 111In-labelled silicon nanoparticles in a rat model of myocardial infarction. 21st International Symposium on Radiopharmaceutical Sciences, 26–31 May 2015, University of Missouri Columbia, Missouri, USA (Abstract + Poster presentation).

[119] Terracciano M., Lamberti A., Santos H.A., Martucci N.M., Shahbazi M.A., Correira A., Ruggiero I., Rendina I., De Stefano L., Rea I.

Diatomite nanoparticles as potential drug delivery systems. 3rd International Conference on BioPhotonics 2015, 20–22 May 2015, Florence, Italy (Abstract + Selected oral presentation).

[118] Liu D., Zhang H., Herranz-Blanco B., Shahbazi M.-A., Wang C.-F., Mäkilä E., Balasubramanian V., Cito S., Zhang Y., Sikanen T. M.,

Weitz D. A., Salonen J., Hirvonen J., Santos H. A.* Smart and multitasking nanomedicines for personalized therapy and diagnostics: a microfluidic approach, 4th International Conference on Multifunctional, Hybrid and Nanomaterials (Hybrid Materials 2015), 9-13 March 2015, Sitges, Spain (Abstract + Selected oral presentation).

[117] Ferreira M., Tölli M., Kinnunen S., Rysä J., Mäkilä E., Correia A., Salonen J., Hirvonen J., Ruskoaho H., Santos H. In vivo evaluation

of porous silicon biomaterials for treatment of myocardial infarction. Keystone Symposia Conference – Heart Disease and Regeneration: Insights from Development (X1), 1–6 March 2015, Copper Mountain Resort, Copper Mountain, Colorado, USA (Abstract + Poster presentation).

[116] Saarinen J., Darville N., Isomäki A., Santos H., Strachan C., Van den Mooter G., Peltonen L. Anti-Stokes Raman scattering (CARS)

microscopy as a visualization method for nanocrystal-cell interactions. The Fourth Annual FPTP Network Meeting, 21–23rd January 2015, Department of Pharmacy, Copenhagen, Denmark (Abstract + Poster presentation).

2014 (33) [115] Tölli M.A., Ferreira M.P.A., Kinnunen S.M., Rysä J., Mäkilä E.M., Szabó Z., Serpi R.E., Ohukainen P.J., Välimäki M., Correia A.,

Salonen J.J., Hirvonen J.T., Ruskoaho H.J., Santos H.A. Biocompatibility of porous silicon micro- and nanoparticles in vitro in cardiomyocytes and in vivo in cardiac tissue. American Heart Association Scientific Sessions & Exhibit 2014, 15–19th November 2014, McCormick Place, Chicago, USA (Abstract + Poster presentation).

[114] Darville N., Saarinen J., Isomäki A., Antikainen O., Santos H.A., Strachan C., Mooter G. Van den. Label-free imaging of nonfluorescent drug nanocrystals in various biological matrices using coherent anti-stokes Raman scattering (CARS) microscopy. 2014 AAPS Annual Meeting and Exposition, 2-6 November 2014, San Diego, USA (Abstract + Poster presentation).

[113] Sarparanta M., Wang C.-F., Mäkilä E., Hyvönen M., Laakkonen P., Salonen J., Hirvonen J., Santos H.A., Airaksinen A.J.

Biodistribution and delivery of sorafenib with 111In-labeled undecylenic-acid –modified thermally hydrocarbonized porous silicon (UnTHCPSi) particles in mice bearing subcutaneous PC3-MM2 xenografts. The World Molecular Imaging Congress (WMIC), 17-20 September 2014, Seoul, Korea (Abstract + Poster presentation).

[112] Paaver U., Heinämäki J., Kassamakov I., Ylitalo T., Hæggström E., Santos H.A., Yliruusi J., Laidmäe I., Veski P., Kogermann K. Quasi-

dynamic dissolution of electrospun polymeric nanofibers loaded with poorly water-soluble drug. CESPT 2014 – 10th Central European Symposium on Pharmaceutical Technology, 18-20 September 2014, Portoroz, Slovenia (Abstract + Poster presentation).

[111] Mori M., Fontana F., Mäkilä E., Salonen J., Hirvonen J., Caramella C.M., Santos H.A. In vitro assessment of platelet lysate-loaded

porous silicon microparticles onto fibroblast cells. 3rd International Meeting on Pharmaceutical Sciences (RICiFa), 1819th Spetember 2014, Cordoba, Argentina (Abstract presentation).

[110] Sözeri E., Isomäki A., Saarinen J., Santos H.A., Strachan C.J. CARS imaging of Caco-2 cell cultures. CESPT 2014 – 10th Central European

Symposium on Pharmaceutical Technology, 18-20 September 2014, Portoroz, Slovenia (Abstract + Oral presentation). [109] Sözeri E., Isomäki A., Saarinen J., Santos H.A., Strachan C.J. Probing intestinal cell culture structures using CARS microscopy. 8th

PSSRC Annual Symposium, 16-18 September 2014, Ljubljana-Portorož, Slovenia (Abstract + Oral presentation). [108] Shahbazi M.-A., Almeida P.V., Mäkilä E.M., Kaasalainen M.H., Salonen J.J., Hirvonen J.T., Santos H.A. Double layer polymer coated

porous silicon nanovehicles for enhanced cellular interaction and endosomal escape. CRS Nordic Chapter – Drug Transport and Delivery Symposium in Helsinki, 26-27 August 2014, Helsinki, Finland (Abstract + Poster presentation).

[107] Araújo F., Shrestha N., Shahabzi M.-A., Granja P.L., Sarmento B., Santos H.A. Characterization of chitosan-based nanoparticles

for improving oral delivery of GLP-1. CRS Nordic Chapter – Drug Transport and Delivery Symposium in Helsinki, 26-27 August 2014, Helsinki, Finland (Abstract + Oral presentation).

[106] Shrestha N., Shahbazi M.-A., Araújoa F., Zhang H., Mäkilä E., Kauppila J., Sarmento B., Salonen J., Hirvonen J., Santos H.A. Chitosan-modified porous silicon microparticles for enhanced intestinal permeability of insulin. CRS Nordic Chapter – Drug Transport and Delivery Symposium in Helsinki, 26-27 August 2014, Helsinki, Finland (Abstract + Oral presentation).

[105] Wang C.-F., Mäkilä E., Bonduelle C., Rytkonen J., Almeida S., Salonen S., Lecommandoux S., Hirvonen J., Santos H.A. Effect of the

surface functionalization of porous silicon nanoparticles on the cell uptake and prevention of complement C3 activation. CRS Nordic Chapter – Drug Transport and Delivery Symposium in Helsinki, 26-27 August 2014, Helsinki, Finland (Abstract + Poster presentation).

[104] Liu D., Zhang H., Herranz-Blanco B., Mäkilä E., Lehto V.-P., Salonen J., Hirvonen J., Santos H.A. Microfluidic assembly

monodisperse polymer/porous silicon composites for precisely controlled multidrug delivery. CRS Nordic Chapter – Drug Transport and Delivery Symposium in Helsinki, 26-27 August 2014, Helsinki, Finland (Abstract + Poster presentation).

[103] Sözeri E., Isomäki A., Saarinen J., Santos H.A., Strachan C.J. Label-free imaging of live intestinal cells using CARS microscopy. CRS

Nordic Chapter – Drug Transport and Delivery Symposium in Helsinki, 26-27 August 2014, Helsinki, Finland (Abstract + Oral presentation).

[102] Darville N., Saarinen J., Isomäki A., Antikainen O., Santos H.A., Strachan C., Van den Mooter G. Coherent anti-stokes Raman

scattering (CARS) microscopy as a tool for label-free investigation of nanoparticlecell interactions in various biological matrices. CRS Nordic Chapter – Drug Transport and Delivery Symposium in Helsinki, 26-27 August 2014, Helsinki, Finland (Abstract + Oral presentation).

[101] Mäkilä E., Kivelä H., Santos H.A., Salonen J. Mesoscale confinement effects on indomethacin. 11th European Symposium on

Thermal Analysis and Calorimetry, 17-21 August 2014, Espoo, Finland (Abstract + Poster presentation). [101] Zhang H., Liu D., Shahbazi M., Mäkilä E., Herranz-Blanco B., Salonen J., Hirvonen J., Santos H.A. Fabrication of multistage porous

silicon microparticles for enteric cancer drug delivery by microfluidics. 2nd Annual Conference on International Translational Nanomedicine (ITNano), 25–27 July 2014, Northeastern University, Boston, USA (Abstract + Poster presentation).

[99] Zhang H., Liu D., Shahbazi M.-A., Mäkilä E., Salonen J., Hirvonen J., Santos H.A. Microfluidic templated multistage porous

silicon based platform for enhanced enteric cancer drug delivery. The 41st Annual Meeting & Exposition of the Controlled Release Society, 13-16 July 2014, Chicago, Illinois, USA (Abstract + Poster presentation).

[98] Sözeri E., Isomäki A., Saarinen J., Santos H.A, Strachan C. Label-free imaging of Caco-2 cell cultures using cars microscopy:

Method optimisation. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 31April 3 2014, Lisbon, Portugal (Abstract + Poster presentation).

[97] Araújo F., Granja P.L., Santos H.A, Sarmento B. Characterization of chitosan-based nanoparticles to increase the therapeutic

effect of GLP-1 orally delivered. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 31April 3 2014, Lisbon, Portugal (Abstract + Poster presentation).

[96] Paaver U., Veski P., Laidmäe I., Santos H.A., Yliruusi J., Kirsimäe K., Kogermann K., Heinämäki J. Development of a novel

nanofibrous delivery system for poorly water-soluble -sitosterol. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 31April 3 2014, Lisbon, Portugal (Abstract + Poster presentation).

[95] Fussell A.L., Mah M., Offerhaus H.L., Niemi S.-M., Salonen J., Santos H.A., Strachan C. Coherent anti-Stokes Raman scattering

(CARS) microscopy providing in depth imaging of drug loaded mesoporous MCM-41 silica. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 31April 3 2014, Lisbon, Portugal (Abstract + Oral presentation).

[94] Herranz-Blanco B., Mäkilä E., Kaasalainen M., Salonen J., Arriaga L.R., Mirza S., Weitz D.A., Hirvonen J., Santos H.A. pH-Responsive

polymeric micellar encapsulation of porous silicon nanoparticles by microfluidic nanoprecipitation for controlled drug delivery.

9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 31April 3 2014, Lisbon, Portugal (Abstract + Poster presentation).

[93] Tölli M., Ferreira M.P.A, Kinnunen S., Rysä J., Mäkilä E., Szabo Z., Serpi R., Hirvonen J., Salonen J., Ruskoaho H., Santos H.A. In vivo

biocompatibility of porous silicon biomaterials for heart failure. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 31April 3 2014, Lisbon, Portugal (Abstract + Poster presentation).

[92] Shrestha N., Mäkilä E., Salonen J., Hirvonen J., Santos H.A. Porous Silicon based micro-particulate systems for oral delivery of

Insulin: Comparison of different surface morphology, pore size and surface modification of porous silicon micro-particles. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 31April 3 2014, Lisbon, Portugal (Abstract + Poster presentation).

[91] Liu D., Zhang H., Herranz-Blanco B., Mäkilä E., Salonen J., Hirvonen J., Santos H.A. Microfluidic assembly of monodisperse

multistage pH-responsive polymer/porous silicon composites for precisely controlled multi-drug delivery. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 31April 3 2014, Lisbon, Portugal (Abstract + Poster presentation).

[90] Almeida P.V., Shahbazi M.-A., Mäkilä E., Kaasalainen M., Salonen J., Hirvonen J., Santos H.A. Amine-modified hyaluronan-coated

porous silicon nanoparticles for breast cancer therapy. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 31April 3 2014, Lisbon, Portugal (Abstract + Poster presentation).

[89] Shahbazi M.-A., Almeida P.V., Mäkilä E., Kaasalainen M., Salonen J., Hirvonen J., Santos H.A. Polymer conjugated porous silicon nanocomposites for enhanced cellular trafficking and endosomal escape. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 31April 3 2014, Lisbon, Portugal (Abstract + Poster presentation).

[88] Näkki S., Rytrönen J., Nissinen T., Riikonen J., Ek P., Zhang H., Santos H. A., Xu W., Lehto V.-P. Enhanced colloidal stability of

thermally oxidized mesoporous silicon by dual PEGylation. PSST-2014, Porous Semiconductors – Science and Technology Conference, 9–14 March 2014, Benidorm, Spain (Abstract + Poster presentation).

[87] Mäkilä E., Cavallaro A.P., Santos H.A, Voelcker N.H., Salonen J. Plasma polymerization of allylamine on porous silicon

microparticles. PSST-2014, Porous Semiconductors – Science and Technology Conference, 9–14 March 2014, Benidorm, Spain (Abstract + Poster presentation).

[86] Shahbazi M.-A., Wang C.-F., Almeida P.V., Mäkilä E., Kaasalainen M., Airaksinen A., Sarparanta M., Salonen J., Hirvonen J., Santos

H.A. Novel porous silicon nanocomposites for cancer therapy. PSST-2014, Porous Semiconductors – Science and Technology Conference, 9–14 March 2014, Benidorm, Spain (Abstract + Oral presentation).

[85] Pessi J., Miroshnyk I., Santos H., Yliruusi J., Weitz D.A., Mirza S. Microfluidic approach for preparing protein loaded

polycaprolactone microspheres. The Third Annual FPTP Network Meeting – Biomedicinskt centrum BMC, 29–31 January 2014, Uppsala, Sweden (Abstract + Short presentation).

[84] Wang C.-F., Mäkilä E., Kaasalainen M., Salonen J., Hirvonen J., Santos H.A. Methotrexate-conjugated to PSi for sustain release

and enhance the cell uptake. The Third Annual FPTP Network Meeting – Biomedicinskt centrum BMC, 29–31 January 2014, Uppsala, Sweden (Abstract + Short presentation).

[83] Santos H.A. ERC StG: Multistagemultifunctional porous silicon nanovectors for directed theranostics. The Third Annual FPTP

Network Meeting – Biomedicinskt centrum BMC, 29–31 January 2014, Uppsala, Sweden (Abstract + Invited speaker). 2013 (18) [82] Santos H.A. Porous silicon nanomaterials to revolutionize drug targeting and delivery. Controlled Release Society Italian Local

Chapter, University of Pavia, 2123 November 2013, Pavia, Italy (Abstract + Invited speaker). [81] Mirza S., Miroshnyk I., Herranz-Blanco B., Weitz D., Santos H.A. Continuous microfluidic platform for encapsulation of

mesoporous nanocarriers for cancer drug delivery. 2013 AAPS Annual Meeting and Exposition, 10–14 November 2013, Henry B. Gonzalez Convention Center, San Antonio, USA (Abstract + Poster presentation).

[80] Zhang H., Shahbazi M.-A., Mäkilä E., Silva T.H., Reis R.L., Salonen J., Hirvonen J., Santos H.A. Sustained release of prednisone and

mesalamine from diatom exoskeletons: bioinspiration for the development of safe oral drug delivery devices to tackle gastrointestinal diseases. TERM STEM 2013, 10–12 October 2013, Porto Palácio Congress Hotel & Spa, Porto, Portugal (Abstract + Poster presentation).

[79] Paaver U., Heinämäki J., Kassamakov I., Ylitalo T., Hæggström E., Santos H.A., Yliruusi J., Laidmäe I., Veski P., Kogermann K. In-situ monitoring of drug release from pharmaceutical drug-loaded nanofibers. Arstiteaduskonna Aastapäev meeting, 10–11 October 2013, Tartu, Estonia (Abstract + Poster presentation).

[78] Paaver U., Laidmäe I., Santos H.A., Yliruusi J., Veski P., Kogermann K., Heinämäki J. Development of a novel nanofibrous delivery

system for a poorly water-soluble -sitosterol. Arstiteaduskonna Aastapäev meeting, 10–11 October 2013, Tartu, Estonia (Abstract + Poster presentation).

[77] Wang C.-F., Liu D., Mäkilä E., Salonen J., Sarparanta M., Airaksinen A., Hirvonen J., Santos H.A. Peptide-modified porous silicon

nanoparticles via copper-free click chemistry for targeting drug delivery. ULLA Summer School, 7-13 July 2013, London, UK (Abstract + Poster presentation).

[76] Pessi J., Miroshnyk I., Santos H., Yliruusi J., Weitz D.A., Mirza S. Microfluidic approach for preparing protein loaded polymer

microspheres. AIChE Annual Meeting, 3-8 November 2013, San Francisco, CA, USA (Abstract + Poster presentation). [75] Paaver U., Laidmäe I., Santos H.A., Yliruusi J., Veski P., Kogermann K., Heinämäki J. Electrospun nanofibers as a novel delivery

system for a poorly water-soluble -sitosterol. 5th BBBB International Conference, 26-28th September 2013, Athens, Greece (Abstract + Poster presentation).

[74] Almeida P., Shahbazi M.-A., Mäkilä E., Salonen J., Hirvonen J., Santos H.A. Preparation, characterization and cytocompatibility

of amphiphilic block copolymers-coated porous silicon nanoparticles. 25th European Conference on Biomaterials, 8–12th September 2013, Madrid, Spain (Abstract + Poster presentation).

[73] Herranz B., Liu D., Arriaga L., Mirza S., Weitz D.A., Santos H.A. Mesoporous silicon-solid lipid composited nanocarriers prepared

via microfluidic technique for drug delivery applications. 25th European Conference on Biomaterials, 8–12th September 2013, Madrid, Spain (Abstract + Poster presentation).

[72] Shahbazi M.-A., Zhang H., Mäkilä E., Almeida P., Salonen J., Hirvonen J., Santos H.A. Biocompatibility of nanoporous silicon with

immune cells and erythrocytes depends on surface chemistry. 25th European Conference on Biomaterials, 8–12th September 2013, Madrid, Spain (Abstract + Poster presentation).

[71] Wang C.-F., Mäkilä E., Liu D., Sarparanta M., Airaksinen A., Salonen J., Hirvonen J., Santos H.A. Enhanced intracellular uptake and drug delivery of targeting peptides modified porous silicon nanoparticles via copper-free click chemistry. The European CLINAM

& ETPN Summit, 23-26th June 2013, Basel, Switzerland (Abstract + Short oral presentation and poster). [70] Kinnari P., Hyvönen M., Mäkilä E., Kaasalainen M., Rivinoja A., Salonen J., Hirvonen J., Laakkonen P., Santos H.A., Tumor-homing

peptide boosts porous silicon nanovectors accumulation in vivo. The European CLINAM & ETPN Summit, 23-26th June 2013, Basel, Switzerland (Abstract + Short oral presentation and poster).

[69] Araújo F., Santos H.A., Granja P., Sarmento B. GLP-1 and GLP-1 analogs nanotechnology based systems for prevention and therapy of

diabetes. Vth training School on Bioencapsulation, 9–12th April 2013, Nantes, France (Abstract + Poster presentation). [68] Mäkilä E., Bimbo L.M., Kaasalainen M., Airaksinen A., Kukk E., Santos H.A., Salonen J. Modification of thermally carbonized

porous silicon with organosilane for biomedical applications. Physics days 2013, 14–16th March 2013, Dipoli, Espoo, Finland (Abstract + Poster presentation).

[67] Zhang H., Shahbazi M.-A., Mäkilä M., da Silva T.H., Reis R.L., Hirvonen H., Santos H.A. Diatom enhanced the drug delivery for

colon inflammation disease. 4th International Congress BioNanoMed 2013 – Nanotechnology enables Personalised Medicine, 13– 15 March 2013, Krems, Austria (Abstract + Poster presentation).

[66] Liu D.F., Mäkilä E., Zhang H., Herranz B., Kaasalainen M., Kinnari P., Salonen J., Hirvonen J., Santos H.A. Nanostructured porous

silicon-solid lipid nanocomposite: towards enhanced cytocompatibility and stability, reduced cellular association, and prolonged drug release. 4th International Congress BioNanoMed 2013 – Nanotechnology enables Personalised Medicine, 13–15 March 2013, Krems, Austria (Abstract + Poster presentation).

[65] Liu D., Mäkilä E., Zhang H., Herranz B., Kaasalainen M., Kinnari P., Salonen J., Hirvonen J., Santos H.A. Porous silicon-solid lipid

nanocomposite: enhanced stability, reduced cellular association and prolonged drug release. 24th Annual Symposium of the

Finnish Society of Physical Pharmacy, 7th February 2013, Turku, Finland (Abstract + Poster presentation).

2012 (9) [64] Herranz B., Arriaga L., Liu D., Mirza S., Weitz D.A., Santos H.A. Encapsulation of mesoporous silicon microparticles via the

microfluidic technique for sustained drug delivery. 53rd New England Complex Fluids Meeting, 30th November 2012, University of Harvard, Cambridge MA, USA (Abstract + Short oral presentation).

[63] Vale N., Mäkilä E., Salonen J., Gomes P., Hirvonen J., Santos H.A. In vitro evaluation of ethionamide-loaded porous silicon

microparticles. The 3rd Portuguese Meeting on Medicinal Chemistry, 28–29 November 2012, Aveiro, Portugal (Abstract + Poster presentation).

[62] Santos H.A., Bimbo L.M., Salonen J., Airaksinen A.J., Linder M.B., Hirvonen J. Nanostructured porous silicon nanoparticles for

drug delivery and diagnostic applications. The 9th Central European Symposium on Pharmaceutical Technology, 20–22 September 2012, Dubrovnik, Croatia (Abstract + Oral presentation).

[61] Bimbo L., Sarparanta M., Mäkilä E., Laaksonen T., Laaksonen P., Salonen J., Linder M., Hirvonen J., Airaksinen A., Santos H. Surface modified nanoporous silicon particles for improved cell viability. The 9th Central European Symposium on Pharmaceutical Technology, 20–2 September 2012, Dubrovnik, Croatia (Abstract + Oral presentation).

[60] Kinnari P., Mäkilä E., Salonen J., Rivinoja A., Laakkonen P., Hirvonen J., Santos H.A. Peptide-modified porous silicon nanoparticles

for brain tumor targeting. The 9th Central European Symposium on Pharmaceutical Technology, 20–2 September 2012, Dubrovnik, Croatia (Abstract + Poster presentation).

[59] Liu D., Mäkilä E., Salonen J., Hirvonen J., Santos H. Solid Lipid-coated porous silicon nanoparticles: characterization and in vitro

evaluation. The 9th Central European Symposium on Pharmaceutical Technology, 20–2 September 2012, Dubrovnik, Croatia (Abstract + Poster presentation).

[58] Santos H.A., Bimbo L.M., Sarparanta M., Makila E., Salonen J., Laaksonen T., Linder M.B., Airaksinen A., Hirvonen J. Hydrophobin-

coated nanoporous silicon for controlled drug delivery and therapy applications. PSST-2012, Porous Semiconductors – Science and Technology Conference, 25–30 March 2012, Malaga, Spain (Abstract + Oral presentation).

[57] Bimbo L.M., Sarparanta M., Mäkilä E., Laaksonen T., Laaksonen P., Salonen J., Linder M.B., Hirvonen J., Airaksinen A. J., Santos

H.A. Biofunctionalization of porous silicon nanoparticles for drug delivery applications. 3rd International Congress BioNanoMed 2012 – Nanotechnology enables Personalised Medicine, 1-2 March 2012, Krems, Austria (Abstract + Poster presentation).

[56] Santos H.A., Bimbo L.M., Sarparanta M., Mäkilä E., Salonen J., Linder M.B., Airaksinen A.J., Hirvonen J. Biocompatibility of

nanoporous silicon materials for controlled drug release, diagnostics and therapy. 3rd International Congress BioNanoMed 2012 – Nanotechnology enables Personalised Medicine, 1-2 March 2012, Krems, Austria (Abstract + Oral presentation).

2011 (13) [55] Limnell T., Mäkilä E., Heikkilä T., Salonen J., Murzin D.Y., Kumar N., Laaksonen T., Peltonen L., Hirvonen J., Santos H.A. Preparation and

characterization of drug formulations of ordered and nonordered mesoporous silica microparticles . Eur. J. Pharm. Sci. 2011, 44 (S1),

S125–S126. 4th BBBB – Bled International Conference on Pharmaceutical Sciences, 29th September–1st October 2011, Bled, Slovenia (Abstract + Poster presentation).

[54] Bimbo L. M., Sarparanta M., Mäkilä E., Laaksonen T., Peltonen L., Lehto V.-P., Airaksinen A.J., Salonen J., Hirvonen J., Santos H.A.

Mesoporous silicon particles as biocompatible drug delivery agents. Eur. J. Pharm. Sci. 2011, 44 (S1), S129–S130. 4th BBBB – Bled International Conference on Pharmaceutical Sciences, 29th September–1st October 2011, Bled, Slovenia (Abstract + Poster presentation).

[53] Kinnari P., Mäkilä E., Heikkilä T., Salonen J., Hirvonen J., Santos H.A. Stability studies of itraconazole-loaded mesoporous silicon

and non-ordered mesoporous silica microparticles. Eur. J. Pharm. Sci. 2011, 44 (S1), S131–S132. 4th BBBB – Bled International

Conference on Pharmaceutical Sciences, 29th September–1st October 2011, Bled, Slovenia (Abstract + Poster presentation). [52] Bimbo L.M., Sarparanta M., Mäkilä E., Laaksonen T., Peltonen L., Lehto V.-P., Salonen J., Airaksinen A.J., Hirvonen J., Santos, H.A.

Mesoporous silicon particles as biocompatible drug delivery agents for enhancement of drug permeation. 5th PSSRC Symposium, 26-27 September 2011, Helsinki, Finland (Abstract + Poster + Short oral presentation).

[51] Sarparanta M., Bimbo L.M., Mäkilä E., Salonen J., Santos H.A., Laaksonen T., Hirvonen J., Lehto V.-P., Laaksonen P., Linder M.B.,

Airaksinen A.J. 18F-Radiolabeling as a tool in the evaluation of porous silicon particles for drug delivery. XX Helsinki Drug Research Congress, 19-21 September 2011, Helsinki, Finland (Abstract + Oral presentation).

[50] Bimbo L.M., Sarparanta M., Mäkilä E., Laaksonen T., Peltonen L., Lehto V.-P., Salonen J., Airaksinen A.J., Hirvonen J., Santos, H.A.

Mesoporous silicon particles as delivery agents for enhanced drug permeation. XX Helsinki Drug Research Congress, 19-21 September 2011, Helsinki, Finland (Abstract + Poster presentation).

[49] Limnell T., Mäkilä E., Heikkilä T., Salonen J., Murzin D.Y., Kumar N., Laaksonen T., Peltonen L., Hirvonen J., Santos H.A. Drug

delivery formulations of ordered and non-ordered nanoporous silica particles. XX Helsinki Drug Research Congress, 19-21 September 2011, Helsinki, Finland (Abstract + Poster presentation).

[48] Sarparanta M., Bimbo L.M., Mäkilä E., Salonen J., Santos H.A., Laaksonen T., Hirvonen J., Lehto V.-P., Laaksonen P., Linder M.B.,

Airaksinen A.J. Fluorine-18 radiolabeling as a tool to evaluate novel porous silicon based nano- and microcarriers for drug delivery. FinMedChem 2011, 15–16 September 2011, Helsinki, Finland (Abstract + Poster presentation).

[47] Sarparanta M., Bimbo L.M., Mäkilä E., Salonen J., Santos H.A., Laaksonen T., Hirvonen J., Lehto V.-P., Laaksonen P., Linder M.-B.,

Airaksinen A.J. 18F-radiolabeled porous silicon based nano- and microcarriers for drug delivery and imaging. 2011 World Molecular Imaging Congress, 7-10 September 2011, San Diego, California, USA (Abstract + Poster presentation).

[46] Sarparanta M., Bimbo L.M., Mäkilä E., Salonen J., Santos H.A., Laaksonen T., Hirvonen J., Lehto V.-P., Laaksonen P., Linder M.B.,

Airaksinen A.J. Fluorine-18 radiolabeling as a tool to evaluate novel porous silicon based nano- and microcarriers for drug delivery. 19th International Symposium on Radiopharmaceutical Sciences, 28th August–2nd September 2011, Amsterdam, The Netherlands (Abstract + Poster presentation).

[45] Bimbo L.M., Mäkilä E., Sarparanta M., Laaksonen T., Airaksinen A.J., Lehto V.-P., Salonen J., Hirvonen J., Santos H.A. Mesoporous

silicon particles as emerging nanomedicine carriers. 3rd European Summer School in Nanomedicine, 14–19 June 2011,

Wittenberg, Germany (Abstract + Oral presentation). [44] Bimbo L.M., Sarparanta M., Mäkilä E., Laaksonen T., Lehto V.-P., Peltonen L., Airaksinen A.J., Salonen J., Hirvonen J., Santos H.A.

Multifunctional porous silicon for therapeutic drug delivery and imaging. 3rd PharmScifair, 13–17 June 2011, Prague, Czech Republic (Abstract + Poster presentation).

[43] Bimbo L.M., Mäkilä E., Sarparanta M., Laaksonen T., Lehto V.-P., Airaksinen A.J., Salonen J., Hirvonen J., Santos H.A.

Biocompatibile functionalization of silicon nanoparticles. 3rd PharmScifair, 13–17 June 2011, Prague, Czech Republic (Abstract + Invited speaker).

2010 (10) [42] Bimbo L.M., Sarparanta M., Salonen J., Riikonen J., Mäkilä E., Airaksinen A., Lehto V.-P., Hirvonen J., Santos H. A. Nanoporous

silicon materials in drug delivery applications. 23rd European Conference on Biomaterials (ESB2010), 11–15 September 2010, Tampere, Finland (Abstract + Keynote presentation).

[41] Vale N., Santos H.A., Mäkilä E., Salonen J., Hirvonen J., Gomes P. New times, new trends for ethionamide. 16th World Congress

of Basic and Clinical Pharmacology, WorldPharma2010, 17–23 July 2010, Bella Center, Copenhagen, Denmark (Abstract + Poster presentation).

[40] Miroshnyk I., Trows S., Santos H., Peltonen L., Heinämäki J., Hussain M.D., Yliruusi J., Mirza S. Linking dissolution rate of

ibuprofen-nicotinamide cocrystals to thermodynamic properties of the conformers. 37th Annual Meeting and Exposition of The Controlled Release Society, 10-14 July 2010, Oregon Convention Center, Portland, Oregon, U.S.A. (Extended Abstract + Poster presentation).

[39] Bimbo L.M., Sarparanta M., Airaksinen A.J., Mäkilä E., Laaksonen T., Peltonen L., Lehto V.-P., Hirvonen J., Salonen J. Santos H.A.

In vitro and in vivo compatibility of mesoporous silicon particles for oral drug delivery. 8th International Conference and Workshop on Biological Barriers – in vitro Tools, Nanotoxicology, 21 March–1 April 2010, Saarland University Saarbrücken, Germany (Abstract + Poster presentation).

[38] Sarparanta M., Mäkilä E., Heikkilä T., Salonen J., Lehto V.-P., Santos H.A., Hirvonen J., Airaksinen A.J. Biodistribution of 18F-

labeled thermally hydrocarbonized porous silicon nanoparticles. 7th International Conference Porous Semicondictures Science

& Technology (PSST-2010), 14–19th March 2010, València, Spain (Abstract + Oral presentation). [37] Santos H.A., Bimbo L.M., Salonen J., Riikonen J., Mäkilä E., Laaksonen T., Peltonen L., Lehto V.-P., Hirvonen J. Towards enhanced

bioavailability and feasibility of nanoporous silicon materials as an alternative for oral drug delivery. 7th World Meeting on Pharmaceutics, Biopharmaceutics, and Pharmaceutical Technology, 8–11th March 2010, La Valletta, Malta (Extended Abstract + Oral presentation).

[36] Heikkilä T., Limnell T., Santos H.A., Ojanen S., Kumar N., Murzin D.Y., Peltonen L., Laaksonen T., Louhi-Kultanen M., Hirvonen J.,

Salonen J., Lehto V.-P. Stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15. 7th World Meeting on Pharmaceutics, Biopharmaceutics, and Pharmaceutical Technology, 8–11th March 2010, La Valletta, Malta (Extended Abstract + Poster presentation) & 21st Symposium of Physical Pharmacy, 28 January 2010, Old Mill, Turku, Finland (Abstract + Poster presentation).

[35] Rotko T., Mäkilä E., Santos H., Laaksonen T., Salonen J., Hirvonen J., Peltonen L. Tablet formulations of drug-loaded mesoporous

silicon particles: enhanced dissolution for poorly soluble drugs. 7th World Meeting on Pharmaceutics, Biopharmaceutics, and

Pharmaceutical Technology, 8–11th March 2010, La Valletta, Malta (Extended Abstract + Oral presentation) & 21st Symposium

of Physical Pharmacy, 28 January 2010, Old Mill, Turku, Finland (Abstract + Poster presentation) & 7th International Conference Porous Semicondictures Science & Technology (PSST-2010), 14–19th March 2010, Valencia, Spain (Abstract + Poster presentation).

[34] Bimbo L.M., Sarparanta M., Airaksinen A.J., Mäkilä E., Laaksonen T., Peltonen L., Lehto V.-P., Hirvonen J., Salonen J., Santos H.A.

Biodistribution and biocompatibility of orally administered nanoporous silicon particles. 7th World Meeting on Pharmaceutics,

Biopharmaceutics, and Pharmaceutical Technology, 8–11th March 2010, La Valletta, Malta (Extended Abstract + Poster presentation) &

21st Symposium of Physical Pharmacy, 28 January 2010, Old Mill, Turku, Finland (Abstract + Poster presentation). [33] Santos H.A., Bimbo L.M., Salonen J., Mäkilä E., Riikonen J., Heikkilä T., Laaksonen T., Peltonen L., Lehto V.-P., Hirvonen J. Cellular

responses to porous silicon micro- and nanoparticles. 21st Symposium of Physical Pharmacy, 28 January 2010, Old Mill, Turku, Finland (Abstract + Poster presentation).

2009 (11) [32] Mirza S., Miroshnyk I., Trows I., Santos H., Peltonen L., Heinämäki J.H., Yliruusi J. Solid-phase behaviour of indomethacin-

nicotinamide cocrystals during dissolution. AAPS Annual Meeting and Exposition, 7–12th November 2009, Los Angeles, USA (Abstract + Poster presentation).

[31] Mirza S., Miroshnyk I., Santos H., Peltonen L., Sandler N., Heinämäki J.H., Yliruusi J. Cocrystal approach to dissolution rate

modulation of active pharmaceutical ingredients. 12th European Symposium on Comminution and Classification (ESCC09), 15–

18th September 2009, Helsinki University of Technology, Espoo/Otaniemi, Finland (Abstract + Oral presentation). [30] Heikkilä T., Mäkilä E., Ojanen S., Qu H., Louhi-Kultanen M., Riikonen J., Salonen J., Kumar N., Murzin D.Y., Santos H.A., Laaksonen T.,

Peltonen L., Hirvonen J., Lehto V.-P. Effect of comminution on microparticle properties of mesoporous silicon and silica materials. 12th European Symposium on Comminution and Classification (ESCC09), 15–18th September 2009, Helsinki University of Technology, Espoo/Otaniemi, Finland (Abstract + Oral presentation).

[29] Santos H.A., Riikonen J., Heikkilä T., Salonen J., Peltonen L., Lehto V.-P., Hirvonen J. Toxicity of nano- and micro-sized porous

silicon in human intestine epithelial cells. 36th Annual Meeting and Exposition of The Controlled Release Society, 18-22 July 2009, Bella Center, Copenhagen, Denmark (Extended Abstract + Poster presentation).

[28] Riikonen J., Santos H.A., Mäkilä E., Salonen J., Hirvonen J., Lehto V.-P. The physical state and dissolution of drug molecules in

mesoporous silicon. 36th Annual Meeting and Exposition of The Controlled Release Society, 18-22 July 2009, Bella Center, Copenhagen, Denmark (Extended Abstract + Poster presentation).

[27] Santos H.A, Riikonen J., Heikkilä T., Salonen J., Bimbo L., Laaksonen T., Peltonen L., Lehto V.-P., Hirvonen J. Evaluation of the

cytotoxicity of meso/nanoporous silicon based material. 2nd Pharmaceutical Sciences Fair & Exhibition (PharmSciFair), 7–12 June 2009, Nice, France (Abstract + Oral Presentation).

[26] Mirza S., Miroshnyk I., Trows S., Santos H., Peltonen L., Sandler N., Heinämäki J.H., Yliruusi J. Pharmaceutical co-crystals as

molecular-based platform for dissolution rate enhancement of drugs. 2nd Pharmaceutical Sciences Fair & Exhibition (PharmSciFair), 7–12 June 2009, Nice, France (Abstract + Poster presentation).

[25] Santos H.A., Salonen J., Riikonen J., Heikkilä T., Peltonen L., Lehto V.-P., Hirvonen J. Size-dependent in vitro toxicity of porous

silicon micro- and nanoparticles. Nanotech Conference & Expo 2009, 3–7 May, Houston, TX, USA (Abstract + Poster presentation).

[24] Santos H.A., Riikonen J., Heikkilä T., Salonen J., Peltonen L., Mäkilä E., Laaksonen T., Kumar N., Murzin D., Lehto V.-P., Hirvonen J. Feasibility of silica/silicon-based mesoporous materials for oral drug delivery applications. 20th Symposium of Physical Pharmacy, 28–29 January 2009, Orion Corp. Training centre, Tuohilampi, Vihti, Finland (Abstract + Poster presentation).

[23] Laaksonen T., Limnell T., Santos H., Heikkilä T., Riikonen J., Salonen J., Peltonen L., Lehto V.-P., Hirvonen J. Drug dissolution studies

on mesoporous silicon particles – a theoretical approach. 20th Symposium of Physical Pharmacy, 28–29 January 2009, Orion Corp. Training centre, Tuohilampi, Vihti, Finland (Abstract + Poster presentation).

[22] Heikkilä T., Santos H.A., Kumar N., Murzin D.Y., Salmi T., Riikonen J., Mäkilä E., Salonen J., Peltonen T., Hirvonen J., Lehto V.-P. In

vitro cytotoxicity of ordered mesoporous silica MCM-41 and SBA-15 microparticles. 20th Symposium of Physical Pharmacy, 28– 29 January 2009, Orion Corp. Training centre, Tuohilampi, Vihti, Finland (Abstract + Poster presentation).

2008 (13) [21] Mirza S., Miroshnyk I., Trows S., Santos H., Peltonen L., Sandler N., HHeinämäki J., Yliruusi J. Enhancing dissolution rate of poorly

soluble drugs: a co-crystal approach. AAPS Annual Meeting and Exposition, 16–20th November 2008, Atlanta, GA, USA (Abstract + Poster presentation).

[20] Heikkilä T., Santos H., Salonen J., Riikonen J., Mäkilä E., Laaksonen T., Peltonen L., Kumar N., Murzin D., Salmi T., Hirvonen J.,

Lehto V.-P. Mesoporous silicon and silica as materials for oral delivery of poorly soluble drugs: cytotoxicity and formulation compatibility. 35th Annual Meeting & Exposition of the Controlled Release Society, 12–16th July 2008, Hilton New York, New York, USA (Extended Abstract + Poster presentation).

[19] Santos H.A., Riikonen J., Heikkilä T., Salonen J., Peltonen L., Mäkilä E., Laaksonen T., Kumar N., Murzin D., Lehto V.-P., Hirvonen J.

Biocompatibility of mesoporous silicon microparticles. Eur. J. Pharm. Sci. 2008, 34(1), S36–S37. 19th Helsinki Drug Research

2008, 9–11th June 2008, Biomedicum, Helsinki, Finland (Abstract + Poster presentation). [18] Laaksonen T., Limnell T., Santos H., Heikkilä T., Riikonen J., Salonen J., Peltonen L., Lehto V.-P., Hirvonen J. Drug dissolution studies

on mesoporous silicon particles – a theoretical approach. Eur. J. Pharm. Sci. 2008, 34(1), S35. 19th Helsinki Drug Research

2008, 9–11th June 2008, Biomedicum, Helsinki, Finland (Abstract + Poster presentation). [17] Santos H.A., Heikkilä T., Riikonen J., Lautenschlager T., Laaksonen T., Peltonen L., Salonen J., Kumar N., Murzin D.Y., Lehto V.-P.,

Hirvonen J. Investigating cell toxicity and drug dissolution profiles using mesoporous silica and silicon based materials. 6th World Meeting on Pharmaceutics, Biopharmaceutics, and Pharmaceutical Technology, 7–10th April 2008, Barcelona, Spain (Extended Abstract + Oral Presentation).

[16] Laaksonen T., Limnell T., Santos H., Heikkilä T., Riikonen J., Salonen J., Peltonen L., Lehto V.-P., Hirvonen J. Drug dissolution studies

on mesoporous silicon particles – a theoretical approach. 6th World Meeting on Pharmaceutics, Biopharmaceutics, and

Pharmaceutical Technology, 7–10th April 2008, Barcelona, Spain (Extended Abstract + Poster presentation). [15] Heikkilä T., Santos H., Kumar N., Murzin D.Y., Salmi T., Riikonen J., Mäkilä E., Salonen J., Peltonen L., Hirvonen J., Lehto V.-P. In

vitro cytotoxicity of ordered mesoporous silica MCM-41 and SBA-15 microparticles. Physics Days 2008, 27–29th March 2008, Turku, Finland (Abstract + Poster presentation).

[14] Salonen J., Mäkilä E., Riikonen J., Heikkilä T., Santos H., Kaukonen A.-M., Peltonen L., Laaksonen T., Hirvonen J., Kilpeläinen M.,

Vlasova M., Herzig K.-H., Mönkäre J., Järvinen K., Lehto V.-P. Surface chemistry effects in drug delivery applications of porous

silicon. Porous Semicondictures Science & Technology (PSST-2008), 10–14th March 2008, Mallorca, Spain (Extended Abstract + Oral Presentation).

[13] Heikkilä T., Riikonen J., Mäkilä E., Salonen J., Saarela J., Santos H., Peltonen L., Hirvonen J., Kumar N., Murzin D.Y., Salmi T., Lehto V.-P.

Compatibility screening of mesoporous silicon/silica materials with poorly water-soluble drugs. Porous Semicondictures Science &

Technology (PSST-2008), 10–14th March 2008, Mallorca, Spain (Extended Abstract + Poster presentation). [12] Santos H.A., Heikkilä T., Riikonen J., Lautenschlager T., Peltonen L., Salonen J., Kumar N., Murzin D.Y., Salmi T., Kemell M., Ritala

M., Lehto V.-P., Hirvonen J. Cell toxicity of mesoporous silica/silicon based materials. 7th Conference and Workshop on Biological Barriers and Nanomedicine – Advanced Drug Delivery and Predictive non-vivo Testing Technologies, 20–29th February 2008, Saarland University, Saarbrücken, Germany (Abstract + Poster presentation).

[11] Laaksonen T., Limnell T., Santos H., Heikkilä T., Riikonen J., Salonen J., Peltonen L., Lehto V.-P., Hirvonen J. Drug dissolution studies

on mesoporous silicon particles – a theoretical approach. 19th Annual Symposium of Physical Pharmacy, 24th January 2008, Vantaa Heureka Science Centre–Helsinki, Finland (Abstract + Poster presentation).

[10] Heikkilä T., Riikonen J., Mäkilä E., Salonen J., Saarela J., Kumar N., Murzin D.Y., Salmi T., Santos H., Peltonen L., Hirvonen J., Lehto

V.-P. Compatibility screening of mesoporous silicon/silica materials with poorly water-soluble drugs. 19th Annual Symposium

of Physical Pharmacy, 24th January 2008, Vantaa Heureka Science Centre–Helsinki, Finland (Abstract + Poster presentation). [9] Santos H.A., Heikkilä T., Riikonen J., Lautenschlager T., Peltonen L., Salonen J., Kumar N., Murzin D.Y., Salmi T., Kemell M., Ritala

M., Lehto V.-P., Hirvonen J. In vitro studies of mesoporous silica/silicon microparticles: toxicity and dissolution. 19th Annual

Symposium of Physical Pharmacy, 24th January 2008, Vantaa Heureka Science Centre–Helsinki, Finland (Abstract + Poster presentation).

2007 (3) [8] Santos H.A., Heikkilä T., Riikonen J., Lautenschlager T., Peltonen L., Salonen J., Kumar N., Murzin D.Y., Salmi T., Kemell M., Ritala M., Lehto

V.-P., Hirvonen J. Cytotoxicity and drug dissolution tests of mesoporous silica and silicon microparticles. Nanomedicine and Drug delivery Symposium NanoDD’07, 2nd–3rd November 2007, Northeastern University, Boston–Massachusetts, USA (Abstract + Poster presentation).

[7] Laaksonen T., Santos H., Heikkilä T., Peltonen L., Kumar N., Murzin D.Y., Lehto V.-P., Hirvonen J. Failure of MTT as a toxicity

testing agent for mesoporous silicon microparticles. Innovation in Drug Delivery–From Biomaterials to Devices, 30th

September– 3rd October 2007, Naples, Italy (Abstract + Poster presentation). [6] Heikkilä T., Riikonen J., Saarela J., Salonen J., Kumar N., Murzin D.Y., Salmi T., Santos H., Lautenschlager T., Peltonen L., Hirvonen

J., Lehto V.-P. Compatibility screening of mesoporous silica/silicon based drug carriers with poorly water-soluble drugs.

ScanBalt Biomaterials Days 2007, 2628th September 2007, Turku, Finland (Abstract + Poster presentation).

2006 (1) [5] Santos H.A., García-Morales V., Murtomäki L., Manzanares J.A., Kontturi K. Preparation of nanostructures composed of dextran-

sulfate ruthenium nanoparticles and their interaction with phospholipid monolayers at a liquid–liquid interface. International

Society of Electrochemistry57th Annual Meeting, 27th August1st September 2006, Edinburgh, Scotland (Abstract + Poster presentation).

2005 (1) [4] Santos H.A., Chirea M., García-Morales V., Silva F., Manzanares J.A., Kontturi K. Electrochemical study of interfacial composite

nanostructures: polyelectrolyte/gold nanoparticle multilayers assembled on phospholipid/dextran sulfate monolayers at a liquid-liquid interface. Electrochem2005, September 2005, Newcastle, England (Abstract + Poster presentation).

2004 (2) [3] Santos H.A., Roozeman R.-J., Kontturi K. Interfacial interaction between dextran sulfate and lipid monolayers at air-liquid and

liquid-liquid interfaces: an electrochemical study. International Society of Electrochemistry55th Annual Meeting, September 2004, Thessaloniki, Greece (Poster presentation).

[2] Santos H.A., Kontturi K. Interaction of glycosaminoglycans with lipid monolayers. International Society of

Electrochemistry55th Annual Meeting, September 2004, Thessaloniki, Greece (Abstract). 2003 (1) [1] Santos H.A., Pereira C.M., Silva A.F. Ion transfer through DPPC films. New Trends in Molecular Electrochemistry and XII

Meeting of the Portuguese Electrochemical Society, September 2003, Lisbon, Portugal (Abstract + Poster presentation).